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Clostridium difficile is a spore-forming, anaerobic Gram-positive bacteria that 
results in infection in the gastrointestinal (GI) tact. C. difficile has been known as the 
costliest bacteria in terms of human mortality and financial burden. Furthermore, the 
current treatments that exist for C. difficile infection (CDI) are inefficient and expensive 
and often result in disease reoccurrence due to the release of spores. Therefore, it is an 
important medical requirement to develop novel antibacterial compounds to effectively 
treat CDI. As such this PhD project has investigated the modification of the binaphthyl 
hydrophobic region of the lead compound-1 (AVX-13616) with alkyl and benzyl 
substituted phenyltriazole and naphthalenetriazole peptidomimetics towards the 
discovery of new CDI inhibitors.  
An effective and modular synthetic route was developed to prepare twenty-nine 
novel mono- and di-cationic peptide derivatives which incorporated a phenyltriazole or 
naphthalenetriazole group with the aim to achieve better water solubility over previously 
prepared analogues by our group which were difficult to deliver in mouse model 
experiments because of their poor water solubilities. Chapter 2 describes the successful 
synthesis of these analogues. In some cases, the attempted synthesis of the 1,5-triazole 
moiety using the Ru-catalysed click reaction were unsuccessful when sterically hindered 
azide and alkyne substrates were employed. We found, however, that the magnesium 
promoted click reaction conditions reported by Sharpless et al. were useful for the 






The difficulties encountered in preparing sterically hindered 1,5-triazoles initiated a 
general study into this synthetic problem. The results of this study are reported in Chapter 
4.   
The new analogues prepared here were tested against a wide range of bacterial 
strains and two fungal strains by collaborators at three independent laboratories. These 
results are reported in Chapter 3. The twenty-nine peptide derivatives had variable 
minimum inhibitory concentration (MIC) values from the antimicrobial screening. All of 
the compounds displayed MIC values in the range of 2 – 128 μg/mL against both Gram-
positive and Gram-negative bacterial pathogens. The naphthyl-triazole dicationic 
compounds 42 and 43 showed the best broad-spectrum antibacterial activities, displaying 
MIC values of 8 μg/mL against S. aureus, 8 μg/mL against MRSA, 8 μg/mL against E. 
faecalis and 8 – 16 μg/mL against S. pneumoniae. The compounds, 29 – 30, 33 and 43 – 
45, exhibited weak antifungal activity (MIC = 8 – 32 μg/mL) against C. albicans and C. 
neoformans. The compounds 41 and 42, however showed MIC values of 4 μg/mL against 
C. neoformans. 
Compounds 41 and 43 (naphthalenetriazole derivatives) exhibited similar 
antibacterial activity against C. difficile (MIC = 8 μg/mL); these molecules were also 
structurally similar except for the nature of their hydrophobic termini (cyclohexyl and 
benzyl, respectively). A cytotoxicity analysis revealed that these compounds had 
relatively low cytotoxicity (CC50 = 32 μg/mL). Overall compound 41 showed similar 
antibacterial activity against C. difficile (MIC = 8 μg/mL) to the lead compound-1 (MIC  





= 8 μg/mL), better water solubility (5 times better than lead compound-1) and low 
cytotoxicity (CC50 = 32 μg/mL); these properties favored compound 41 for further in vivo 
testing in a CDI mouse model.  
Compound 41 was synthesized on a larger scale (≈ 300 mg) for further studies in 
an in vivo CDI mouse model to identify its potential as an in vivo CDI inhibitor. At 24 
hours post-infection, compound 41 appeared to be protecting the mice from disease as the 
mice lost the least amount of weight and had mild diarrhoea. Furthermore, compound 41 
displayed some promising activity, despite not completely protecting the mice over the 
second day period of this trial and the mice had to be culled after 42 h due to weight loss 
from the disease. 
In summary, a total of 29 novel phenyltriazole and naphthyltriazole peptide 
derivatives were synthesized via a modular synthetic route and tested against various 
Gram-positive and Gram-negative bacteria. Compound 41 showed better antibacterial 
activity against C. difficile, good water solubility and low cytotoxicity; these properties 
favored the compound for further in vivo testing in a CDI mouse model. Compound 41 
displayed some promising activity at 24 h, despite not completely protecting the mice in 










1.0 – Introduction 
1.1 – Resistance to Antibacterial agents 
Antibacterial resistance to known antibiotics is, and will continue to be, a severe 
threat to the current human healthcare services and overall security.1-6 Inflammation 
disease is the second biggest medical threat globally (17 million deaths/year) and bacterial 
infections from antibiotic resistant is presently viewed as a "rising universal disease" by 
the World Health Organization (WHO) and the US Centers for Disease Control and 
Prevention (CDC).6-7 The CDC evaluates that antibiotic resistance is responsible for 
23,000 deaths and more than two million inflammation diseases every year in the USA.2 
The WHO has begun an "Universal Action Plan on Antimicrobial Resistance" around the 
world to control the severity of drug resistance. Both the WHO and CDC have released a 
list of drug resistance microbes that are presently thought to be a critical threat to current 
human healthcare services and overall security.8 Bacterial strains have developed 
resistance to the most common antibacterial agents and the regularity of hypervirulent 
strains just potentiates the problem.9-10 Therefore, the requirement for novel antibacterial 
agents with new mechanisms of action is urgently needed. 
Bacterial resistance arises in three ways: 1. natural resistance in certain types of 
bacteria, 2. genetic mutation and, 3. by one bacterium acquiring resistance from another 
via horizontal gene transfer.9 All classes of microbes can develop resistance, including 
fungi and viruses. Bacterial resistance to antibiotics has developed quickly since the 
introduction of penicillin during the 1930s, and 85% of clinically isolated Staphylococci 





Vancomycin was quickly permitted for use as an antibacterial agent because its 
effective treatment against penicillin resistant bacteria was needed urgently.11 Methicillin, 
the first semi-synthetic penicillin, was developed by Beecham in 1959 and was rapidly 
introduced as an antimicrobial agent because of its efficacy against penicillin resistant  
bacteria.11 The consequent rise of methicillin-resistant Staphylococcus aureus (MRSA) 
and its developed resistance to most other common antibacterial agents led to vancomycin 
becoming “the best medicine" for the treatment of MRSA. This led to an increase in 
vancomycin usage to treat MRSA and also to treat the rising cases of Clostridium difficile 
infection (CDI) during the 1970’s. The massive consumption of oral vancomycin for the 
treatment of CDI caused the rise of vancomycin resistant enterococci (VRE) in 1986. 
Vancomycin resistant S. aureus (VRSA) additionally developed via parallel gene 
transmission from VRE in a patient in 2002, who had been occasionally treated with 
vancomycin.11 Some microbes have developed resistance against many antibacterial 
agents and these multi-drug resistant (MDR) pathogens are a major concern for the current 
healthcare system. Informally the resistant bacterial isolates are called "superbugs" and 
are currently a serious concern and therefore a strong motivation for the invention of new 
antibacterial agents.12-13  
Recently, vancomycin has been supplanted to treat VRSA, MRSA and all Gram-
positive microbial diseases by tigecycline, linezolid, daptomycin and 
quinupristin/dalfopristin.10-11 Both linezolid and daptomycin have been used generally to 
treat Gram-positive diseases; in this way, resistance of these two antibacterial agents has 





impervious to antibacterial agents  because of their impermeable external membrane and 
their efflux pumps (for eliminating undesired chemicals out of the cell).13 Multi-drug 
resistance in Gram-negative microorganisms is rapidly increasing, so there is an urgent 
need for the development of novel antibacterial agents with better efficacy compared to 
present antibiotics to treat such related inflammations.13 Thus, antibacterial drug 
discovery has shifted its focus on the development of novel antibacterial agents against 
MDR Gram-negative microbial inflammations.13 The ESKAPE microorganisms (i.e. 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter spp.) are six anti-microbial 
resistant bacterial strains that have been perceived by the Infectious Diseases Society of 
America (IDSA) as the key organisms behind most nosocomial inflammations.5 These 
microorganisms have been classified based on their harmfulness, steadiness, tendency for 
obstacle and pathogenicity.5 Remarkably, P. aeruginosa and A. baumannii showed an in-
built ability to oppose antibacterial agents, probably due to their capability of surviving in 
hazardous environments. The lack of sustainable choices of medication for Gram-negative 
microbial infections has even led to the reintroduction of polymyxin B and polymyxin E 
(colistin), despite known toxicity issues – polymyxins are relatively large cyclic cationic 
peptides with potent antimicrobial activity.13 
Regrettably, microbial resistance is unavoidable, and each bacterium will 
eventually develop resistance to any antibacterial agent. There is an increased chance for 
the development of a resistant bacterial strain by increased exposure to antibiotics. In this 





50% of antibiotics consumption) and the abuse and overuse by modern medicine has 
worsen the problem of resistance by accelerating the process.15 In 2015, a  five year plan 
was announced by the US White House on abuse of antibacterial agents in the agriculture 
industry where this is a major issue.7 Furthermore a program called “National Action Plan 
for Combating Antibiotic-Resistant Bacteria” was announced by the US White House – 
the objective of this program was financial support to novel anti-microbial drug discovery 
research for the treatment of MDR bacterial infections.7 The resistance of pathogenic 
bacteria toward antibacterial agents has become a serious issue, so the WHO recently 
cautioned of a 'post-antibiotic time'; where regular diseases and minor injuries will 
demonstrate as deadly because of the absence of reasonable anti-microbial therapies.16 
Thus, novel antibacterial agents with distinctive mechanism of actions are desperately 
required to tackle the rising problem of bacterial resistance. 
 
1.2 – Clostridium difficile infection  
 C. difficile is a spore-forming, anaerobic Gram-positive microbe that results 
in moderate to severe illness in the gastrointestinal (GI) tact. This bacterium produces 






   
    Figure 1.1 – C. difficile forming an endospore (red).19 
(Electron micrograph pic) 
 
C. difficile infection (CDI) happens when the common GI microbiota is 
compromised; this licenses C. difficile to grow well in the GI tract. Most standard oral 
antibiotics, as well as penicillins, can target the healthy GI microflora – this undesirable 
effect gives C. difficile up to a 20% chance to survive in the gut.17 C. difficile produces 
vigorous endospores that are spread by the fecal-oral course; these spores are impenetrable 
to most anti-infectives, hand sanitizers and heat. The hospital environment allows ideal 
conditions for C. difficile spores, which can live for a significantly long time and helps 
the spread of C. difficile spores via nosocomial contamination; also known as hospital 
acquired contamination which usually occurs via healthcare workers, patients and hospital 
equipment. The other major threat of CDI is earlier antibiotic treatment.18 Broad range 
anti-microbial treatment commonly destroys the GI microflora while treating C. difficile 
infection. Most of the broad-spectrum antibacterial agents such as fluoroquinolones, 
ampicillin/amoxicillin, clindamycin and cephalosporins eradicate the commensal GI 





Patients having a C. difficile contaminated GI system endure indications such as 
diarrhoea, abdominal cramping, abdominal pain and pseudomembranous colitis (PMC – 
a serious gastric illness). CDI-related PMC can be so serious as to warrant colectomy (i.e. 
resection of the colon) for which there is a ~55% death rate for patients that proceed to 
medical surgery.21 Furthermore, poisonous megacolon can arise because of CDI, wherein 
the patient encounters serious colonic irritation and stomach distension.20 CDI shows an 
overall demise rate up to 8%18 and re-occurrence of disease occurs in up to 20% of cases 
treated with first-line drugs (vancomycin or metronidazole).22 Once the spores have 
reached to the GI, the accessible bile salts initiate germination of the spores to convey the 
vegetative C. difficile cells. The illness obtained by CDI basically creates two destructive 
elements (Toxin A and Toxin B) that are released by the vegetative C. difficile cells; these 
toxins develop colonic disease and damage epithelial tissue which causes loss of liquid 
(diarrhoea). A third toxin (known as CDT or matched toxin) is found in significant levels 
in hypervirulent C. difficile strains; the role of this poison in disease has not yet been 
elucidated.20 
As of late, both the earnestness and recurrence of CDI cases have increased due to 
epidemics of hypervirulent C. difficile strains, for example ribotype 027 – also known as 
strain B1/NAP1/027.17 The hypervirulent ribotype 027 produces larger quantities of 
toxins than common C. difficile strains – these poisons are responsible for the infirmity 
side effects of diarrhoea and PMC.18 Thus, ribotype 027 shows higher death rates than 





The inescapability of C. difficile contamination invokes an enormous monetary 
burden on the current therapeutic services administrations (>$1 billion every year in the 
USA);17, 23 another assessment put CDI-related human medicinal services administration 
costs at $4.8 billion in 2008.18 The CDC gave a report in 2013 entitled 'Resistance Threats 
to Antibiotics' in which C. difficile was noted as the prime microbial threat to humans and 
the toughest test for the social insurance system.3 A continuous update by the CDC 
revealed that CDI is responsible for approximately 500,000 diseases and 15,000 deaths 
consistently in the USA – the largest increase in any of the bacterial threats recorded by 
the CDC.23 Due to the elevated levels of illness, expenditure, recurrence, deaths and the 
absence of satisfactory therapies for CDI, there is considerable motivation to pursue 
innovative antibacterial agent that successfully prevent CDI. 
Antibacterial selectivity for C. difficile is an important factor for a relatively 
efficient CDI antibacterial agent. The elimination of all GI microbiome by broad-spectrum 
antimicrobial agents results in an ideal environment for C. difficile spores to develop; thus, 
the maintenance or restoration of commensal GI microflora is necessary for stopping CDI 
recurrence.17-18, 20 This explains why CDI is so difficult to treat with conventional 
antimicrobial agents and why CDI reoccurs in 15-30% of patients who have been treated 
with vancomycin.17 Fecal transplantation has become a feasible strategy for treating cases 
of severe CDI, as it replaces the commensal GI microflora physically.17-18, 20 The typical 
antibacterial agents (i.e. metronidazole and vancomycin) suffer from efficacy concerns, 
especially CDI recurrence due to their lack of selectivity for C. difficile and their lack of 





the lack of ability to develop a specific antibody response to the toxins released by C. 
difficile; healthy adults naturally develop antibodies against toxins A and B.17 Non-
chemotherapeutic treatments (i.e. medical surgery) are available, but they are only utilized 
when traditional drugs have been unsuccessful. Surgical treatments are permanent – most 
involve subtotal colectomy in an effort to substantially reduce the infection and diseased 
bowel.18 Existing C. difficile medications fail to treat CDI with no recurrence. Thus, there 
is a demand for more efficacious antibacterial agents for CDI treatment. A well-tolerated 
and reliable drug that can selectively target C. difficile (and its spores), without effecting 
the GI microbiome intact, would be vital in the treatment of severe and recurrent CDI. 
 
1.3 – Available medicines for C. difficile infection (CDI) 
There are currently only three medicines used to treat CDI. They are vancomycin, 
metronidazole and fidaxomicin.20, 22, 24 Only vancomycin and fidaxomicin are FDA 
approved for treatment of CDI. Vancomycin was the only FDA approved treatment for 
CDI until 2011 when fidaxomicin was also approved. Metronidazole is widely used to treat 
CDI in mild to moderate and recurrent cases despite not having FDA approval. 
 
1.3.1 – Metronidazole 
 
Metronidazole (Figure 1.2) is an imidazole derivative that has been utilized 
initially as an antiprotozoal medicine to treat Trichomonas vaginalis and giardiasis, 
eventually found to be effective against both Gram-positive and Gram-negative pathogens 





treat inflammatory diseases. It is a possible medicine for mild CDI if vancomycin or 
fidaxomicin is inaccessible.27-28 
 
     
                     Figure 1.2 – Metronidazole 
Metronidazole is marketed under the brand name Flagyl, Filmet and Metro. 
During the 30 years of utilization, metronidazole was eminent because a low resistance 
profile was observed.28 Metronidazole can be administered orally, intravenously and 
topically and shows ideal pharmacokinetics for a systemic anti-infective. Metronidazole 
is an inexpensive medicine that has a straightforward structure that permits efficient and 
cost-effective bulk production (~$0.86 USD/dose).25  
Metronidazole shows potency through a free radical mechanism where the nitro 
group is reduced in vivo to a reactive 'nitro radical anion' which is unstable and readily 
decomposes to give an imidazole radical and a nitrite ion.20, 28 The imidazole radical and 
nitrite ion cause oxidative damage to DNA strands, resulting in apoptosis. Metronidazole 
has supplanted vancomycin to treat milder illness of CDI as it is less expensive and has a 
comparative efficacy profile.25 Most orally taken metronidazole is absorbed systemically 
which is not suitable for C. difficile treatment.27-28 Low oral bioavailability is fundamental 









1.3.2 – Vancomycin 
Vancomycin (Figure 1.3) is a glycopeptide antibacterial agent that is utilized for 
the treatment of various bacterial inflammations. This compound was developed by the 
Eli Lilly pharmaceutical organization in 1959. Vancomycin was isolated from a soil 
sample from the rainforests of Borneo from the microorganism Amycolatopsis orientalis.9 
Fermentation of A. orientalis efficiently yields vancomycin on an industrial scale. This 
production technique is financially more viable than total synthesis due to its complex 
chemical structure.11 Vancomycin costs ~$31 USD per dose; which is relatively expensive 










               Figure 1.3 – Vancomycin (glycopeptide antibiotic) 
The glycopeptides represent a complex class of molecular structures; the main 
tricyclic structure comprises peptide, ether and biphenyl moieties with a disaccharide 
attached to one of the phenol rings. Vancomycin is known to work by obstructing the 
development of the bacterial cell wall. The binding of vancomycin to the terminal D-





enzyme from cross-connecting the peptide as a component of the bacterial cell wall.9 
Vancomycin displays antibacterial activity (MIC) ≤ 0.50 µg/mL against C. difficile and 
207 C. difficile strains.26 Vancomycin displays numerous traits that make it perfect for 
extreme CDI treatment such as a low oral bioavailability and a potent MIC against C. 
difficile. But unfortunately, it has a few disadvantages i.e. lack of selectivity for C. 
difficile, recurrence of CDI following treatment, cost and production.11, 25 In particular, 
vancomycin plays a significant role in treating MRSA and other MDR microbes and thus 
it will never be given full permit for the treatment of mild or moderate CDI. 
 
1.3.3 – Rifaximin 
Rifaximin (Figure 1.4) is from the rifamycin group of semi-synthetic antibiotic. 
This drug is amazingly highly potent against C. difficile and furthermore displays broad-
spectrum activity. 
Rifaximin showed an antibacterial activity (MIC) of ≤ 0.015 µg/mL against 110 
pathogenic C. difficile strains while maintaining low solubility in water.25, 31 After oral 
dosing, the intestinal concentration of this drug remains high with 97% of the dose 
recovered as unaltered rifaximin in the faeces. The drug maintains systemic bioavailability 










Figure 1.4 – Rifaximin 
Ongoing investigations have shown that rifaximin can be used for resistant CDI 
treatment – as a "salvage therapy" where several classic drugs have failed to do.25, 33 These 
examinations indicated that the drug is well-tolerated by most patients and that it has had 
some success in cases such as resilient CDI treatment, including a few strains containing 
the  NAP1/BI/027 ribotype.33 C. difficile resistance against rifamycin is growing as an 
issue with around 2% of present strains displaying rifaximin resistance. There is 
developing worry that the percentage of resistance strains will increase in the future.33 
Rifaximin may also be used as an extension to vancomycin for treating patients with 
relapsing C. difficile infection. However, the quality of evidence of these studies was 
judged to be low. Although exposure to rifamycin may increase the risk of resistance in 











1.3.4 – Fidaxomicin 
Fidaxomicin (Figure 1.5) is a macrocyclic anti-microbial agent which is explicitly 
utilized to treat CDI and was endorsed by the FDA in 2011. Fidaxomicin has an intricate 
structure containing an unsaturated macrolide with two sugar units connected; the 
molecule was isolated from the fermentation of Dactylosporangium aurantiacum.22 






            Figure 1.5 – Macrolide structure of fidaxomicin 
Fidaxomicin showed antibacterial activities (MIC) in the range of 0.008 – 0.25 
μg/mL for 90% of C. difficile isolates screened and also delivered promising results in 
CDI treatment.22 Significantly, fidaxomicin displays narrow-spectrum antimicrobial 
potency; the medication specifically inhibits C. difficile and does not kill the useful GI 
microbiota.20, 29 The rate of CDI recurrence was 22.6% for vancomycin and 11.7% for 
fidaxomicin.30 Therefore, fidaxomicin better reduces the recurrence rate of CDI, when 
compared to vancomycin. The reason behind the lower rate of fidaxomicin recurrence is 
thought to be due to it allowing the commensal GI microbiome to remain unblemished 
while also inhibiting C. difficile.30 These two properties are believed to be responsible for 
fidaxomicin's decreased rates of CDI recurrence.29 Fidaxomicin inhibits RNA polymerase 





significant cytotoxicity of fidaxomicin is not a major problem as its systemic absorption 
is negligible.20 The medication shows the same level of tolerability as reference 
medications (i.e. vancomycin and rifaximin).29 Fidaxomicin prevents harmful strains and 
diminishes the spore loads of C. difficile better than vancomycin. Studies are in progress 
to determine whether fidaxomicin can act as a prophylactic for CDI or as a post-antibiotic 
‘chaser’ to inhibit antibiotic treatment-produced CDI.25 
 
1.3.5 – Resistance of C. difficile to available medicines/drugs 
 C. difficile has shown lower vulnerability to the basic chemotherapeutics 
(vancomycin, metronidazole and fidaxomicin), however resistance has not been spread 
widely. For instance, C. difficile strains with lower susceptibility to metronidazole (MIC 
> 32 μg/mL) have been archived recently.34 Furthermore, the Anaerobe Research Unit, 
UK - found four isolates of C. difficile with lower susceptibility to metronidazole while 
screening nearly 30 isolates.34 This lower susceptibility has clinical noteworthiness due to 
oral administration of metronidazole (because of the high systemic absorption).20 The 
lower susceptibility to metronidazole shown by C. difficile is not enduring as it is 
frequently lost after freeze-thawing or passaging of the bacteria.20 The lower susceptibility 
to vancomycin (MIC - 4 μg/mL) and fidaxomicin (MIC - 6 μg/mL) has additionally been 
seen in C. difficile isolates.20 The spread of C. difficile resistance is a developing issue and 







1.4 – Development of CDI inhibitors  
There are a few potential novel C. difficile inhibitors presently in different phases 
of advancement. Some of these CDI inhibitors will be described briefly with respect their 
potency, efficacy and clinical trials. 
 
Nitazoxanide and derivatives 
 
Nitazoxanide (Figure 1.6) is a nitrothiazolamide group compound that is utilized 
to treat intestinal parasites i.e. Cryptosporidium and Giardia. The drug was authorized by 




                               Figure 1.6 – Amixicile (left) and Nitazoxanide (right)  
Nitazoxanide displayed antibacterial activities (MIC) in the range 0.3-1.0 µg/mL 
against C. difficile.22 When the medication was first trialed against CDI, it was found to 
be  less active than  metronidazole and was shown to be effective in cases where 
metronidazole was not.39, 41 Further tolerability investigations of nitazoxanide 
incorporated a correlation with vancomycin for a double-blind study and the outcomes 
indicated that vancomycin and nitazoxanide were similarly dynamic against CDI.41 
Nitazoxanide disrupts cell wall biosynthesis by repressing the pyruvate:ferredoxin 
oxidoreductase system.22, 25 Nitazoxanide restrains the thiamine pyrophosphate nutrient 





yet does not influence the complete chemical system. The pyruvate:ferredoxin 
oxidoreductase is a nonselective enzyme system for many beneficial microflorae in the 
gut but is a semi-selective enzyme system for the C. difficile target. The beneficial 
microflora makes use of pyruvate dehydrogenase enzyme system instead of utilizing the 
pyruvate:ferredoxin oxidoreductase enzyme system.40 Nitazoxanide accumulates in the 
intestine before excretion due to its poor water solubility.40  
Amixicile (Figure 1.6) is a hydrochloride salt structurally related to nitazoxanide. 
It was discovered from a library of 250+ nitazoxanide derivatives and its hydrochloride 
salt nature increased water solubility. The increased solubility helps in 
pyruvate:ferredoxin oxidoreductase inhibitory activity. Amixicile showed a superior 
survival rate (56%) compared to nitazoxanide (22%) and vancomycin (15%) in an 
optimized murine model of CDI studies. Amixicile and nitazoxanide have low CDI 
recurrence rates whereas vancomycin and fidaxomicin exhibited CDI recurrence in mice 
infected with CDI.40 These promising results have confirmed that these nitrothiazolide 
derivatives are upcoming new CDI inhibitors and a few more investigations are required 
to consider if these two compounds are safe and more effective in the treatment of CDI.  
 
Ridinilazole 
Ridinilazole (formerly called - SMT19969) (Figure 1.7) is a dimer of 
benzimidazole with a pyridine linker that shows selectively antimicrobial potency against 
C. difficile but is not effective on any other Gram-positive and Gram-negative pathogens 





the range of 0.125 – 0.25 µg/mL against several strains of C. difficile.42, 43 The mechanism 
of action "needs to be fully ascertained" but the studies have declared that ridinilazole is 
involved in the inhibition of bacterial cell division – the medication is additionally known 
to diminish toxins and loads of C. difficile spores.43 
 
 
              
            Figure 1.7 – Ridinilazole  
Summit Pharmaceutical International has finished phase I clinical studies on 
ridinilazole and the results show excellent tolerability, low systemic absorption and 
specific focus on C. difficile without making collateral damage to the natural gut flora, 
and accordingly a decrease in the CDI recurrence rate. Additionally, ridinilazole passed 
supremacy criteria over vancomycin in multicentre phase II trials on CDI patients.43 In 
preclinical studies, ridinilazole had established a strong bactericidal viability against all 
strains of C. difficile tested and Summit Pharmaceutical International is presently trialing 
this compound in phase III clinical trials.43 
 
Surotomycin 
Surotomycin (formerly known as CB-183,315; Figure 1.8) was discovered by 
Cubist Pharmaceuticals and developed by Merck & Co (who acquired Cubist 
Pharmaceuticals). This antibacterial agent is an orally administered, cyclic lipopeptide 
and is derived via semi-synthesis of the natural product daptomycin.20 Surotomycin 





safety studies of phase II clinical trials confirmed that surotomycin at two doses i.e. 125 
mg/day or 250 mg/day was tolerable and at that dose the medication had a higher cure 




Figure 1.8 – Surotomycin 
The CDI survival rate for surotomycin was (83.6%) better than that of vancomycin 
(79%).36 Phase III clinical trials of this antibiotic were discontinued in 2017 due to its 
non-superiority to current therapies.36  
 
Cadazolid 
Cadazolid (Figure 1.9) is a crossover anti-microbial agent of the oxazolidinone 
class created by Actelion Pharmaceuticals. The structure of cadazolid is a hybrid of the 
known oxazolidinone and fluoroquinolone antibiotics. Cadazolid displayed antibacterial 
activities (MIC) in the range of 0.125 – 0.50 µg/mL against C. difficile isolates and 
obstructs biosynthesis of the bacterial cell wall. Cadazolid also restrains sporulation and 
toxin formation; moreover, cadazolid has low oral bioavailability and selectively shows 










Figure 1.9 – Cadazolid  
Cadazolid effectively finished phase I and II clinical trials with better efficacy and 
similar tolerability to vancomycin. The results of Phase III clinical trials concluded with 
mixed results but precise details were not disclosed.46 
 
CRS3123 
A novel diaryldiamine CRS3123 (previously REP3123; Figure 1.10) showed 
antibacterial activity (MIC) of 1.0 µg/mL against 108 clinical isolates of C. difficile and 
is presently under development with NIAID (National Institute for Allergy and Infectious 
Diseases).22, 37 CRS3123 is a novel potent small molecule that inhibits methionyl-tRNA 




                                               Figure 1.10 – CRS3123  
C. difficile infection treatment with CRS3123 in a hamster model, resulted a 
significant improvement in survival rate when compared to vancomycin. Hamsters (62%-





were dead by day 17 (rate of dose 0.5 mg/kg and 5 mg/kg, respectively).22 The phase I 
clinical trials of CRS3123 have been disclosed as overall well tolerated over a wide range 
of doses. This safety profile supports further investigation of CRS3123 as a treatment for 
CDI.38 
 
1.5 – Development of binaphthylpeptide derivatives as an antibacterial agent 
In our research laboratory, there has been a progressing research project focused 
on the discovery of novel antibacterial compounds initially around a binaphthylpeptide 
scaffold.47, 48-54 The key moieties that grant antimicrobial potency to this group of 
compounds are displayed on the unique lead compound-1; AVX-13616 (Figure 1.11). The 
basic characteristics of compound 1 includes a hydrophobic 1,1'-binaphthyl moiety, an 
isopentyl group connected to one of the naphthyl rings and a peptide back-bone connected 
to the other naphthyl ring. The peptide back-bone includes one to three amino acids 
(compound 1 has three), importantly one of the amino acids should contain a cationic (i.e. 



















The amino acids arginine and lysine have been seen as an essential in providing 
an antimicrobial potency to this class of derivatives. The hydrophobic terminus is 
important for guaranteeing antimicrobial potency, despite the fact that bifurcation at this 
end does not appear to be vital.47, 54 These binaphthylpeptide analogues for the most part 
show a wide range of Gram-positive antibacterial potency, for example AVX-13616 
displayed antibacterial activities (MIC) of 2.0 µg/mL against VRSA and 4.0 µg/mL 
against VRE. Notably, AVX-13616 additionally showed antibacterial potency against S. 
aureus and MRSA strains that were resistant to linezolid. This compound showed 
decreased potency against Gram-negative microbes i.e. K. pneumoniae and E. coli with 
minimum inhibitory concentration (MIC) of  >32.0 µg/mL and 16.0 µg/mL, 
respectively.49 In 2010, compound-1 (AVX-13616) was licensed to Valevia 
Pharmaceuticals and the organization planned to develop AVX-13616 as a medication in 
the form of creams, foams, gels, lotions and ointments for wound related infections of 
body surfaces such as skin and mucous membranes.55 In vitro studies showed that 
resistance to the binaphthyl peptides grows gradually in contrast to vancomycin; for S. 
aureus 18 passages were required to induce vancomycin resistance, while AVX-13616 
required in excess of 50 passages for in vitro resistance to develop.49 Bacteria that 
inevitably evolved decreased vulnerability to AVX-13616 did not show cross-resistance 
to vancomycin.49 These results demonstrated that vancomycin and AVX-13616 do not 
share the same mode of action.  Generally, these peptide analogues are non-drug like as 
they have greater number of heteroatoms and their mono and dicationic nature gives them 





appropriate for in vivo investigations on C. difficile infected mice because of their poor 
water solubilities; therefore, highlighting the need for more water-soluble derivatives. 
Ongoing investigations showed that different 1,2,3-triazole analogues of 
compound 1 showed antimicrobial potency (MIC) in the range of 2.0 – 8.0 µg/mL against 
C. difficile.47, 53 Lead derivatives 2 and 3 were synthesized as peptidomimetic analogues 
of compound 1 and these were found to show exceptional in vitro antimicrobial potency 
against both hypervirulent C. difficile and S. aureus (Figure 1.12 and 1.13).54 In the in 
vivo murine model studies on CDI mice, compounds 2 and 3 showed some encouraging 
preliminary outcomes.47 The current project aims to develop a library of novel derivatives 
around the lead compounds 2 and 3 for further SAR studies with endeavors being made 
to improve antimicrobial potency and selectivity for C. difficile.56 Furthermore, it was 














Figure 1.12 – Lead compound 2 with a table of antibacterial activities against S. aureus (ATCC 
29213), MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC 49619), C. difficile 















Figure 1.13 – Lead compound 3 with a table of antibacterial activities against S. aureus (ATCC 29213), 
MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC 49619), C. difficile (ATCC 
700057, C. difficile (RT027 – NSW132) and E. coli (ATCC25922). 
 
1.6 – Concepts and synthetic strategies for designing target compounds 
1.6.1 – Incorporation of a peptidomimetic bioisostere  
A previous researcher47 in our group made analogues around compound 1 by 
substitution of the amide moiety (Figure 1.14a – blue circle) with a peptidomimetic 
bioisostere (i.e. 1,2,3-triazole ring; Figure 1.14c – blue segment). Previous investigations 
have affirmed that a 1,2,3-triazole ring is a suitable bioisostere for a typical peptide moiety 
as it shows a comparable planarity, dipole (Figure 1.14b and 1.14c) and spatial 
arrangement of polar atoms.57-58 1,4-Disubstituted-1,2,3-triazoles also have the possibility 
to donate and accept hydrogen bonds like normal amides.58 Furthermore, they are viewed 
























Figure 1.14 – a) Portion of lead compound 1 with targeted amide group (blue dotted rectangle)  
           b) Amide moiety (blue) and corresponding dipole moment (red)  
                       c) 1,2,3-Triazole moiety (blue) and corresponding dipole moment (red). 
 
  
In our laboratory, previous research has involved the replacement of a terminal 
amide (Figure 1.14a – blue circle) with a substituted 1,2,3-triazole moiety in the peptide 
chain of AVX-13616. The triazole moieties were installed via ‘copper(I)-catalyzed 
alkyne-azide cycloaddition’ (CuAAC) from the azide and alkyne precursors showed in 











Scheme 1.1 – Previously synthesized triazole analogues showing their “click” chemistry precursors. 
 
1.6.2 – Modification of the aromatic core 
In this current project, it was planned to build upon these previous studies. A 
hydrophobic binaphthyl core (F) (red circle in Scheme 1.2) or its biphenyl analogue (A) 
(blue circle in Scheme 1.2) is mandatory for the antibacterial potency of AVX-13616 and 





triazoles (B-E) and the binaphthyl hydrophobic core (F) structure will be replaced by the 




















Scheme 1.2 – Aromatic core replacement showing the changes from biphenyl core 
to phenyl-1,2,3-triazole cores and binaphthalene core to naphthalene-1,2,3-triazole 
cores. 
 
These modifications were expected to provide peptide derivatives with better water 
solubilities than those previously synthesized due to the enhanced polarity of these 1,2,3-
triazole derivatives. 
1.6.3 – Design and synthesis of derivatives 
The different N-phenyltriazole and N-naphthyltriazole peptide structures will be 





from each other based on two key structural parameters i.e., the aromatic core (Section 
1.6.2), and the number and type of amino acids present in the peptide back-bone. In 
compounds 47 – 49, the peptide moiety will be attached to the triazole group rather than 
the phenyl or naphthyl ring as in the other derivatives 21 – 46. All these analogues 21 – 
49 will be synthesized to allow structure-activity relationship (SAR) comparisons 
between specific analogues.  
Past examination has demonstrated that monocationic derivatives can show 
valuable antibacterial potency;47, 54 therefore, simple monocationic derivatives 21 – 34 
will be targeted as well, because smaller and more synthetically accessible molecules are 
always preferable. Each synthesized scaffold will be derivatized by variation of the 
hydrophobic terminus (R) and Cu-catalysed ‘click reactions’ will be utilized for 


































     Figure 1.16 – Proposed di-cationic derivatives 35 - 49 with variable hydrophobic structural elements (R)  
 
1.6.4 – Synthesis of analogues via a modular approach 
 To synthesize multiple analogue variations from a relatively simple synthetic 
route, a modular approach will be adopted. The different structural analogues 21 – 49 are 





formation via Cu-catalysed click reactions will allow formation of analogues from various 
building blocks (Figure 1.17) that hold these key reactive functional groups: amine (NH2), 
acid (COOH), azide (N3) and alkyne (C≡CH). The acid building block can be coupled to 
primary amines through formation of the required amide bonds. Furthermore, alkyne 
building blocks can be coupled with the requisite azide building blocks to construct the 
necessary 1,2,3-triazole moieties. 
 
 
Figure 1.17 – Precursor building blocks for the modular approach to synthesis of analogues: 
the acid and amine moieties (blue) can be readily linked together via peptide coupling 
methods while the azide and alkyne functionalities (red) can also join together via CuAAC 
reactions. 
 
Dual functionalization of the β-azidoamine 56 residue with both a group capable 
of peptide coupling (i.e. an acid) and a group capable of CuAAC reaction (i.e. an alkyne) 














Scheme 1.3 – Modular approach to synthesis of analogues: acid and amine 
functionalities (blue) are combined into an amide bond while the azide and alkyne 
functionalities (red) are coupled together via 1,2,3-triazole moiety 
 
Dual functionalization of the β-azidoamine 57 residue with both a group capable of peptide 
coupling (i.e. an acid) and a group capable of CuAAC reaction (i.e. an alkyne) allows rapid 











Scheme 1.4 – Modular approach to synthesis of analogues: acid and amine 
functionalities (blue) are combined into an amide bond while the azide and alkyne 






1.6.5 – Proposed synthetic routes and challenges 
The previously mentioned forerunner building blocks (Figure 1.17) will be 
synthesized from known and new synthetic precursors. The previously mentioned 
analogues (section 1.6.3) will be accomplished from peptide coupling and CuAAC 
reactions followed by side-chain N-deprotection and HCl salting. This iterative 
derivatization of the different scaffold types will facilitate the formation of a library of 
novel antibacterial derivatives. Most importantly, the proposed synthesis will require 
three protecting groups i.e. Boc (I), Pbf (J) and Fmoc (K) (Figure 1.18). These protecting 






               Figure 1.18 – Nitrogen protecting group structures and abbreviations 
Boc and Fmoc protecting groups can be utilized to protect primary amines as 
carbamates and the Pbf protecting group can be utilized to protect guanidino residues via 
formation of an arylsulfonimide. Boc protected lysine and Pbf protected arginine amino 
acid sidechains can be utilized, and these two protecting groups can be deprotected 
together in the last step of a reaction sequence which permits the side chains to be 
unreactive throughout the entire synthetic process except for the last step. The Fmoc group 
will be used in known synthetic strategies for building the unprotected β-azidoamine 





The designed synthetic routes (Schemes 1.5 – 1.10) will permit the divergent 
synthesis of numerous scaffolds from straightforward precursors. This synthetic strategy 
will allow various scaffold varieties to be prepared from the key precursor building blocks, 
which can be derivatized to generate a number of potential antibacterial products. 
Schemes 1.5 – 1.10 employ the same pairs of β-azidoamines (56 and 57) coupling 
partners with the different acids 50 – 54. Scheme 1.11 illustrates the β-azidoamine 57 
coupled to the acid 55 resulting in products 47 – 49 in which the peptide side chain is 























































































                    
   



































1.7 – Project Aims 
It is an important medical requirement to develop novel antibacterial compounds 
to effectively treat CDI. Therefore, a joint research project (NHRMC Project; Grant No. 
APP1124032) was established between the University of Wollongong (drug design and 
synthesis), the University of Western Australia (microbiology) and Monash University 
(pharmacology) to synthesize and develop potent CDI chemotherapeutics. The aims of 
this project are: 
• To incorporate a more polar hydrophilic moiety (i.e. a 1,2,3-triazole moiety) into 
the hydrophobic region of the lead binaphthylpeptides 2 and 3 to increase 
gastrointestinal stability and solubility.   
  
• To modify the hydrophobic binaphthyl core of 2 and 3 by making N-phenyl-
1,2,3-triazole and N-naphthyl-1,2,3-triazole derivatives in an attempt to 
increase compound solubility. 
  
• To synthesize both dicationic and monocationic peptidomimetics. 
• To design and establish a viable and scalable synthesis of several novel 
triazole-containing scaffolds. 
 
• To ascertain the antimicrobial activity of the synthesized derivatives against 
Gram-positive bacteria, Gram-negative bacteria and fungi via MIC assays. 
• To develop and utilize a comparative solubility assay for determining the 
relative water solubilities of the synthesized compounds. 
 







• To ascertain an efficacy of one or more compounds as a CDI chemotherapeutic 
via testing in an in vivo CDI mouse model. 
• To design and identify a novel hit compound that could be utilized in the 
effective treatment of CDI.  
and 
 
• To explore the structure-activity relationships of the synthesized compounds by 
utilizing the obtained MIC data. 
      
The knowledge gained from this project would contribute to our understanding of the 



















2.0 – Synthesis: results and discussion 
2.1 – Synthesis of precursor building blocks 
This chapter describes the synthesis of the proposed targeted antibacterial 
derivatives from commercially available precursors. The known compounds are noted 
with literature references.  
2.1.1 – Synthesis of the aromatic core structures 
2.1.1.1 – Synthesis of the carboxylic acid 50 
The synthesis and incorporation of a 1,4-disubstituted-1,2,3-triazole ring in drug 
like molecules has become a widespread practice and the common ‘click reaction’ [i.e., a 
Cu-catalysed azide-alkyne cycloaddition (CuAAC)] is the most reliable methodology for 
the formation of these moieties.57–59 Therefore, the strategy for the formation of the key 
intermediate 50 (Scheme 2.1) followed a two-step process of a ‘click reaction’ followed 
by O-alkylation.  
 
Scheme 2.1 – Synthesis of acid 50 from the alkyne 69 via Cu-catalysed [3 + 2] 
cycloaddition reaction between alkyne 69 and benzyl azide, followed by O-alkylation of 70 
with bromoacetic acid to obtain target acid 50. 
 
The reaction of benzylazide with the alkyne 69 in the presence of Cu(II)/sodium 
ascorbate in t-BuOH/H2O for 12 h at rt gave the triazole 70 in 80% yield after purification 





revealed a characteristic singlet resonance for the triazole proton at δH 7.72. The molecular 
structure of compound 70 was further verified by the presence of an ion peak at m/z 
252.1136 in the HRMS (ESI) that was assigned to the protonated molecular ion ([M + 
H]+) (calculated for C15H14N3O 252.1137).  
The base-promoted O-alkylation of 70 with bromoacetic acid was achieved using 
K2CO3 in dry THF at reflux (Scheme 2.1) and after acidification produced acid 50 in 80% 
yield. This reaction sequence was also effective on a larger scale with an 88% yield of 50 
obtained starting with 2.00 g of the precursor alkyne 69.  
Analysis of the 1H NMR spectrum of acid 50 revealed a characteristic singlet 
resonance at δH 8.46 for the triazole proton. The C-5 carbon of the triazole ring resonated 
at δC 123.8 and was assigned from the gHSQC correlation of the triazole proton (δH 8.46) 
to this 13C NMR resonance (Figure 2.1).                            
       
Figure 2.1: gHSQC spectrum of compound 50 (400 MHz, CDCl3). The one bond correlation  






Analysis of the gHMBC spectrum of 50 showed the resonance at δC 143.8 
correlated to δH 8.46 and was assigned to the quaternary carbon of the triazole. Further 
the resonance at δC 170.8 was assigned to the carbonyl carbon of the carboxylic acid group 
as it correlated to the methylene protons (δH 4.70) of the carboxylic acid side chain (Figure 
2.2). 
         
                 Figure 2.2: gHMBC spectrum of compound 50 (400 MHz, CDCl3). The two-bond correlations  
   between the triazole proton and C-4, H-1'' and carbonyl carbon of COOH are highlighted. 
 
The molecular structure of compound 50 was further verified by the presence of 
the ion peak at m/z 332.1003 in the HRMS (ESI) that was assigned to the sodiated 
molecular ion ([M + Na]+) (calculated for C17H15N3O3Na 332.1011). 
Mechanism of the CuAAC reaction: 
The CuAAC reaction mechanism (Scheme 2.2) starts with the addition of a Cu(I) 
catalyst that can be added directly or prepared in situ from a Cu(II) salt by reduction using 





ascorbate avoids oxidation of the active Cu(I) catalytic species to the inactive Cu(II) 
species.62-63 This allows the reaction to be performed in an open-air environment without 
the requirement for an inert atmosphere. 
The active catalytic species Cu(I) reacts with the Cu-π bonded alkyne to form the 
copper acetylide A. The π-bound copper of the copper acetylide A coordinates with the 
azide to form the azido copper acetylide B. Then first nitrogen of the azido copper 
acetylide B coordinates with the π-bound copper to form a six-membered copper 
metallacycle C. The 2nd copper atom acts as a stabilizing donor ligand and ring contraction 
results in the triazolyl-copper derivative D that further undergoes protonolysis to deliver 












Scheme 2.2 – Proposed catalytic cycle for the CuACC reaction: [Cu] represents a Cu(I) complex 
that is coordinated to the requisite number of ancillary ligands. The mechanism allows for control 






The regioselectivity for the 1,4-disubstituted-1,2,3-triazole product is  controlled 
by the binding orientation of the azide and alkyne components to the active Cu(I) 
complex, which controls the orientation of the resultant [3 + 2]-cycloaddition.59, 62-63 This 
orientation mechanism was confirmed by multiple CuAAC studies that included kinetic 
analysis and DFT calculations.59, 62-65 Kinetic analysis confirmed that the reaction is 2nd 
order with respect to the concentration of Cu(I); this involves the prospective role of a di-
nuclear acetylide-bridged Cu(I) complex as an active species62-63 (Scheme 2.2). Notably, 
the mild catalytic reaction conditions produced consistent, clean and high-yielding 
reactions for the preparation of 1,4-disubstituted-1,2,3-triazoles. 
 
2.1.1.2 – Synthesis of the carboxylic acids 51 and 53 
The synthesis of acids 51 and 53 from their respective precursors 71 and 74 was 
accomplished in three steps: (i) an O-alkylation, (ii) a one pot process of azidation and a 
CuAAC reaction, and (iii) an ester hydrolysis of 73 and 76 using base which produced, 















Scheme 2.3 – Synthesis of acid 51 and 53 from respective alcohol precursor 71 and 74 via 
O-alkylation of alcohol 71 and 74 to give iodo ester 72 and 75, followed by a one pot 
(azidation/click reaction) synthesis of 73 and 76, then ester hydrolysis of 73 and 76 to 
furnish target acids 51 and 53. 
 
The base-promoted O-alkylation reaction of 71 and 74 with ethyl bromoacetate 
produced the ethers 72 and 75 in yields of 52% and 93%, respectively (Scheme 2.3). The 
known ether 72 exhibited spectroscopic data that were in agreement with those values 
reported previously.78 The intermediates 72 and 75 were then treated with 5-methyl-1-
hexyne in the presence of CuI/NaN3/Na.ascorbate and racemic trans-N,N'-
dimethylcyclohexane-1,2-diamine in DMSO and water (5:1) at 75 °C and gave esters 73 
and 76 in yields of 87% and 25%, respectively. In this one-pot azidation and copper 
catalyzed click reaction process, the diamine ligand assists in the azidation reaction by 
acting as a ligand for copper(I) or (II). The copper(I) then catalyzes the subsequent 
CuAAC reaction. Analysis of the 1H NMR spectra of esters 73 and 76 revealed 





corresponding 1,2,3-triazole protons. The molecular structures of compounds 73 and 76 
were further confirmed by the presence of the ion peaks at m/z 318.1831 and m/z 
368.1985, respectively, in the HRMS (ESI) assigned to the protonated molecular ions ([M 
+ H]+) (calculated for C17H24N3O3 318.1818 and C21H26N3O3 368.1974, respectively).  
The target acid 51 was realized in a yield of 62% from hydrolysis of the ester 73 
with 7% KOH solution in ethanol. The 1H NMR spectrum of 51 showed the characteristic 
resonance for the triazole proton at δH 8.20 (s, 1H). The C-5 carbon of the triazole ring 
resonated at δC 123.5 and was assigned by analysis of the gHSQC spectrum which showed 
a correlation of this resonance to the triazole proton (δH 8.20) (Figure 2.3). 
 
                
Figure 2.3: gHSQC spectrum of compound 51 (400 MHz, CDCl3). The one bond correlation  
between the triazole proton and C-5 is highlighted. 
 
The gHMBC spectrum analysis revealed that the resonance at δC 147.6 correlated 





   
            Figure 2.4: gHMBC spectrum of compound 51 (400 MHz, CDCl3). The two-bond correlations  
between the triazole proton and C-4, H-1''' and carbonyl carbon of COOH are highlighted. 
 
Further the resonance at δC 170.8 was assigned to the carbonyl carbon of 
carboxylic acid group as it correlated to the methylene protons (δH 4.77) of the acid side 
chain (Figure 2.4). The molecular structure of compound 51 was further established by 
the presence of an ion peak at m/z 290.1513 in the HRMS (ESI) that was assigned to the 
protonated molecular ion ([M + H]+) (calculated for C15H20N3O3 290.1505). 
The desired carboxylic acid 53 was realized in a yield of 85% from the hydrolysis 
of the ester 76 using 7% KOH solution in ethanol. The 1H NMR spectrum of 53 showed 
the characteristic singlet resonance of triazole proton at δH 7.67 which was correlated in 





      
Figure 2.5: gHSQC spectrum of compound 53 (400 MHz, CDCl3). The one bond correlation  
between the triazole proton and C-5 is highlighted. 
 
In the gHMBC spectrum, the resonance at δH 7.67 correlated to the resonance at 
δC 148.0 for C-4 (Figure 2.6), while the resonance at δC 170.4 was assigned to the carbonyl 
carbon of the carboxylic acid side chain as it correlated to the methylene protons that 





      
           Figure 2.6: gHMBC spectrum of compound 53 (400 MHz, CDCl3). The two-bond correlations  
           between the triazole proton and C-4, H-1''' and carbonyl carbon of COOH are highlighted. 
 
The molecular structure of compound 53 was further verified by the presence of 
an ion peak at m/z 340.1667 in the HRMS (ESI) that was assigned to the protonated 
molecular ion ([M + H]+) (calculated for C19H22N3O3 340.1661). 
 
2.1.1.3 – Synthesis of the carboxylic acid 52 
The acid 52 which possesses a 1,5-triazole ring, was synthesized from the 
aryliodide  72 in three steps (i) azidation, (ii) a ruthenium-catalysed click reaction by using 
Cp*RuCl(PPh3)2 (this catalyst is known to result in the formation of a 1,5-triazole; the 







Scheme 2.4 – Synthesis of acid 52 from the iodo ester 72 via an azidation of iodo ester 72, 
then Ru-catalysed [3 + 2] cycloaddition of azide 77, followed by ester hydrolysis of 78 to 
achieve the target acid 52. 
 
The azide 77 was synthesized in 70% yield by azidation of 72 (1.00 g, 3.26 mmol) 
in the presence of CuI/NaN3/ Na.ascorbate and racemic trans-N,N'-dimethylcyclohexane-
1,2-diamine in DMSO and water (5:1) at 80 °C (Scheme 2.4). Analysis of the 13C NMR 
spectrum revealed the resonance at δC 129.1 was assigned to the azide substituted carbon 
(C-N3) in 77, in contrast in the starting material 72 the analogous carbon (C-I) was 
assigned to a more shielded resonance at δC 86.5. This change in chemical shift supported 
the formation of the required azide 77 with additional evidence from the analysis of the 
FTIR spectrum and the assignment of an azide stretch to the band at νmax 2116 cm
-1. The 
molecular structure of compound 77 was further confirmed by the presence of an ion peak 
at m/z 244.0715 in the HRMS (ESI) that was assigned to the sodiated molecular ion ([M 
+ Na]+) (calculated for C10H11N3O3Na 244.0698). 
The azide 77 was treated with 5-methyl-1-hexyne in the presence of 
Cp*RuCl(PPh3)2





yield. Analysis of the 1H NMR spectrum of 78 showed the characteristic triazole 
resonance as a singlet at δH 7.56. This chemical shift was significantly upfield of that in 
its regioisomer 73 which resonated at δH 8.16, which is consistent with the deshielding 
effect of the N-aryl substituent in 73. The molecular structure of ester 78 was further 
verified by the presence of an ion peak at m/z 340.1638 in the HRMS (ESI) that was 
assigned to the sodiated molecular ion ([M + Na]+) (calculated for C17H23N3O3Na 
340.1637). The target acid 52 was synthesized in 78% yield from the base catalyzed 
hydrolysis of the ester 78 (Scheme 2.3). The 1H NMR spectrum of 52 showed the 
characteristic singlet resonance of the triazole proton at δH 7.56. The C-4 carbon of the 
triazole ring resonated at δC 131.1 and was assigned by analysis of the gHSQC spectrum 
which showed a correlation between this resonance and the triazole proton at δH 7.56 
(Figure 2.7). 
      
   Figure 2.7: gHSQC spectrum of compound 52 (400 MHz, CDCl3). The one bond correlation  





Analysis of the gHMBC spectrum of 52 displayed a resonance at δC 140.8 which 
correlated to δH 7.56, this was assigned to the C-5 carbon of the triazole. Further, the 
resonance at δC 170.0 was assigned to the carbonyl carbon of the carboxylic acid as it 
correlated to the methylene protons (δH 4.57) of the carboxylic acid side chain (Figure 
2.8).  
                              
            Figure 2.8: gHMBC spectrum of compound 52 (400 MHz, CDCl3). The two-bond correlations  
            between the triazole proton and C-5, H-1''' and carbonyl carbon of COOH are highlighted. 
 
The molecular structure of acid 52 was further verified by the presence of an ion 
peak at m/z 312.1329 in the HRMS (ESI) that was assigned to the sodiated molecular ion 
([M + Na]+) (calculated for C15H19N3O3Na 312.1324). 
Mechanism for the Ru-catalysed cycloaddition reaction: 
The Ru-catalysed click reaction requires the presence of a catalytic quantity of 





reaction to be successfully conducted in non-dried solvents under an inert atmosphere. 
The Ru-catalyzed azide−alkyne cycloaddition (RuAAC) is proposed to occur via 
formation of the Ru-complex A, which undergoes an oxidative coupling process to give 
the ruthenacycle B. In this step, first the new carbon−nitrogen bond is formed between 
the more electron rich carbon of the alkyne and the terminal, electrophilic nitrogen of the 











        
        Scheme 2.5: Mechanism of Ru-catalysed cycloaddition reaction 
 
A reductive elimination process then forms a ruthenated-triazole intermediate 
which upon hydrolysis gives the 1,5-disubstituted triazole product (Scheme 2.5). DFT 
calculations support this mechanistic proposal and indicate that the reductive elimination 





2.1.1.4 – Synthesis of the carboxylic acid 54 
The synthesis of acid 54 from the precursor 79 was accomplished in multiple steps 
involving (i) nitration, (ii) reduction, (iii) an azidation, (iv) Mg-promoted click reaction, 
(v) demethylation, (vi) O-alkylation and (vii) an ester hydrolysis (Scheme 2.6). 
Scheme 2.6 – Synthesis of acid 54 from 2-methoxynaphthalene 79 via nitration/reduction and azidation of 
starting material 79, then Mg promoted [3 + 2] cycloaddition and demethylation of azide 82, followed by 
O-alkylation and ester hydrolysis of 84 to achieve the target acid 54. 
 
The nitro intermediate 80 was synthesized in 22% yield from 2-
methoxynaphthalene 79 by nitration using HNO3 in acetic anhydride at -20 °C (Scheme 
2.6). Analysis of the 1H NMR spectrum of the nitro compound 80 displayed six proton 
resonances in the aromatic region, whereas precursor 79 displayed seven aromatic proton 





was absent in the 1H NMR spectrum of the nitro compound 80. The spectroscopic data 
were found to be in agreement with those previously reported.80  
Reduction of the nitro compound 80 was achieved by treatment with Fe in 
EtOH/AcOH/H2O
81 under sonication conditions at rt to achieve the amine 81 in 82% yield 
(Scheme 2.6). Analysis of the 1H NMR spectrum of amine 81 revealed a broad singlet 
resonance at δH 4.22 (2H) assigned to the -NH2 group. The spectroscopic data were found 
to be in agreement with those previously reported.81  
The azide 82 was isolated in 31% yield under Sandmeyer conditions from the 
amine 81 in the presence of NaNO2/NaN3 in 3 N HCl at rt (Scheme 2.6). Analysis of the 
1H NMR spectrum of azide 82 showed the disappearance of the broad singlet resonance 
at δH 4.22, which was assigned to the NH2 group of 81. Analysis of the 
13C NMR spectrum 
revealed a resonance at δC 122.4 assigned to the azide substituted carbon (C-N3) of 82, 
whereas the analogous carbon (C-NH2) of 81 was assigned to a more shielded resonance 
at δC 120.2. The molecular structure of azide 82 was further confirmed by the presence of 
an ion peak at m/z 172.0789 in the HRMS (ESI) that was assigned to the protonated 
molecular ion ([M + H – N2]
+) (calculated for C11H10NO 172.0762). 
Initially the azide 82 was treated with 5-methyl-1-hexyne in the presence of 
Cp*RuCl(PPh3)2 in 1,4-dioxane at 70 
°C for 12 h. This resulted in the formation of 1-
amino-2-methoxynaphthalene 81 in 16% yield, with none of the desired triazole product 
83 formed. It was speculated that 0.2 equivalents of PPh3 from the ruthenium catalyst 
resulted in the formation of the amine 81 via a Staudinger reaction on the azide group of 












Scheme 2.7– Attempted synthesis of the click product 83  
 
Proposed mechanism for the formation of 81: 
The proposed reaction mechanism proceeds through the formation of 
an iminophos- phorane 82a via nucleophilic addition of the triphenylphosphine to the 
terminal nitrogen atom of the azide and then exclusion of diatomic nitrogen to form 82b. 
The intermediate 82b undergoes hydrolysis to produce the amine 81 and 
triphenylphosphine oxide (Scheme 2.8). 
 









Following the failure of the Ru-catalyzed conditions to produce the 1,5-triazoles, 
attention turned to the Mg-promoted click reaction conditions.92 Therefore, following 
conditions reported by Sharpless92 the azide 82 was treated with chloromagnesium-5-
methyl-1-hexynilide (prepared in situ by treating 5-methyl-1-hexyne with EtMgCl) in dry 
THF at 50 °C to produce the triazole 83 in 81% yield (Scheme 2.6). Analysis of the 1H 
NMR spectrum of 83 showed the characteristic triazole singlet resonance at δH 7.71. The 
molecular structure of triazole 83 was further established by the presence of the ion peak 
at m/z 296.1750 in the HRMS (ESI) that was assigned to the protonated molecular ion 
([M + H]+) (calculated for C18H22N3O 296.1763). For further spectroscopic evidence for 
the formation of the 1,5-triazole regioisomer 83, please see discussion on page 123.  
 The O-demethylation of 83 was achieved by treatment with BBr3 in DCM 
at -78 °C to realize the naphthol 84 in 82% yield (Scheme 2.6). The 1H NMR spectrum of 
naphthol 84 displayed a broad singlet resonance at δH 10.31, which was assigned to the 
OH group. The molecular structure of compound 84 was further verified by the presence 
of an ion peak at m/z 282.1602 in the HRMS (ESI) that was assigned to the protonated 
molecular ion ([M + H]+) (calculated for C17H20N3O 282.1606).  
 The base-promoted O-alkylation of 84 with ethyl bromoacetate produced ester 85 
in 58% yield (Scheme 2.6). Subsequent hydrolysis of 85 using 7% KOH solution in 
ethanol produced the target acid 54 in 85% yield (Scheme 2.6). Analysis of the 1H NMR 
spectrum of 54 revealed the characteristic triazole proton resonance at δH 7.74 (s, 1H). 





gHSQC correlation of the triazole proton (δH 7.74) to the resonance at δC 131.4 (Figure 
2.9). 
    
 Figure 2.9: gHSQC spectrum of compound 54 (400 MHz, CDCl3). The one bond correlation  
 between the triazole proton and C-4 is highlighted. 
 
 
The gHMBC spectrum allowed the assignment of the resonance δC 141.4 to the 
quaternary C-5 carbon of the triazole (Figure 2.10), while the resonance of the carbonyl 
carbon of the carboxylic acid at δC 170.0 correlated to the methylene protons (δH 4.72) of 





     
            Figure 2.10: gHMBC spectrum of compound 54 (400 MHz, CDCl3). The two-bond correlations  
            between the triazole proton and C-5, H-1''' and carbonyl carbon of COOH are highlighted. 
 
The molecular structure of compound 54 was further confirmed by the presence 
of an ion peak at m/z 340.1666 in the HRMS (ESI) that was assigned to the protonated 
molecular ion ([M + H]+) (calculated for C19H22N3O3 340.1661). 
Mechanism for the Mg-promoted cycloaddition reaction: 
The accepted mechanism (Scheme 2.9) starts with the formation of 
chloromagnesium acetylide by treatment of the alkyne with EtMgCl. Then nucleophilic 
addition of the acetylide to the terminal nitrogen atom of the azide occurs, followed by 
spontaneous five membered ring closure to the chloromagnesium-4-metallotriazole 
species. Hydrolysis of this species then gives the 1,5-disubstituted triazole product, which 
is regioisomeric with the product formed using the Cu-catalysed azide-alkyne 





      
 
Scheme 2.9: Proposed mechanism of Mg-promoted cycloaddition reaction 
 
2.1.1.5 – Synthesis of the carboxylic acid 55 
The synthesis of acid 55 from precursor 86 was accomplished in multiple steps 
involving (i) azidation, (ii) an O-alkylation, (iii) Mg-promoted click reaction, (iv) THP 
deprotection, (v) an O-alkylation and (vi) an ester hydrolysis (Scheme 2.10). 
 
Scheme 2.10 – Synthesis of acid 55 from 2-aminophenol 86 via an azidation, O-alkylation 
and Mg promoted [3 + 2] cycloaddition of 86, then THP deprotection and O-alkylation of 






The azide 87 was isolated in 60% yield following a Sandmeyer reaction on 2-
aminophenol 86 in the presence of NaNO2/NaN3 in 3 N HCl at rt (Scheme 2.10). The 
spectroscopic data of 87 were found to be in agreement with those previously reported.79  
The base-promoted O-alkylation of azide 87 with 1-bromo-3-methylbutane was 
achieved with K2CO3 in dry DMF at rt (Scheme 2.10) and produced the ether 88 in 84% 
yield. The ether 88 was treated with the chloromagnesium acetylide formed from the 
reaction of tetrahydro-2-(2-propynyloxy)-2H-pyran (1.1 eq) with EtMgCl in dry THF at 
50 °C to achieve the triazole 89 in 55% yield (Scheme 2.10). The 1H NMR spectrum of 
89 displayed the characteristic resonance of the triazole ring proton at δH 7.76 (s, 1H). The 
molecular structure of compound 89 was further established by the presence of an ion 
peak at m/z 368.1964 in the HRMS (ESI) that was assigned to the sodiated molecular ion 
([M + Na]+) (calculated for C19H27N3O3Na 368.1950). 
The THP deprotection of 89 was achieved using p-toluenesulfonic acid. 
monohydrate in MeOH at rt to obtain the alcohol 90 in 80% yield (Scheme 2.10). Analysis 
of the 1H NMR spectrum of 90 showed a characteristic broad singlet resonance at δH 3.95, 
which was assigned to the hydroxy group of the newly formed alcohol 90. The molecular 
structure of compound 90 was further verified by the presence of an ion peak at m/z 
284.1393 in the HRMS that was assigned to the sodiated molecular ion ([M + Na]+) 
(calculated for C14H19N3O2Na 284.1375). 
The base-promoted an O-alkylation of 90 with ethyl bromoacetate produced ester 
91 in 69% yield (Scheme 2.10). The desired carboxylic acid 55 was realized in 81% yield 





characteristic singlet resonance for the triazole proton at δH 7.88 which was correlated in 
the gHSQC spectrum to the resonance at δC 132.7 which was assigned to C-4 (Figure 
2.11). 
    
 Figure 2.11: gHSQC spectrum of compound 55 (400 MHz, CDCl3). The one bond correlation  
 between the triazole proton and C-4 is highlighted. 
 
In the gHMBC spectrum, the resonance at δH 7.88 correlated to the resonance at 
δC 135.7 which was assigned to the quaternary C-5 carbon (Figure 2.12), while the 
resonance at δC 173.1 was assigned to the carbonyl carbon of the carboxylic acid as it 





    
            Figure 2.12: gHMBC spectrum of compound 55 (400 MHz, CDCl3). The two-bond correlations  
            between the triazole proton and C-5, H-1''' and carbonyl carbon of COOH are highlighted. 
 
The molecular structure of acid 55 was further confirmed by the presence of an 
ion peak at m/z 320.1603 in the HRMS (ESI) that was assigned to the protonated 
molecular ion ([M + H]+) (calculated for C16H22N3O4 320.1610). 
 
2.1.2 – Synthesis of the N-protected β-azidoamines 
2.1.2.1 – Synthesis of the N-protected β-azidoamine 56 
The synthesis of β-azidoamine 56 from commercially available Fmoc-(D)-
Arg(Pbf)-OH 92 was achieved by carboxylic acid reduction, iodination and subsequent 







Scheme 2.11 – Synthesis of the azide 56 from the arginine precursor 92 via reduction of the 
carboxylic acid 92 to give alcohol 93, followed by iodination and then azidation/N-
deprotection to furnish target azide 56. 
 
Reduction of the precursor acid 92 was achieved via the mixed anhydride formed 
by the treatment of the acid 92 with isobutyl chloroformate and N-methylmorpholine 
which upon NaBH4 reduction gave the alcohol 93 in 73% yield. The alcohol was iodinated 
with I2/PPh3/imidazole in CH2Cl2; this step was followed by an azidation reaction at rt 
and a N-Fmoc deprotection at 50 °C with NaN3 in DMF to give the target β-azidoamine 
56 in 80% yield over the two steps (Scheme 2.11). Compound 56 exhibited spectroscopic 
data that were in agreement with those reported previously.47 
 
Mechanism for the formation of 56: 
The reaction mechanism starts with the formation of the iodo phosphonium salt 
which reacts with the alcohol 93 to give the triphenyloxyphosphonium salt 93a. 
The nucleophilic displacement of this intermediate 93a by an iodide anion produces the 
iodide 93b (Scheme 2.12) and triphenylphosphine oxide. Further nucleophilic 
displacement of the intermediate 93b by azide anion produces the corresponding azide 





proton (on the β-carbon) of the Fmoc group by azide to give the resonance stabilized 14π 
– aromatic anion 93c. This stabilized anion 93c then triggers the departure 




Scheme 2.12 – Mechanism for the β-azido-amine 56 formation 
 
2.1.2.2 – Synthesis of N-protected β-azidoamine 57 
The synthesis of doubly N-protected β-azidoamine 57 was achieved via a peptide 
coupling reaction of β-azidoamine 56 with commercially available Fmoc-L-Lys(Boc)-OH 







Scheme 2.13 – Synthesis of azide 57 from amine 56 via peptide coupling of amine 56 with 
Fmoc-L-Lys(Boc)-OH 94 to give compound 95, followed by Fmoc deprotection of 95 to 
furnish target azide 57 
  
The peptide coupling of β-azidoamine 56 with Fmoc-L-Lys(Boc)-OH 94 in the 
presence of HOBt/EDC.HCl and triethylamine in DCM at rt gave product 95 in 54% yield. 
The intermediate 95 was then subjected to deprotection with piperidine in MeOH at rt to 
give the target azide 57 in 71% yield. Furthermore, a traditional acid/base work-up 
procedure was utilized to purify the β-azidoamine 57 product instead of flash 
chromatography, which led to a substantially increased overall yield from the literature 
value of 64 % to 71% and a significantly easier isolation procedure (Scheme 2.13). 
Compound 57 exhibited spectroscopic data that were in agreement with those reported 
previously.47 
 
Mechanism of peptide coupling: 
Amide bonds are typically constructed from the union of carboxylic acids and 
amines. However, the unification of these two functional groups does not occur 
spontaneously at ambient temperature with the necessary elimination of water only taking 
place at high temperatures (e.g. >200 °C). The higher temperature conditions are typically 





peptide coupling reagents such as HOBt (1-hydroxy-1H-benzotriazole) and EDCI [1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride)] are necessary for amide 
bond formation under mild reaction conditions.70-71 Initially the EDCI activates the 
carboxylic acid as an O-acylisourea intermediate by the reaction of the carboxylate anion 
with EDCI. Then the O-acylisourea reacts with the precursor amine to produce the 
required amide product (Scheme 2.14). A side reaction is also possible by the activated 
O-acylisourea undertaking an intramolecular acyl transfer to provide an inactive N-
acylurea by-product (Scheme 2.14 – red route),70-72 that consumes the acid without 









Scheme 2.14 – Mechanism of EDCI/HOBt promoted amide coupling: both the 






The nucleophilic additive HOBt is added to prevent this side reaction.70-72 The 
active O-acylisourea reacts with HOBt to produce an HOBt ester (Scheme 2.14 – blue 
route) that quickly undergoes aminolysis by reacting with the precursor amine to give the 
desired product amide.70-71  
 
2.2 – Synthesis of the N-protected azides 1 – 11 
2.2.1 – Synthesis of the azides 58, 60 and 62  
The target azides 58, 60 and 62 were achieved in 58 – 69% yield from the coupling 
reaction of the acids 50 – 52 and the β-azidoamine 56 in the presence of HOBt/EDC.HCl 
and triethylamine in DCM at rt for 16 h (Scheme – 2.15). 
 






The 1H NMR spectrum of the azide 58 displayed a broad singlet resonance at δH 
7.51 for the CONH group and the resonance at δC 169.6 was assigned to the carbonyl 
carbon of the new amide group based on the gHMBC correlation of this resonance with 
that of the NH proton. The molecular structure of compound 58 was verified by the 
presence of an ion peak at m/z 751.3108 in the HRMS (ESI) that was assigned to the 
sodiated molecular ion ([M + Na]+) (calculated for C36H44N10O5SNa 751.3109). The other 
azides 60 and 62 in Scheme 2.15, was also fully characterized by NMR and HRMS 
analysis. 
 
2.2.2 – Synthesis of the azides 59, 61 and 63  
The azides 59, 61 and 63 were isolated in 49-78% yield from the coupling reaction 
of the acids 50 – 52 with the β-azidoamine 57 (Scheme – 2.16). 





The structure of 59 was evident from the broad singlet resonance at δH 8.98 for the 
α-CONH group and the resonance at δC 165.5 was assigned to the carbonyl carbon of the 
new amide group based on the gHMBC correlation of this resonance with that of the NH 
proton. The molecular structure of compound 59 was further confirmed by the presence 
of an ion peak at m/z 979.4587 in the HRMS (ESI) that was assigned to the sodiated 
molecular ion ([M + Na]+) (calculated for C47H64N12O8SNa 979.4583). The other azides 
61 and 63 in Scheme 2.16, were also fully characterized by NMR and HRMS analysis. 
 
2.2.3 – Synthesis of the azides 64 and 66 
The required azides 64 and 66 were obtained in yields 66 and 67%, respectively 
from the coupling reaction of the acid 53 and 54 with the β-azidoamine 56 (Scheme – 
2.17). 
 






In the 1H NMR spectrum of the azide 64 showed a broad singlet resonance at δH 
6.66 which was assigned to the CONH group and the resonance at δC 167.5 was assigned 
to the carbonyl carbon of the new amide group based on their gHMBC correlations. The 
molecular structure of compound 64 was further established by the presence of an ion 
peak at m/z 781.3620 in the HRMS (ESI) that was assigned to the sodiated molecular ion 
([M + Na]+) (calculated for C38H50N10O5SNa 781.3584). The other azide 66 in Scheme 
2.17, was also fully characterized by NMR and HRMS analysis. 
 
2.2.4 – Synthesis of the azides 65 and 67   
The coupling reaction of the acids 53 and 54 with the β-azidoamine 57 resulted in 
yields 64 and 67%, respectively of the azides 65 and 67 (Scheme – 2.18). 
          
              





The structure of 65 was evident from the broad singlet resonance at δH 6.85 for the 
α-CONH group. The 13C NMR spectrum showed a resonance at δC 168.1 which was 
assigned to the carbonyl carbon of the new amide group. The molecular structure of 
compound 65 was verified by the presence of an ion peak at m/z 987.5272 in the HRMS 
(ESI) that was assigned to the protonated molecular ion ([M + H]+) (calculated for 
C49H71N12O8S 987.5239). The other azide 67 in Scheme 2.18, was also fully characterized 
by NMR and HRMS analysis 
 
2.2.5 – Synthesis of the azide 68  
The azide 68 was isolated in 70% yield from the coupling reaction of the acid 55 
with the β-azidoamine 57 (Scheme – 2.19). 
       Scheme 2.19 – Synthesis of the azide 68 from the acid 55 via peptide coupling  
The 1H NMR spectrum of 68 displayed a broad singlet resonance at δH 6.97 for the 
α-CONH group. The 13C NMR spectrum showed a resonance of the new amide carbonyl 
group at δC 169.1 was assigned based on their gHMBC correlations. The molecular 
structure of compound 68 was verified by the presence of an ion peak at m/z 989.5029 in 
the HRMS (ESI) that was assigned to the sodiated molecular ion ([M + Na]+) (calculated 






2.3 – Synthesis of derivatives 
2.3.1 – Synthesis of the monocationic derivatives  
The derivatization of the monocationic amino acid derivatives 21 – 34 required a 
two-step transformation – installation of the terminal triazole moieties by using the azides 
58, 60, 62, 64, 66 and alkynes via a CuAAC reaction, followed by N-Pbf group cleavage 
with CH2Cl2/H2O/TFA.  
 
Synthesis of the derivative 21 from the azide 58: 
The hydrochloride salt derivative of 21 was synthesized in 43% yield over the two 
steps from the reaction of azide 58 with 3-cyclohexyl-1-propyne, CuSO4∙5H2O and 
sodium ascorbate in t-BuOH/H2O at rt for 16 h (Scheme 2.20). The N-protected triazole 
derivative so obtained was then subjected to N-Pbf deprotection with TFA and 20 
equivalents of H2O in CH2Cl2 at rt for 16 h followed by the treatment of the resulting TFA 







Scheme 2.20 – Derivatization of the azide 58 via installation of the terminal triazole moiety followed 
by deprotection of the N-Pbf side chain protecting group to give derivative 21 as hydrochloride salt       
 
The 1H NMR spectrum of derivative 21 displayed characteristic resonances that 





2.36 – 2.24 (2H; CH2Cy) and cyclohexyl multiplet resonances at δH 1.84 – 1.40, δH 1.16 
– 1.02 and δH 0.88 – 0.78). Importantly, the 
1H NMR spectrum of 21 showed two singlet 
resonances that were assigned to the two triazole ring protons at δH 8.59 (H5) and δH 7.98 
(Hα). These proton resonances correlated to the carbon resonances at δC 131.2 (C-5) and 
δC 125.4 (C-α), respectively. The carbon resonances at δC 145.8 (C-4) and δC 131.3 (C-β) 
were assigned to the quaternary carbons of the triazole rings based on the gHMBC 
correlations of these carbon resonances to those of their triazole ring protons [δH 8.59 (H5) 
and δH 7.98 (Hα)], respectively. The arginine peptide chain was confirmed from the 
gHMBC correlations of H-1' proton (δH 4.74) with carbon resonances C-2' (δC 50.7), C-3' 
(δC 29.9) and C-α (δC 125.4), respectively. The H-2' proton (δH 4.48-4.42) correlated with 
carbon resonances C-1' (δC 56.2), C-3' (δC 29.9) and C-4' (δC 26.4). Furthermore, H-5' 
proton (δH 3.22-3.12) correlated with carbon resonances C-3' (δC 29.9), C-4' (δC 26.4) and 
guanidine C=N (δC 158.7). The successful N-Pbf deprotection was clearly seen by the lack 
of five characteristic Pbf singlet methyl resonances in the 1H NMR spectrum of derivative 
21. The molecular structure of the derivative 21 was further confirmed by the appearance 
of the ion peak at m/z 599.3562 in the HRMS (ESI) that was assigned to the protonated 
molecular ion [M – HCl + H]+ (calculated for C32H43N10O2 599.3565). 
 
Synthesis of the derivatives 22 – 28 from the azides 60 and 62: 
The derivatives 22 – 28 (Scheme 2.21) were realized in yields ranging from 53 – 
57% over the two steps from the azides 60 and 62 by reaction with their respective alkynes, 





derivatives so obtained were then subjected to N-Pbf deprotection with TFA and 20 
equivalents of H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal HCl 






















Scheme 2.21 – Derivatization of the azides 60 and 62 via installation of the terminal triazole moiety 
followed by deprotection of the N-Pbf side chain protecting group to give derivatives 22 – 28 as 
hydrochloride salts 
 
The 1H NMR spectrum of the derivative 22 showed characteristic resonances 
(11H) that were assigned to the cyclohexyl group at δH 1.86 – 1.50 (m, 6H) and δH 1.48 – 
1.20 (m, 5H). Importantly, the gHSQC spectrum of 22 showed that the two singlet 
resonances assigned to the two triazole ring protons at δH 8.46 (H5) and δH 8.36 (Hα) were 
correlated to the carbon resonances at δC 125.9 (C-5) and δC 125.3 (C-α), respectively. 
The 13C NMR spectrum showed the resonances at δC 147.9 (C-β) and δC 132.8 (C-4) were 





these resonances to those of their triazole ring protons [δH 8.46 (H5) and δH 8.36 (Hα)], 
respectively. The deprotection of N-Pbf was clearly seen by the lack of five characteristic 
Pbf singlet methyl resonances in the 1H NMR spectrum of 22. The molecular structure of 
the derivative 22 was established by the appearance of the ion  peak at m/z 565.3731 in 
HRMS (ESI) that was assigned to the protonated molecular ion [M – HCl + H]+ 
(calculated for C29H45N10O2 565.3727). The other derivatives 23 – 28 in Scheme 2.21, 
were also fully characterized by NMR and HRMS analysis.  
 
Synthesis of the derivatives 29 – 34 from the azides 64 and 66: 
The derivatives 29 – 34 (Scheme 2.22) were prepared in yields ranging from 51 – 
72% over the two steps from the azides 64 and 66 by reaction with their respective 
alkynes, CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-
protected triazole derivatives so obtained were then subjected to N-Pbf deprotection with 
TFA and 20 equivalents of H2O in CH2Cl2 at rt for 16 h followed by the treatment with 
ethereal HCl and purification by precipitation. 
The 1H NMR spectrum of the derivative 29 displayed characteristic resonances 
(11H) for the cyclohexyl group, a singlet resonance at δH 2.72 (1H), and multiplet 
resonances at δH 1.79 – 1.57 (5H) and δH 1.20 – 1.16 (5H). The gHSQC spectrum of 29 
showed that the two singlet resonances assigned to the two triazole ring protons at δH 8.36 
(H5) and δH 8.18 (Hα) were correlated to the carbon resonances at δC 125.7 (C-5) and δC 
125.2 (C-α), respectively. The gHMBC spectrum allowed the assignment of the 





















Scheme 2.22 – Derivatization of the azides 64 and 66 via installation of the terminal triazole moiety 
followed by deprotection of the N-Pbf side chain protecting group to give derivatives 29 – 34 as 
hydrochloride salts 
 
The molecular structure of the derivative 29 was further verified by the appearance 
of the ion peak at m/z 615.3877 in HRMS (ESI) that was assigned to the protonated 
molecular ion, [M – HCl + H]+ (calcd for C33H47N10O2 615.3886). The other derivatives 
30 – 34 in Scheme 2.22, were also fully characterized by NMR and HRMS analysis.  
The derivatives 32 – 34 displayed amide rotamers (i.e. anti and syn) which were 
evident by the presence of smaller, additional resonances in their 1H and 13C NMR spectra. 
 
Rotamers: 
Single C–N bonds that are connected to an adjacent carbon–heteroatom double 





to the delocalization of the nitrogen’s lone pair of electrons; this leads to restricted rotation 
of the C–N bond. If the energy barrier to rotation is high, two distinct rotameric 
conformations will be generated (i.e. anti- and syn-rotamers – Figure 2.13), with the anti-






   
Figure 2.13 – Generic anti- and syn-rotamers  
 
2.3.2 – Synthesis of the dicationic derivatives  
The derivatization of the dual-amino acid derivatives 35 – 49 required a two-step 
transformation – installation of the terminal triazole moieties by using the azides 59, 61, 
63, 65, 67, 68 and respective alkyne intermediates via a CuAAC reaction, followed by 
side chain N-deprotection of the N-Pbf and N-Boc groups with CH2Cl2/H2O/TFA.  
 
Synthesis of the derivatives 35 – 36 from the azide 59: 
The derivatives 35 and 36 (Scheme 2.23) were realized in yields of 55% and 57%, 
respectively over the two steps from the azide 59 by reaction with respective alkynes, 
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole 
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and 
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal 






















Scheme 2.23 – Derivatization of the azide 59 via installation of the terminal triazole moiety followed by 
deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 35 and 36 as 
hydrochloride salts 
 
The 1H NMR spectrum of the derivative 35 showed a resonance for the methylene 
of the benzyl unit as a singlet resonance at δH 4.03 (2H) and a multiplet resonance for the 
phenyl group at δH 7.50 – 7.14 (5H). The gHSQC spectrum of 35 showed that the two 
triazole ring protons at δH 8.74 (H5) and δH 8.23 (Hγ) correlated to the carbon resonances 
at δC 130.0 (C-5) and δC 128.1 (C-γ), respectively. The carbon resonances at δC 143.1 (C-
4) and δC 130.3 (C-δ) were assigned to the quaternary carbons of the triazoles based on 
the gHMBC correlations of these resonances to those of their respective triazole ring 
protons [δH 8.74 (H5) and δH 8.23 (Hγ)]. The arginine peptide chain was confirmed from 
the gHMBC correlations of H-1' proton (δH 4.78) with carbon resonances C-2' (δC 50.9), 





with carbon resonances C-1' (δC 57.2), C-3' (δC 29.7) and C-4' (δC 26.4). Furthermore, the 
H-5' proton (δH 2.92-2.84) correlated with carbon resonances C-3' (δC 29.7), C-4' (δC 26.4) 
and guanidine C=N (δC 158.7).   
The protons and carbons of the lysine peptide chain were assigned based on 
analysis of the gHMBC spectrum which showed correlations of the Lys5 proton (δH 4.46-
4.32) to carbon resonances Lys4 (δC 32.4), Lys3 (δC 24.3) and βC=O (δC 174.5). 
Furthermore, the Lys3 proton (δH 0.94-0.86) correlated to carbon resonances Lys1 (δC 
40.7), Lys2 (δC 28.1) and Lys4 (δC 32.4). The molecular structure of the derivative 35 was 
further confirmed by the appearance of the ion peak at m/z 721.4046 in HRMS (ESI) that 
was assigned to the protonated molecular ion, [M – 2HCl + H]+ (calculated for 
C38H49N12O3 721.4045). The other derivative 36 in Scheme 2.23, was also fully 
characterized by NMR and HRMS analysis.  
 
Synthesis of the derivatives 37 – 40 from the azides 61 and 63: 
The derivatives 37 – 40 (Scheme 2.24) were realized in yields ranging from 56 – 
98% over the two steps from the azides 61 and 63 by reaction with respective alkynes, 
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole 
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and 
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal 




















Scheme 2.24 – Derivatization of the azides 61 and 63 via installation of the terminal triazole moiety 
followed by deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 37 – 40 
as hydrochloride salts 
 
The 1H NMR spectrum of the derivative 37 displayed characteristic resonances that 
were assigned to the methylene protons of the benzyl unit i.e., a singlet resonance at δH 
4.12 (2H) and the multiplet resonances of the phenyl at δH 7.32 – 7.20 (5H). The gHSQC 
spectrum of 37 showed that the two singlet resonances assigned to the two triazole ring 
protons at δH 8.54 (H5) and δH 8.12 (Hγ) were correlated to the carbon resonances at δC 
126.2 (C-5) and δC 125.9 (C-γ), respectively. The gHMBC spectrum allowed the carbon 
resonances at δC 137.5 (C-δ) and δC 133.5 (C-4) to be assigned to the quaternary carbons 
of the triazoles. The molecular structure of the derivative 37 was verified by the 





protonated molecular ion, [M + H]+ (calcd for C36H55N12O3Cl2 773.1236). The other 
derivatives 38 – 40 in Scheme 2.24, were also fully characterized by NMR and HRMS 
analysis.  
 
Synthesis of the derivatives 41 – 46 from the azides 65 and 67: 
The derivatives 41 – 46 (Scheme 2.25) were realized in yields ranging from 46 – 
55% over the two steps from the azides 65 and 67 by reaction with respective alkynes, 
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole 
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and 
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal 
HCl and purification by precipitation. 
The 1H NMR spectrum of the derivative 41 showed characteristic resonances (11H) 
that were assigned to the cyclohexyl group at δH 2.84 – 2.78 (m, 1H), δH 1.74 – 1.60 (m, 
5H) and δH 1.48 – 1.21 (m, 5H). The gHSQC spectrum showed that the two singlet 
resonances which were assigned to the two triazole ring protons at δH 8.30 (H5) and δH 
8.29 (Hγ) correlated to the carbon resonances at δC 125.5 (C-5) and δC 125.1 (C-γ), 
respectively. The carbon resonances at δC 148.7 (C-4) and δC 147.6 (C-δ) were assigned 























Scheme 2.25 – Derivatization of the azides 65 and 67 via installation of the terminal triazole moiety 
followed by deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 41 – 46 
as hydrochloride salts 
 
The molecular structure of the derivative 41 was further established by the 
appearance of the ion peak at m/z 743.4866 in HRMS (ESI) that was assigned to the 
protonated molecular ion, [M – 2HCl + H]+ (calcd for C39H59N12O3 743.4833). The other 
derivatives 42 – 46 in Scheme 2.25, were also fully characterized by NMR and HRMS 
analysis. The derivatives 44 – 46 also displayed amide rotamers (i.e. anti and syn) which 







Synthesis of the derivatives 47 – 49 from the azide 68: 
The derivatives 47 – 49 (Scheme 2.26) were realized in yields ranging from 51 – 
83% over the two steps from the azide 68 by reaction with respective alkynes, 
CuSO4∙5H2O and sodium ascorbate in t-BuOH/H2O at rt for 16 h. The N-protected triazole 
derivatives so obtained were then subjected to N-Boc/N-Pbf deprotection with TFA and 
20 equivalents of the H2O in CH2Cl2 at rt for 16 h followed by the treatment with ethereal 
















Scheme 2.26 – Derivatization of the azide 68 via installation of the terminal triazole moiety followed by 
deprotection of the N-Pbf and N-Boc side chains protecting groups to give derivatives 47 – 49 as 
hydrochloride salts 
 
The 1H NMR spectrum of 47 showed characteristic resonances (11H) for the 





The 1H NMR spectrum of 47 showed two overlapping singlet resonances at δH 8.05 (H4 
and Hγ) which were assigned to the two triazole ring protons from their correlations to 
the carbon resonances at δC 128.4 and δC 120.61. The carbon resonances at δC 132.06 (C-
5) and 132.02 (C-δ) were assigned to the two quaternary carbons of the triazoles, however 
they could not be individually assigned as they could not be distinguished in the HMBC 
spectrum as both triazole protons had the same chemical shift (δH 8.05). The molecular 
structure of the derivative 47 was confirmed by the appearance of the ion peak at m/z 
723.4810 in HRMS (ESI) that was assigned to the protonated molecular ion, [M – 2HCl 
+ H]+ (calcd for C36H59N12O4 723.4782). The other derivatives 48 and 49 in Scheme 2.26, 
were also fully characterized by NMR and HRMS analysis.  
 
Mechanism of N-Boc deprotection: 
The N-Boc group is particularly sensitive to acids and often uses TFA as the 
deprotection agent producing the required free amine and by-products i.e. 2-methyl-1-
propene and CO2 (Scheme 2.27).
61 The acidic deprotection mechanism starts with 
protonation of the carbonyl oxygen of carbamate followed by heterolytic cleavage of the 
bond between O–C(CH3)3 to produce the carbamic acid and the stable t-butyl carbocation 
(Scheme 2.27) that is converted into 2-methyl-1-propene after proton abstraction by 
trifluoroacetate anion. Decomposition of the carbamic acid proceeds spontaneously via 
protonation of carbamic acid nitrogen to give the free amine product which rapidly 
rotonates with excess TFA and CO2 as volatile by product.
61 The overall reaction time is 






Scheme 2.27 – N-Boc deprotection with TFA to produce the required product amine (red)  
and by-products (blue) 
 
Mechanism of N-Pbf deprotection: 
The deprotection of N-Pbf group in the presence of acid requires a longer reaction 
time compared to N-Boc deprotection and an electrophile SO3 scavenger, in this case H2O 
is needed to control the formation of unwanted products via reaction with SO3.
68  
The deprotection of N-Pbf (Scheme 2.28) starts with protonation of the guanidino 
nitrogen followed by heterolytic cleavage of the N – S bond to produce the required 
guanidine as the TFA salt and byproduct arylsulfonyl cation.66, 68-69 The arylsulfonyl 
cation reacts with the trifluoroacetate anion to form an intermediate, followed by 
protonation, with hydrolysis initiating decomposition to produce 2,2,4,6,7-
pentamethyldihydrobenzo[b]furan and SO3.
68-69 The electrophile SO3 can reacts with the 
deprotected guanidine residue and form a sulfamic acid compound,67 therefore water as a 
scavenger is required to stop the formation of sulfamic acid. The overall reaction times 





Acidic conditions were needed for the deprotection of both the N-Boc and N-Pbf 
protecting groups to produce the crude TFA-amine salt after evaporation of the reaction 
mixture solvent, followed by anion exchange with anhydrous HCl in diethyl ether to 
obtain final derivatives as HCl salt for antibacterial screening. The final HCl salts needed 















Scheme 2.28 – Deprotection of the N-Pbf group to produce product guanidine (red) and by-products 
(pink). 
  
In conclusion, a total of 29 novel antibacterial compounds were synthesized and 
fully characterized. The synthesis of these derivatives involved the synthesis of 96 
intermediate compounds (i.e. 87 novel intermediate compounds and 9 known compounds) 





cycloaddition reaction,  Ru-catalyzed cycloaddition reaction, Mg-promoted cycloaddition 




















3.0 – Biological and pharmacological assays: results and discussion 
3.1 – Background information  
This chapter reports the results of the in vitro, in vivo and pharmacological assays 
performed on the deprotected phenyltriazole and naphthalenetriazole peptide derivatives, 
as their HCl-salts, which were described in Chapter 2. These compounds were screened 
in three stages (Figure 3.1). 
 
      
        Figure 3.1 – Summary of the biological screening process used to ascertain antimicrobial activity 
 
Primary antibacterial testing: 
Primary antibacterial testing (in vitro MIC assays) against Gram-positive bacteria 
including C. difficile (Figure 3.1) was performed with project collaborators at the 
University of Western Australia.†  
Secondary antibacterial testing: 
Secondary antibacterial testing (in vitro MIC assays) against Gram-negative 
bacteria including fungi (Figure 3.1) and a cytotoxicity assay was performed by CO-
ADD.#  
   _____________________________ 
                    †
 Prof. Thomas V. Riley, Dr. Katherine A. Hammer and Dr. Dan Knight.
 
             # Community for Open Antimicrobial Drug Discovery (www.co-add.org) – funded by the Wellcome Trust  






C. difficile screening: 
Compounds that displayed significant MIC values in the primary and secondary 
testing stages were moved to third round in vitro MIC testing against the hypervirulent C. 
difficile strain (RT027 – M7404) with project collaborators at Monash University.§ The 
compounds that performed best in vitro were then selected for testing in an in vivo murine 
model of CDI to determine the efficacy and viability of the compound as a potential CDI 
inhibitor (Figure 3.1). 
3.2 – Bacterial species used for In vitro assays (MIC) 
The MIC assays were performed against four Gram-positive, or four Gram-
negative bacterial species and two fungal species. 
Gram +ve Bacterial Species        Primary      Secondary  C. difficile 
    Screening (UWA)  Screening (CO-ADD)   screening (Monash)             
Staphylococcus aureus       ATCC 29213  -           - 
                NCTC 10442 (MRSA) ATCC 43300 (MRSA)            -                                     
Clostridium difficile      ATCC 700057               -             M7404 (RT027)  
                           NSW132 (RT027)           
 Enterococcus faecalis       ATCC 29219             -           - 
Streptococcus pneumoniae      ATCC 49619             -           -  
  
Gram -ve Bacterial Species    
Escherichia coli       ATCC 25922   ATCC 25922          - 
 Klebsiella pneumoniae               -  ATCC 700603 (MDR)           -  
 Acinetobacter baumannii              -    ATCC 19606          - 
 Pseudomonas aeruginosa                     -    ATCC 27853                     - 
 
Fungal Species 
 Candida albicans     -        ATCC 90028          - 
 Cryptococcus neoformans    -                      ATCC 208821          - 
 
  Table 3.1 – Bacterial and fungal species that were tested against in the various in vitro MIC assays 
____________________________ 





The compounds were screened against these bacterial pathogens and fungi to 
measure their broad-spectrum antimicrobial activity i.e. activity against five of the six 
ESKAPE pathogens5 (i.e. Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) 
and their activity against C. difficile strains to find potential CDI inhibitors. 
 
3.2.1 – General methodology for in vitro assays and cytotoxicity assays 
In vitro assays: For primary antibacterial screening, multi-well micro-titer plates were 
loaded with immunized and developed medium and different concentrations of the 
compounds to be tested. Testing concentrations of the compounds ranged from 0.125 
μg/mL to 128 μg/mL in DMSO were typically utilized. The plates were cultured, and the 
resultant bacterial growth inhibition was determined.    
For testing at CO-ADD, initially only one concentration i.e. 32 μg/mL of every 
compound was analyzed to verify antimicrobial potency. Compounds that exhibited 
potency at this concentration then progressed to a comprehensive MIC test. Colistin and 
vancomycin were utilized as positive controls for both Gram-positive and Gram-negative 
bacteria. Fluconazole was used as the positive control for fungi.  
 
Cytotoxicity assays: The cytotoxicity of every compound was evaluated at CO-ADD 
against human embryonic kidney cells (HEK-293 – ATCC CRL – 1573) by using 





inhibit kidney cell growth by 50% (CC50). The experimental procedures for the various 
MIC tests and cytotoxicity test are discussed in Section 6.4.1. 
 
3.2.2 – SAR trends (MIC assay results from UWA and Monash) 
 
Twenty-nine compounds were prepared from 11 distinctive scaffolds. In the SAR 
analysis, the antibacterial activity of the twenty-nine derivatives were compared against 
the antibacterial activity of AVX 13616 (lead compound 1) and the previously synthesized 





















                  





                
               
      _______________________________________________________________           
                        E.           S. E. 
     ipentyl            S. aureus      faecalis pneumoniae coli        C. difficile 
        Compound      R      position     ATCC  NCTC   ATCC      ATCC   ATCC   ATCC      132 
                                       29213  10442      29212        49619    25922    700057   (RT027) 
       __________________________________________________________________________ 
          
              1            -              -     2          2      2           2          16           8   16 
     18       Cy            -    2    4      2           4           8           16   16 
            19       CH2Cy        -               4    4      4           8           8           32   16 
           20          Bn            -               2    4      4           2           8           16   16 
            41          Cy         C-4   16   16     32          16         64           8    8 
     42      CH2Cy      C-4              8     8      8          16        128         16   16 
            43          Bn         C-4    8    8            8           8          32           8    8 
            44          Cy         C-5            16   16     64           4          64         128  128 
     45      CH2Cy      C-5              8    4     16           4          64          32   32 
            46          Bn         C-5   16   16     64           4         128        128  128 
       Vancomycin   -           -                1    1      4           1         >16         0.5   0.5 
       __________________________________________________________________________ 
        
  Table 3.2 – Primary screening data for compounds 41 – 46 in μg/mL (MIC values). RT 700057 tested at 
  UWA and RT027 tested at Monash (The data for compounds 18 – 20 from references 47 and 53) 
 
Compounds 41 – 46 were designed from compounds 18 – 20 by modifying the 





substituent at the C-4 and C-5 positions of the triazole ring of the naphthyl-triazole moiety 
(Table 3.2). Compound 18 (R = Cy) displayed antibacterial activities (MIC values) of 2 
μg/mL and 4 μg/mL against the S. aureus strains, whereas the modified compounds 41 (R 
= Cy) and 44 (R = Cy) displayed MIC values of 16 μg/mL against these strains. 
Compounds 18 – 20 and 45 (R = CH2Cy) showed similar antibacterial activities (MIC) of 
4 μg/mL against S. aureus (NCTC 10442). Compound 19 (R = CH2Cy) exhibited a MIC 
value of 4 μg/mL against the S. aureus strains, whereas the modified compound 42 (R = 
CH2Cy) displayed a MIC of 8 μg/mL against these strains. Apart from compound 45, all 
other compounds (41 – 44 and 46) with an isopentyl substituent at the C-4 or C-5 position 
showed little difference in activity against the S. aureus strains. In general, the modified 
compounds were less active than compounds 18 – 20 (Table 3.2) against the S. aureus 
strains. 
Compounds 42 (R = CH2Cy) and 43 (R = Bn) exhibited MIC values of 8 μg/mL 
against E. faecalis, whereas the other modified compounds 41 (R = Cy) and 44 – 46 (Table 
3.2) had MIC values of 32 μg/mL and 64 μg/mL, respectively against E. faecalis.  
Compound 20 (R = Bn) displayed the best antibacterial activity (MIC = 2 μg/mL) 
against S. pneumoniae among the compounds 18 – 20 (Table 3.2), while the modified 
compounds 44 – 46, having a C-5 substituent all showed similar and significant 
antibacterial activity against this bacterium (MIC = 4 μg/mL). 
Compounds 18 (R = Cy) and 20 (R = Bn) displayed MIC values of 16 μg/mL 
against the two C. difficile strains, however the modified compounds 41 (R = Cy) and 43 










                 
                               
       _______________________________________________________________           
                        E.           S. E. 
     ipentyl            S. aureus      faecalis pneumoniae coli        C. difficile 
        Compound      R      position     ATCC  NCTC   ATCC      ATCC   ATCC   ATCC      132 
                                       29213  10442      29212        49619    25922    700057   (RT027) 
       __________________________________________________________________________ 
          
              1           -              -     2          2      2           2          16           8   16 
     10       Cy            -    2    2      4           8       >128         16   32 
            11       CH2Cy        -               4    4      4           8       >128         32   32 
           12          Bn            -               2    2      4          16        128         32   32 
            29          Cy         C-4    8    8     16          16        128        128 >128 
     30      CH2Cy      C-4             4     4      8           8          32          32   32 
            31          Bn         C-4    4    4            4           4          64          32   32 
            32          Cy         C-5              8    8      8           8          32          32   32 
     33      CH2Cy      C-5              4    4      8           8          16          32   64 
            34          Bn         C-5     8    8     16           4          64          64 >128 
       Vancomycin   -           -                 1    1      4           1         >16         0.5   0.5 
       __________________________________________________________________________ 
        
   Table 3.3 – Primary screening data for compounds 29 – 34 in μg/mL (MIC values). RT 700057 tested at 
 UWA and RT027 tested at Monash (The data for compounds 10 – 12 from references 47 and 53) 
 
Compounds 29 – 34 were designed from the monocationic compounds 10 – 12 by 
modifying the binaphthyl moiety to a naphthyltriazole base structure with variations of 
the isopentyl substituent at the C-4 and C-5 position of the triazole ring of the 





activity (MIC) of 2 μg/mL against S. aureus strains, whereas the modified compounds 29 
(R = Cy) and 32 (R = Cy) had MIC values of 8 μg/mL against the S. aureus strains. 
Compounds 11 (R = CH2Cy), 30 (R = CH2Cy) and 33 (R = CH2Cy) showed similar 
antibacterial activities against the S. aureus strains (MIC = 4 μg/mL). Compound 12 (R = 
Bn) exhibited antibacterial activity (MIC) of 2 μg/mL against both S. aureus strains, 
whereas the modified compounds 31 (R = Bn) and 34 (R = Bn) had MIC values of 4 
μg/mL and 8 μg/mL, respectively against these strains.  
Compounds 10 – 12 exhibited MIC values of 4 μg/mL against E. faecalis, whereas 
the modified compound 31 (R = Bn) displayed similar antibacterial activity with the others 
being less active.   
Compounds 10 – 11 and 30, 32 – 33 showed similar antibacterial activities against 
S. pneumoniae (MIC = 8 μg/mL). While compounds 31 (R = Bn) and 34 (R = Bn) 
displayed better antibacterial activities (MIC = 4 μg/mL) against S. pneumoniae and 
compounds 12 (R = Bn) and 29 (R = Cy) showed the poorest activities (MIC = 16 μg/mL).    
None of the compounds in Table 3.3 were particularly active against E. coli (MIC 
= 16 – >128 μg/mL), while compound 33 (R = CH2Cy) showing the best activity (MIC = 
16 μg/mL).  None of the compounds in Table 3.3 showed significant activities against the 
two C. difficile strains (MIC = 32 – >128 μg/mL).  
A comparison of Tables 3.2 and 3.3 indicated that, in general the monocationic 
compounds in Table 3.3 had better activities against S. aureus than the dicationic 
compounds in Table 3.2. The C-4 substituted dicationic compounds 41 and 43 were the 











             
                     
        
 
 
              
 
       _______________________________________________________________           
                        E.           S. E. 
     ipentyl            S. aureus      faecalis pneumoniae coli        C. difficile 
        Compound      R      position     ATCC  NCTC   ATCC      ATCC   ATCC   ATCC      132 
                                       29213  10442      29212        49619    25922    700057   (RT027) 
       __________________________________________________________________________ 
          
             1            -             -     2          2      2           2          16           8   16 
      6       Cy            -    4    4      4           4          32           8    8 
             7       CH2Cy         -               4    4      4           4          32           8    8 
            8          Bn             -               4    8      8           4          32          32   16 
            21      CH2Cy         -      64        64     64          32       >128        64   64 
     22         Cy          C-4            32    32     32          16         128         32   64 
            23         Cp          C-4   32   32          32          16         128         32   64 
            24      4-F-Ph       C-4            32   32     32             16         128         32   64 
     25         Bn          C-4             32   32     32             16         128         32   64 
            26         Cy          C-5   32   32     32          32       >128       128  128 
     27     CH2Cy       C-5   16    16     16          16         128         64   64 
     28      Bn         C-5   32    32     32          32       >128         32   32 
       Vancomycin   -           -                1      1      4           1          >16         0.5   0.5 
       __________________________________________________________________________ 
          Table 3.4 – Primary screening data for compounds 21 – 28 in μg/mL (MIC values). RT 700057 tested at 






The monocationic compounds 21 – 28 were designed from compounds 6 – 8 by 
modifying the biphenyl to a phenyl-triazole base structure with one derivative having a 
N-benzyl substituent rather than an isopentyl substituent on the triazole ring (Table 3.4). 
This modification led to a decrease in the antibacterial activities from 4 – 32 μg/mL to 16 
– >128 μg/mL against both Gram-positive and Gram-negative bacteria.  
 
Primary screening data for 35-40 and 47-49 
The dicationic compounds 35 – 40 were designed from compounds 14 – 16 by 
modifying the biphenyl group to a phenyl-triazole base structure with 35 and 36 having a 
N-benzyl substituent on the triazole ring, while compounds 37 – 40 had an isopentyl 
substituent at the C-4 and C-5 positions of the triazole ring of the phenyl-triazole moiety. 
These modifications led to a decrease in the antibacterial activity from 2 – 32 μg/mL to 8 








      _______________________________________________________________           
                               E.           S. E. 
     ipentyl            S. aureus      faecalis pneumoniae coli        C. difficile 
        Compound      R      position     ATCC  NCTC   ATCC      ATCC   ATCC   ATCC      132 
                                       29213  10442      29212        49619    25922    700057   (RT027) 
       __________________________________________________________________________ 
          
              1            -              -     2          2      2           2          16           8   16 
     14       Cy            -    8    8      8           2          16           8   16 
            15       CH2Cy        -               4    4      4           2          16           8   16 
           16          Bn            -               8    8      8           4          32          32   16 
            35          Bn            -   32        32     64          16        128        128        128 
     36       CH2Cy        -              32    32     64          16        128        128  128 
            37          Bn         C-4   32   32          64          16        128        128  128 
            38          Cy         C-5            16   32     16              8          64          64   64 
     39      CH2Cy      C-5           128  128   >128          128      >128      128 >128 
            40          Bn         C-5   32   64     32          16        128         64   32 
       Vancomycin   -           -               1    1     4           1         >16        0.5  0.5 
_________________________________________________________________________ 
             Table 3.5 – Primary screening data for compounds 35 – 40 in μg/mL (MIC values). RT 700057 tested at 






The dicationic compounds 47 – 49 were designed from compounds 38 – 40 by 
switching the position of the phenyl and triazole rings. These modifications did not 
increase the antibacterial activity against the two Gram-positive C. difficile strains (Table 
3.6). The testing of compounds 47 – 49 is in progress. 
 
      _______________________________________________________________           
                                E.           S. E. 
     ipentyl            S. aureus      faecalis pneumoniae coli        C. difficile 
        Compound      R      position     ATCC  NCTC   ATCC      ATCC   ATCC   ATCC      132 
                                       29213  10442      29212        49619    25922    700057   (RT027) 
       __________________________________________________________________________ 
          
              1            -              -     2          2      2           2          16           8   16 
     38          Cy         C-5            16   32     16              8          64          64   64 
     39      CH2Cy      C-5           128  128   >128          128      >128      128 >128 
            40          Bn         C-5   32   64     32          16        128         64   32 
     47          Cy         C-5    -    -      -           -            -  - >40 
     48   CH2Cy      C-5    -    -            -           -            -  - >40 
     49      Bn         C-5     -    -            -           -            -  - >40 
       Vancomycin   -           -               1    1     4           1         >16        0.5  0.5 
       __________________________________________________________________________ 
             
              Table 3.6 – Primary screening data for compounds 47 – 49 in μg/mL (MIC values). RT 700057 tested at 







Overall SAR trend: 
The dicationic binaphthyl derivatives 18 – 20 showed MIC values in the range 2 
– 8 μg/mL against all Gram-positive and Gram-negative bacteria tested, except for C. 
difficile (MIC = 16 – 32 μg/mL), while the modified derivatives 41 – 46 displayed MIC 
values in the range of 4 – 16 μg/mL against all Gram-positive bacteria, including C. 
difficile (Table 3.2). Similarly, the monocationic binaphthyl derivatives 10 – 12 exhibited 
MIC values in the range of 2 – 8 μg/mL against all Gram-positive bacteria (except C. 
difficile), whereas the modified derivatives 29 – 34 exhibited MIC values in the range of 
4 – 8 μg/mL (Table 3.3). The dicationic derivatives 41 and 43 both exhibited MIC values 
of 8 μg/mL against the C. difficile but none of the monocationic derivatives were as active. 
The above results suggest that most of the modified naphthyl dicationic derivatives 
41 – 46 (Table 3.2) were less active (MIC = 8 – 64 μg/mL) against Gram positive bacteria 
(except C. difficile), whereas modified naphthyl monocationic derivatives 29 – 34 (Table 
3.3) were more active (MIC = 4 – 8 μg/mL) against Gram positive bacteria (except C. 
difficile). Furthermore, the modified naphthyl dicationic derivatives 41 and 43 (Table 3.2) 
were more active (MIC = 8 μg/mL) against Gram positive C. difficile strains, whereas the 
modified naphthyl monocationic derivatives 29 – 34 (Table 3.3) were not active (MIC = 
32 – >128 μg/mL) against these C. difficile strains. These results promoted compound 41 
to be chosen for in vivo studies in a murine model against CDI. 
Furthermore, the dicationic biphenyl derivatives 14 – 16 had MIC values in the 
range of 2 – 8 μg/mL against all Gram-positive bacteria, whereas the modified derivatives 





3.6). Similarly, the monocationic biphenyl derivatives 6 – 8 exhibited antibacterial 
activity (MIC) in the range of 4 – 8 μg/mL against all Gram-positive bacteria but the 
modified derivatives 21 – 28 exhibited MIC values in the range of 32 – 64 μg/mL (Table 
3.4). These results suggested that changing a phenyl ring of the biphenyl moiety with a 
triazole ring often led to a decrease in the antibacterial activity. 
The potency of naphthalene dicationic derivative 41 against the C. difficile (MIC 
= 8 μg/mL; Table 3.2) was particularly better than the potency of the related naphthalene 
monocationic derivative 29 (MIC = 32 μg/mL; Table 3.3). 
The compounds 41 – 43 displayed antimicrobial activity against the Gram-positive 
bacteria in the range of 8 – 16 μg/mL but were not active against E. coli (Table – 3.2). 
Additionally, two compounds (41 and 43) were recognized as potential CDI inhibitors 
due to their in vitro activities against the C. difficile strains (MIC = 8 μg/mL) and their 
good water solubility profiles (see section 3.2.6 and Table – 3.9). 
Out of the 29 compounds tested, only 12 derivatives from the mono- and di-
cationic derivatives of 1,4-disubstituted-naphthyl-1,2,3-triazoles 29 – 31 and 41 – 43 and 
1,5-disubstituted-naphthyl-1,2,3-triazoles 32 – 34 and 44 – 46 exhibited MIC values in 
range of 4 – 16 μg/mL against S. aureus in secondary screening. None of the compounds 
exhibited antibacterial activity against Gram-negative bacteria but surprisingly a few 
compounds, 29 – 30, 33 and 43 – 45, exhibited weak antifungal activity (MIC = 8 – 32 
μg/mL) against C. albicans and C. neoformans (Tables 3.7). The compounds 41 and 42 







Secondary Screening Data 
         ________________________________________________________                                                
 Compound           S.       P.       K.        A.        E.         C.        C.          CC50 
                           aur.       aer.      pneu.    bau.     coli       alb.     neo.      
                   ________________________________________________________ 
            
        21     16    >32    >32     >32     >32       >32       32           >32 
        22     32    >32    >32     >32     >32       >32      >32          >32 
        23     32     >32    >32     >32     >32       >32      >32          >32 
        24     32    >32    >32     >32     >32       >32      >32          >32 
        25     32    >32    >32     >32     >32       >32      >32          >32 
        26     32    >32    >32     >32     >32       >32      >32          >32  
27     16    >32    >32     >32     >32       >32      >32          >32 
        28     32    >32    >32     >32     >32       >32      >32          >32 
29      8    >32    >32     >32       32         32        16 32 
30      4    >32    >32     >32       32         16         8             32 
31      8    >32    >32     >32       32         32        16 32  
32                 8     32     >32      32       32          32       >32         21.9 
33      4    >32     >32       32      32         16         8            >32 
34    16    >32     >32     >32     >32         32       >32          23.5   
        35        16    >32    >32     >32     >32         32      >32          >32 
36     32    >32    >32     >32     >32         32      >32          >32 
       37     16    >32    >32     >32       32         16        32          >32  
       38     16    >32    >32     >32     >32         16       16          >32  
       39     32    >32    >32     >32     >32        >32       16  32  
       40     32    >32    >32     >32     >32         16        16          >32  
       41      8      32    >32       32       32       >32         4             32 
       42      4      16      32       32       32         32         4             16  
       43      8      32    >32       32       32       >32         8             32 
__________________________________________________________________ 






   Secondary Screening Data 
         ________________________________________________________                                                
 Compound           S.       P.       K.        A.        E.         C.        C.          CC50 
                           aur.       aer.      pneu.    bau.     coli__   alb.__ neo.      
                   ________________________________________________________ 
                           
        44      8     32     >32      32      32       >32         8            >32 
               45      8       32     >32      32      32         32         8            >32 
               46     16     32     >32    >32      32       >32      >32          >32      
  _________________________________________________________________ 
               Table 3.7 (Continued) – Secondary antimicrobial screening data in μg/mL (MIC and CC50 values).       
  
Most of the compounds were tested for partial cytotoxicity by using the same 
concentration (32 μg/mL) that was utilized for the initial MIC testing at CO-ADD. 
Compounds are usually analyzed for cytotoxicity at significantly higher concentrations. 
This low-concentration analysis allows the calculation of CC50 data (i.e. the concentration 
of drug which is cytotoxic to 50% of cells) via curve-fitting and extrapolation of the low-
concentration cytotoxicity data. Some of the potent derivatives were unable to display 
significant cytotoxicity at low concentrations and hence curve fitting was impossible; a 
CC50 value could not be inferred from the data. These compounds have recorded a CC50 
value > 32 μg/mL as they are unable to display significant cytotoxicity at the verified 
concentrations. Cytotoxicity tests were achieved in replicate and the lower CC50 data is 
reported in Table 3.7.  
Most of the compounds showed little cytotoxicity with 32, 34 and 42 exhibiting 
cytotoxicity (CC50) at 21.9 μg/mL, 23.5 μg/mL and 16 μg/mL, respectively (Table 3.7). 





μg/mL); but compound 42 showed significant cytotoxicity (CC50 – 16 μg/mL). Notably, 
the lead compound 41 (MIC – 8 μg/mL against C. difficile) displayed moderate 
cytotoxicity (CC50 = 32 μg/mL).  
 
(CO-ADD) Secondary Screening - Control Data: 
In the CO-ADD screening, vancomycin and colistin were used as positive controls 
for the Gram-positive and Gram-negative bacteria, respectively (Table 3.8). Fluconazole 
was used as a positive control for C. albicans and C. neoformans (Table 3.8). Tamoxifen 
was used as a positive control for cytotoxicity assay (Table 3.8). The antibiotics were 
provided in 4 concentrations, with 2 above and 2 below its MIC value, and plated into the 





Secondary Screening - Control Data 
_________________________________________________________________________________________________________________________________ 
 
       S.     P.     K.    A.      E.     C.     C.     Cytotoxicity 
                    aureus        aeruginosa      pneumoniae    baumannii             coli              albicans         neoformans     (CC50) 
            ATCC            ATCC            ATCC            ATCC             ATCC             ATCC           ATCC      (HEK-293)    
Compound           43000            27853           700603            19606             25922  90028           208821           ATCC 
                (MRSA)                   CRL-1573 
_________________________________________________________________________________________________________________________________ 
 
Vancomycin   1  >32   >32  >32    >32      -        -               - 
  
   Colistin           >32  0.25   0.25  0.25   0.125      -        -                   - 
 
Fluconazole   -             -      -     -       -   0.125     0.25     - 
 




   Table 3.8 – MIC or CC50 values for the various control inhibitors utilized in the secondary antimicrobial screening – reported in μg/mL. 
 





3.2.3 –Overview of MIC assay results and lead compound identification 
The newly synthesized compounds displayed antimicrobial activities in a range from 
active (MIC = 4 μg/mL) to inactive (MIC = >128 μg/mL) (Table 3.2 – 3.6 and 3.8). Many of 
the compounds showed an antibacterial activity against the Gram-positive bacteria rather 
than the Gram-negative bacteria; compounds generally being 2 – 4 times more potent against 
the Gram-positive strains. For example, compound 30 displayed an MIC value of 4 μg/mL 
against S. aureus but against E. coli the MIC value was 32 μg/mL (Table 3.3). Additionally, 
all the Gram-positive strains, including C. difficile, was less susceptible to the assessed 
compounds especially the hypervirulent C. difficile strain (RT027) (Tables 3.2 – 3.6). The 
additional membrane of Gram-negative bacteria is identified as an interruption for drug 
absorption.13 MIC values in the range of 4 – 32 μg/mL were observed against the Gram-
positive bacteria (Tables 3.2 – 3.6), whereas against the Gram-negative bacteria the MIC 
values are in the range of 32 – >128 μg/mL (Tables 3.2 – 3.6).  
 
Lead compounds:  
Compounds 41 – 43 exhibited the best antibacterial activities against both strains of 
C. difficile from the 29 derivatives tested in the primary and secondary screening. 
Compounds 41 – 43 also exhibited antimicrobial activity (MIC = 4 – 32 μg/mL) against 
Gram-positive bacteria. Compound 42 exhibited some activity (MIC = 16 μg/mL) against 
Gram-negative P. aeruginosa. Compounds 41 – 43 (Figure 3.2) exhibited antibacterial 
activities of 8 – 16 μg/mL against C. difficile in the primary screening. Compounds 41 and 
43 showed low cytotoxicity (CC50 = 32 μg/mL and 32 μg/mL), however compound 42 
exhibited some cytotoxicity (CC50 = 16 μg/mL) (Figure – 3.2). These studies concluded that 







































Figure 3.2 – MIC and CC50 values (μg/mL) for lead compounds 41 – 43.  
(See Table 3.1 for the specific bacterial strains that were tested) 
 
Compound 41 was chosen for an in vivo CDI mouse model study as it exhibited an 
MIC value of 8 μg/mL against the C. difficile in preliminary screening at University of 
Western Australia and follow-up screening against the hypervirulent C. difficile strain 
(M7404 – RT027) at Monash University disclosed the same MIC value of 8 μg/mL. 
Additionally, compound 41 exhibited only mild cytotoxicity (CC50 = 32 μg/mL; Table 3.8) 







3.2.4 – Mechanism of action 
 
MBC (minimum bactericidal concentration) screening of all synthesized compounds 
were performed at UWA. Several reports have earlier disclosed that ‘membrane 
depolarization’ was a possible mechanism of action for the antimicrobial potency of 
numerous cationic peptide compounds.73-76 Other reports have specified that ‘lysis of the 
cellular membrane’ was another mechanism of action that causes the death of bacteria 
through enzyme mediated lysis which occurs after the drug causes the bacteria to form a 
defective cell wall.73, 76 The MBC data was not included in the analysis as most of the 
compounds displayed MBC data that were almost equally related with their measured MIC 
data.  
 
3.2.5 – HPLC purity assay 
To confirm sample purity for the in vivo CDI murine model, compound 41 was 
subjected to reverse-phase HPLC analysis by using acetonitrile (non-polar) and H2O (polar) 
(both with 0.1% v/v TFA) as solvents. A gradient elution from 0:100 → 100:0 
(acetonitrile:H2O) over 40 min was applied and the compound was eluted between 30 – 40 
min. At 215 nm, HPLC analysis was confirmed the purity of the compound 41 was > 98%.  
 
3.2.6 – Comparative solubility assay 
 
The previously prepared binaphthyl compounds were generally insoluble in the 10% 
DMSO/H2O solution which was used in the mouse model study of CDI. Hence, a 
comparative solubility assay was established to examine the solubility profile of the prepared 





mouse model of CDI. Lead compound 1 (AVX-13616) was employed as a model compound 
for this assay and all other final derivatives were compared with this lead.   
Five milligrams of lead compound 1 was dissolved in 50 μL of DMSO and then 5 μL 
H2O aliquots were added with sufficient manual agitation in between H2O additions. 
Addition of H2O was continued until a precipitation or turbidity and cloudiness was apparent 
(which was did not disappear upon agitation). Compound 1 precipitated after the addition of 
15 μL H2O.  
For example, if a test compound required 30 μL of water to produce precipitation or 
turbidity and cloudiness from its DMSO solution, then that test compound solubility was 
calculated as two times more soluble than compound 1 (i.e. solubility ratio – 2). This 
solubility ratio was used to calculate the relative solubility of the test compound allowing 
comparison between several similar compounds. The solubility assay was performed on eight 


















Solubility Assay Data 
            ______________________________________________________________________ 
 
Compound    H2O ppt. vol    Solubility Ratio        ClogP 
                                (µL)      (Compound : 
     Compound-1) 
                 ______________________________________________________________________ 
 
        1                            15   1          7.47 
       37                    110           7.33          2.73 
       40                    105  7          3.98 
       29                     90   6          4.01 
       41                     75   5          4.46   
       42                     70           4.66          4.99    
       43                     60   4          3.91 
       44                     70           4.66          4.39 
       46                     60              4          3.93 
     _____________________________________________________________________ 
 Table 3.9 – Comparative solubility assay data and CLogP calculated using (Chemdraw 16.0) of compounds. 
 
The CLogP data (calculated using Chemdraw 16.0) for the tested compounds are also 
added to the solubility table (Table – 3.9). The ClogP data confirmed that the tested 
compounds showed ClogP values in the range of 2.73 – 4.99 due to the replacement of the 
hydrophobic binaphthyl ring in compound 1 (ClogP 7.47) with the more polar phenyl-1,2,3-
trizole or naphthyl-1,2,3-triazole group. The phenyltriazole compound 37 showed a ClogP 
value of 2.73, lower than that of the naphthyltriazole compound 42 (Table – 3.9) which 





was as expected with the larger hydrophobic groups decreasing the solubility of the 
compound in water.     
As expected, the dicationic phenyltriazole compound 37 was more soluble than its 
related naphthyl analogue 43 (Table 3.9). This impact is further illustrated by the dicationic 
naphthalenetriazole derivative 46 and the subsequent phenyltriazole analogue 40 which is 
almost two times more soluble (Table 3.9). Moreover, altering the position of the isopentyl 
group from the C – 4 position to the C – 5 position does not have an impact on solubility; for 
example, compound 37 (isopentyl group at the C – 4 position on the triazole) has the same 
solubility as the corresponding isomer 40 (isopentyl group at C – 5 position on the triazole). 
This effect is further illustrated by the compounds 43 and 46 which both have the same 
solubilities (Table 3.9). Furthermore, a flexible hydrocarbon termini (i.e. Cy) was usually 
more soluble than an aromatic termini i.e. Bn.  
 
3.3 – In vivo assay: murine model of CDI 
3.3.1 – General methodology 
The murine model of CDI was conducted with project collaborators at Monash 
University. The murine model of CDI was performed by pretreating cohorts of five mice that 
had been earlier infected via oral gavage with hypervirulent M7404 C. difficile spores. The 
infection was allowed to develop for 12 h before the trial drug was administered every 12 h 
for five days. The mice received a single dosage of 2.5 mg of compound 41 (i.e. 100 mg/kg 
for an average 25 g mouse) administered in a solvent mixture of 10% DMSO and H2O at 
each 12 h dosing period. The mice body weight was checked every day. If a mouse lost 10% 
of its body weight in the first 24 h, then the infection was developing, and the mouse was 





cohort was utilized to measure effectiveness of that drug. Other physiological parameters 
such as cage appearance scores and faecal consistency scores were additional measures for 
the efficacy of the drug in this murine trial. The experimental data of the in vivo CDI model 
can be found in Section 3.3.3 and the experimental procedures can be found in Section 6.4.3. 
 
3.3.2 – Preliminary trials 
Compound 41 was selected for a murine model of CDI study because of its better 
antimicrobial potency against C. difficile and its better water solubility profile (Section 3.2.7). 
Compound 41 was prepared on a larger scale i.e. nearly 300 mg for the purpose of in vivo 
mouse model of CDI at Monash University. In the first trial, attempts were made to 
administer compound 41 through drinking water, but the mice refused to drink the adulterated 
water. As a result, the mice were dehydrated and lost weight due the effects of the infection.    
 
3.3.3 – Secondary trial 
In the secondary CDI mouse model trial, the solution (10% v/v DMSO/H2O) of the   
compound 41 was administered to mice by oral gavage.   
The mice that were treated with compound 41 (orange line in Figure 3.3) showed 
80% survival rate until 24 h, then continued at the same survival rate for another 6 h. After 
42 h, the survival rate dropped to 60 – 65% (compared with a 40% survival rate in the DMSO 






Kaplan-Meier survival curve: 
 
 
                           
 
                                  
                                                               
          





Figure 3.3 – Kaplan-Meier survival curve for the in vivo CDI mouse trial of compound – 41 (Orange).  
XX refer to other compounds, not described in this thesis, that were tested concurrently with 41. 
 
 
The mice that were treated with compound 41 lost the least amount of weight at 24 h 
(Figure 3.4) and after 42 h, the mice lost 18% weight. 
 


















Figure 3.4 – Percentage weight loss for the compound – 41 (Orange) cohort in the in vivo CDI mouse model. 
XX refer to other compounds, not described in this thesis, that were tested concurrently with 41. 
 
The mice that were treated with compound 41 had moderately soft stools, that appeared 
















   
Figure 3.5 – Faecal consistency scores for the compound – 41 (Orange) cohort in the in vivo CDI mouse     
model. XX refer to other compounds, not described in this thesis, that were tested concurrently with 41. 
 
Stool scoring system: 
(0) Normal stool: Solid stool that is firm when subjected to pressure with forceps. Mouse  
has no sign of soiling around the anus and passes the stool quickly and easily. 
(1) Mildly soft stool: Formed stools that appear moist on the outside and have a slightly  
sticky consistency. Stools will easily submit to pressure applied with forceps. Mouse 
has no sign of soiling around the anus but passes faeces quickly and easily. 
(2) Moderately soft stool: Irregularly formed stools that do not hold a normal shape. Stool  
appears very moist and is difficult to pick up with forceps. Mouse has some signs of 
soiling around anus and takes a longer than normal time to pass the stool. 
(3) Diarrhoea: Stool has no form and/or has a mucous-like liquid appearance with  
minimal solid present. Considerable soiling around the anus and the fur around tail. 
Mouse takes a long time to pass stool if at all. 
 
The mice given compound 41 had a lower cage appearance score when compared to 


















      Figure 3.6 – Cage condition score for the compound – 41 cohort in the in vivo CDI mouse model.  
      XX refer to other compounds, not described in this thesis, that were tested concurrently with 41. 
 
Cage appearance scoring system: 
0 – Normal cage. 
1 – Faeces stuck to the side of cage, but clean nest and saw dust. 
2 – Mildly soiled nest.  
3 – Moderately soiled nest. 
4 – Severely soiled nest. 
 
The mice appeared to be physically changed based on the score of physiological 
appearance as they showed signs of reduced grooming with their coats starting to appear 

































        Figure 3.7 – Physiological appearance score for the compound – 41 cohort in the in vivo CDI mouse model.       
        XX refer to other compounds, not described in this thesis, that were tested concurrently with 41. 
 
 
Physiological appearance scoring system: 
0 – Normal activity, alertness, breathing and movement/gait. 
 
1 – Mouse shows signs of reduced grooming with coat starting to appear rough/scruffy with  
      slight piloerection. 
2 – Mouse appears slightly hunched with mildly scruffy coat but moves when the cage is  
      disturbed.  Possible diminished alertness, squinted eyes or lethargy. 
3 – Mouse has isolated itself from cage mates, displays hunched posture and unkempt coat.  
Mouse does not move when cage is disrupted and has little response to external  
environment or handling. Possible laboured breathing or eye discharge. 
 
3.3.4 – Conclusions from murine model of CDI study 
In the initial murine model of CDI study, attempts were made to administer 
compound 41 through the drinking water, but the mice refused to drink the adulterated water. 
Therefore, the mice were dehydrated, followed by lost weight because of the infection. 
In the secondary trial of this study, compound 41 was administered via oral gavage. 





The mice given compound 41 lost the least amount of weight at 24 hours and had the mild 
diarrhoea (as shown by the faecal consistency score and cage appearance score). 
Furthermore, the mice had a lower cage appearance score when compared to the DMSO 
controls, (suggesting that this compound was also delaying diarrhoea) and also mice had 
survived until 42 hours. Compound 41 displayed some promising activity, despite not 
completely protecting the mice in the murine model of CDI study and the mice had to be 
culled after 42 h due to weight loss from the disease (Figure 3.4).   
Compound 43 also displayed similar in vitro antimicrobial potency as compound 41 
(MIC = 8.0 µg/mL) against hypervirulent C. difficile with better water solubility, indicating 
that this compound should be prepared on a larger scale for future in vivo mouse model 
studies. Further drug developments will likely focus on structural modifications of the N-
naphthyltriazole series. These modifications could include switching the positions of 
naphthalene group and triazole ring. These modifications might produce novel 
peptidomimetics with increasing antibacterial activity and good water solubility; which is an 









4.0 – Click methodology: results and discussion 
In Chapter 2, it was noted that the attempted synthesis of 5-isopentyl-1-(2-
methoxynaphthalen-1-yl)-1H-1,2,3-triazole 83 from 1-azido-2-methoxynaphthalene 82 
using Cp*RuCl(PPh3)2 in 1,4-dioxane at 70 
°C for 12 h (Chapter 2; Section – 2.1.1.4; Scheme 
2.7), resulted in the formation of 1-amino-2-methoxynaphthalene 81 in 16% yield. None of 
the desired 1,5-triazole product 83 was formed. It was suspected that the 0.2 equivalents of 
PPh3 from the ruthenium catalyst resulted in the formation of the amine 81 via a Staudinger 
reaction of the azide group of 82. To confirm the involvement of PPh3, when the azide 82 
was treated with Cp*RuCl(PPh3)2 in the absence of 5-methyl-1-hexyne at 70 
°C in 1,4-
dioxane the amine 81 was also produced in 16% yield (Scheme 4.1). The steric bulk of the 
arylazide and the Cp*RuCl(PPh3)2 catalyst were most likely the reason for the lack of 








Scheme 4.1 – Attempted synthesis of the click products 83, 111 and 114 from azides 82, 97 and 99  
 
Consistent with this premise was the fact that the reaction of azide 97 (R = Me) with 
5-methyl-1-hexyne in the presence of Cp*RuCl(PPh3)2 at 70 
°C for 12 h resulted in formation 
of the amine 96 in 14% yield and none of the desired triazole 111 was formed (Scheme 4.1). 
In contrast, the less hindered azide 99 produced the desired cycloaddition product 114 in 63% 





Cp*RuCl(PPh3)2 at 70 
°C for 12 h (Scheme 4.1). These results suggest that the more hindered 
azides 82 and 97 are undergoing a Staudinger reaction with the PPh3 derived from the Ru-
catalyst rather than undergoing the desired cycloaddition reaction. These results initiated our 
study using as an alternative method, the Mg-promoted click reaction conditions developed 
by Sharpless et al.92 We assumed that this would result in a less sterically demanding reactive 
intermediate and would be more fruitful. This chapter reports the outcomes of a study of the 
cycloaddition reactions of hindered naphthyl azides and alkynes. 
4.1 – Synthesis of 1,5-triazoles via magnesium-promoted cycloaddition reactions 
The results of the study of the magnesium-promoted cycloaddition reactions of the 
azides 82, 97 and 99 with a variety of relatively hindered, electron rich and electron deficient 
alkynes are shown in Schemes 4.2 – 4.4. The results of the reactions with azide 82 are shown 
in Scheme 4.2. The alkynes were first treated with EtMgCl (1.2 equivalents) in dry THF at 
50 °C for 30 min to generate the corresponding chloromagnesium acetylide. A solution of 
the azide in dry THF was then added slowly dropwise to the acetylide at rt and the mixture 
was then heated at 50 °C for 3 – 12 h.   
     





The reaction between azide 82 and chloromagnesium-5-methyl-1-hexylide gave the 
1,5-triazole 83 (Scheme 4.2) in 81% yield. The 1H NMR spectrum of 83 displayed the 
characteristic resonances of the naphthalene group as a doublet resonance at δH 8.03 (J = 9.1 
Hz, 1H), a doublet of doublet resonance at δH 7.85 (J = 7.4, 2.0 Hz, 1H) and as multiplet 
resonances at δH 7.45 – 7.37 (3H) and δH 6.99 – 6.96 (1H) (Figure 4.1). The characteristic 
singlet resonance at δH 3.87 was assigned for the OMe group (Figure 4.1). The characteristic 
resonances (11H) that were assigned to the isopentyl group appeared as multiplet resonances 
at δH 2.45 – 2.34 (2H), δH 1.47 – 1.35 (3H) and the two doublet resonances at δH 0.74 (J = 
7.8 Hz, 3H) and δH 0.71 (J = 7.8 Hz, 3H) (Figure 4.1). The characteristic singlet resonance 
at δH 7.71 was assigned to the triazole ring proton H-4 (Figure 4.1).  
   
Figure 4.1: 1H NMR spectrum of compound 83 (400 MHz, CDCl3) 
 
The C-4 carbon of the triazole ring resonated at δC 131.6 and was assigned from the 





   
Figure 4.2: gHSQC spectrum of compound 83 (500 MHz, CDCl3). The one bond correlation  
between the triazole proton and C-4 is highlighted 
 
 
The gHMBC spectrum of 83 allowed the assignment of the resonance at δC 140.7 to 
the quaternary C-5 carbon of the triazole ring (Figure 4.3). 
                            
        Figure 4.3: gHMBC spectrum of compound 83 (500 MHz, CDCl3). The two-bond correlation  






Furthermore, the triazole proton did not show a correlation with the naphthalene C – 
N carbon (C1'') in the gHMBC spectrum. This was consistent with 83 having the expected 
1,5-disubstituted triazole structure (Scheme 4.2), whereas its regioisomers 123 (Figure 4.13) 
showed a correlation between the naphthalene C1'' and the C5 triazole proton, indicating the 
presence of the triazole-1,4-regioisomer.. The molecular structure of compound 83 was 
further established by the presence of the ion peak at m/z 296.1750 in the HRMS (ESI) that 
was assigned to the protonated molecular ion ([M + H]+) (calculated for C18H22N3O 
296.1763). 
The 1,5-triazoles 100 – 105 were also successfully prepared from azide 82 in yields 
ranging from 52 – 89% (Scheme 4.2). The reactions involving 3-fluorophenylacetylene and 
2,4,6-trimethylphenylacetylene required extended reaction times (5 h and 6 h, respectively) 
presumably due to electronic effects (strongly electron withdrawing) and steric effects (2 
ortho Me groups), respectively. The reaction of azide 82 and 3-fluorophenylacetylene gave 
the desired 1,5-triazole 104 (Scheme 4.2) in 86% yield, but the synthesis of 107 from the 
reaction of azide 82 with 4-fluorophenylacetylene was unsuccessful possibly due to the more 
electron-withdrawing effect from fluorine substitution at the para position of the arylalkyne.  
The synthesis of the 1,5-triazoles 106 – 110 (Scheme 4.2) from azide 82 was unsuccessful 
due to the steric hinderance (106 and 110) and electron-withdrawing properties (107 – 109) 
of the corresponding alkynes. The reason for the unsuccessful synthesis of 106 is not clear 
since sterically this product should be more favored than that of 105. In the case of 3- and 4-
nitrophenylacetylenes, the addition of EtMgCl resulted in a black solution indicating an 
undesired reaction between EtMgCl and the alkyne, possible due to an electron transfer 





Under similar reaction conditions to those used for 82, the reactions of the azide 97 
(Scheme 4.3) with alkynes (R = isopentyl, 2-MeO-Ph and 1-naphthyl) were not successful 
 due to the more sterically hindered nature of the azide 97 (2-Me substituent is more sterically 
demanding than the 2-OMe group of azide 82). 
 
Scheme 4.3 – Attempted synthesis of the cycloaddition products 111 – 113 from azide 97    
 
The less sterically demanding naphthyl azide 99 gave the 1,5-triazoles 114 – 116 in 
yields of 10 – 88%. The reaction of the azide 99 with more hindered 2-MeO-phenylacetylene 
giving a low yield of 10%, after heating at 50 °C for 12 h (Scheme 4.4). The synthesis of the 
1,5-triazole 117 was unsuccessful due to the more sterically hindered nature of the alkyne 
(i.e. 1-ethynylnaphthalene). 
 
      Scheme 4.4 – Synthesis of the cycloaddition products 114 – 117 from azide 99    
 
The reaction between azide 99 and chloromagnesium-5-methyl-1-hexylide gave the 





displayed characteristic resonances for the naphthalene group i.e. δH 8.04 (d, J = 8.3 Hz, 1H), 
δH 7.95 (d, J = 8.2 Hz, 1H), δH 7.61 – 7.54 (m, 2H), δH 7.50 – 7.47 (m, 2H) and δH 7.16 (dd, 
J = 8.5, 0.8 Hz, 1H) (Figure 4.4). The isopentyl group showed resonances at δH 2.45 – 2.42 
(m, 2H), δH 1.46 – 1.36 (m, 3H) and δH 0.71 (d, J = 6.2 Hz, 6H) (Figure 4.4). The singlet 
resonance at δH 7.70 was assigned for the triazole ring proton H-4 (Figure 4.4).  
 
   
Figure 4.4: 1H NMR spectrum of compound 114 (500 MHz, CDCl3) 
 





            
Figure 4.5: gHSQC spectrum of compound 114 (500 MHz, CDCl3). The one bond correlation  
between the triazole proton and C-4 is highlighted 
 
The gHMBC spectrum allowed the resonance at δC 140.3 to be assigned to quaternary 





              
         Figure 4.6: gHMBC spectrum of compound 114 (500 MHz, CDCl3). The two-bond correlation  
between the triazole proton and C-5 is highlighted 
 
The triazole proton did not show a correlation with the naphthalene C – N carbon 
(C1''), which was consistent with the 1,5-disubstituted triazole structure of 114 (Scheme – 
4.4). The molecular structure of compound 114 was further confirmed by the presence of the 
ion peak at m/z 266.1668 in the HRMS (ESI) that was assigned to the protonated molecular 
ion ([M + H]+) (calculated for C17H20N3 266.1657). 
The synthesis of the 1,5-triazole 117 (Scheme – 4.4) from the azide 99 was 
unsuccessful due to the highly sterically hindered nature of the alkyne (i.e., 1-
ethynylnaphthalene). The mechanism of Mg-promoted cycloaddition reaction was discussed 






4.2 – Synthesis of 1,5-disubstituted-1,2,3-triazoles using pentamethylcyclopentadienyl 
bis(triphenylphosphine)ruthenium(II) chloride   
A study of the synthesis of phenyl 1,5-triazoles 119 – 122 was also undertaken. The 
azide 118 was treated with four different alkynes using Cp*RuCl(PPh3)2 (10 mol%) as the 
catalyst in 1,4-dioxane at 70 °C for 12 – 48 h. The results are shown in Scheme - 4.5. 
  
 
Scheme 4.5 – Synthesis of the cycloaddition products 119 – 122 from azide 118  
 
The reaction of azide 118 with 5-methyl-1-hexyne gave the 1,5-triazole 119 in 87% 
yield. The 1H NMR spectrum of the 1,5-triazole 119 displayed the characteristic resonances 
of the phenyl group as a multiplet resonance at δH 7.50 – 7.47 (1H), a doublet of doublet 
resonance at δH 7.32 (J = 7.9, 1.7 Hz, 1H) and as multiplet resonance at δH 7.11 – 7.06 (2H) 
(Figure 4.7). The characteristic singlet resonance at δH 3.78 was assigned to the OMe group. 
The characteristic resonances of the isopentyl group were observed at δH 2.47 (t, J = 7.9 Hz, 
2H), δH 1.56 – 1.41 (m, 3H) and δH 0.82 (d, J = 8.0 Hz, 6H) (Figure 4.7). The characteristic 






Figure 4.7: 1H NMR spectrum of compound 119 (500 MHz, CDCl3) 
The C-4 carbon of the triazole ring assigned at δC 131.3 was assigned from the gHSQC 
spectrum (Figure 4.8).  
             
             Figure 4.8: gHSQC spectrum of compound 119 (500 MHz, CDCl3). The one bond correlation            







The gHMBC spectrum of 119 allowed the assignment of the resonance at δC 140.0 to 
the quaternary C-5 carbon of the triazole ring (Figure 4.9). 
             
      Figure 4.9: gHMBC spectrum of compound 119 (500 MHz, CDCl3). The two-bond correlation  
between the triazole proton and C-5 is highlighted 
 
The triazole proton did not show a correlation with the phenyl C – N carbon (C1''); 
which was consistent with the 1,5-disubstituted triazole structures of 120 – 122 (Scheme – 
4.5). The molecular structure of compound 119 was further verified by the presence of the ion 
peak at m/z 246.1618 in the HRMS (ESI) that was assigned to the protonated molecular ion 
([M + H]+) (calculated for C14H20N3O 246.1606). 
The longer reaction time and the lower yield of 121 (58%) was attributed due to the 
more sterically hindered nature of the alkyne. The low yield of 122 (7%) was attributed to 
the highly sterically hindered nature of the alkyne (Scheme – 4.5). The mechanism of the Ru-






4.3 – Synthesis of 1,4-disubstituted-1,2, 3-triazoles from CuAAC reaction 
In this study, the CuAAC reactions of the azides 82 and 118 with a variety of relatively 
sterically hindered alkynes were also examined (Scheme – 4.6). In the case of azide 82, the 
reaction yields were high (79 – 92%) including those for hindered alkynes (R = 2-MeO-Ph, 
1-naphthyl and CMe2OH) and relatively electron deficient alkynes (4-F-Ph and 4-NO2-Ph).  
 
 Scheme 4.6 – Synthesis of the cycloaddition products 123 – 132 from azides 82 and 118 
 
The reaction of azide 82 with 5-methyl-1-hexyne gave the 1,4-triazole 123 in 85% 
yield. The 1H NMR spectrum of the triazole product 123 displayed characteristic resonances 
for the naphthalene group i.e., δH 7.98 (d, J = 11.4 Hz, 1H), δH 7.83 (d, J = 9.5 Hz, 1H), δH 
7.46 – 7.35 (m, 3H) and δH 7.16 (dd, J = 10.5, 0.9 Hz, 1H) (Figure 4.10). The characteristic 
singlet resonance at δH 3.87 was assigned to the OMe group. The isopentyl group showed 
resonances at δH 2.91 – 2.87 (m, 2H), δH 1.73 – 1.69 (m, 3H) and δH 0.99 (d, J = 7.9, 6H) 
(Figure 4.10). The characteristic singlet resonance at δH 7.52 was assigned to the triazole ring 





   
 
Figure 4.10: 1H NMR spectrum of compound 123 (500 MHz, CDCl3) 
The gHSQC spectrum allowed the resonance at δC 124.3 to be assigned to C-5 (Figure 4.11).  
              
             Figure 4.11 gHSQC spectrum of compound 123 (500 MHz, CDCl3). The one bond correlation   







The gHMBC spectrum allowed the resonance at δC 148.1 to be assigned to quaternary 
C-4 of the triazole (Figure 4.12). 
                           
       Figure 4.12: gHMBC spectrum of compound 123 (500 MHz, CDCl3). The two-bond correlation  
between the triazole proton and C-4 is highlighted 
 
 
Unlike its 1,5-triazole regioisomer 83, the triazole proton of 1,4-triazole 123 showed 
a correlation with the naphthalene C – N carbon at δC 113.1 (C1") (Figure 4.13); which was 





                          
Figure 4.13: gHMBC spectrum of compound 123 (500 MHz, CDCl3). The two-bond correlation  
between the triazole proton and C-1'' is highlighted 
 
The molecular structure of compound 123 was further confirmed by the presence of 
the ion peak at m/z 296.1771 in the HRMS (ESI) that was assigned to the protonated 
molecular ion ([M + H]+) (calculated for C18H22N3O 296.1763). The CuAAC reactions of 
phenylazide 118 were also efficient giving the 1,4-triazoles 130 – 132 in yields of 60 – 96%. 
The results are shown in Scheme – 4.6. The mechanism of CuAAC reaction was discussed 
in section – 2.1.1.1; Scheme – 2.2 of Chapter-2. 
The 1H NMR spectrum of the 1,5-triazole 83 (Scheme – 4.2) showed the characteristic 
singlet resonance at δH 7.71 for the triazole ring proton, whereas the triazole proton in its 
regioisomer 1,4-triazole 123 (Scheme – 4.6) resonated at δH 7.52. The 
13C NMR spectrum of 
the 1,5-triazole 83 (Scheme – 4.2) showed the C-4 resonances at δC 131.6 and the quaternary 
C-5 at δC 140.7, whereas its regioisomeric 1,4-triazole 123 (Scheme – 4.6) showed 





Similarly, the 1H NMR spectrum of the 1,5-triazole 119 (Scheme – 4.5) revealed a 
characteristic singlet resonance at δH 7.55 for the triazole ring proton, whereas its regioisomer 
1,4-triazole 130 (Scheme – 4.6) showed the corresponding resonance at δH 7.81. For the 1,5-
triazole 119 (Scheme – 4.5), the resonance for the C-4 was at δC 131.3 and for the quaternary 
C-5 at δC 140.0, whereas for its regioisomer 1,4-triazole 130 (Scheme – 4.6) the C-5 and 
quaternary C-4 resonances were at δC 122.7 and δC 147.9, respectively.   
As a general trend, the C-5 carbon resonances of the 1,4-disubstituted 1,2,3-triazoles 
resonated around δc 124 ± 3 ppm, whereas the corresponding C-4 carbon resonances of the 




          Figure 4.14: 13C NMR as a tool for distinguishing between 1,4- and 1,5- disubstituted 1,2,3-triazoles 
In conclusion, the Mg-promoted cycloaddition reactions produced the 1,5-triazoles 
83, 100 – 105 (Scheme 4.2) in yields ranging from 52 – 89% for the azide 82 and the 
corresponding alkynes (i.e. 5-methyl-1-hexyne, cyclohexylacetylene, 2- and 4-
methoxyphenylacetylene, 2-methylphenylacetylene, 3-fluorophenylacetylene and 2,4,6-
trimethylphenylacetylene). The synthesis of the 1,5-triazoles 106 – 110 (Scheme 4.2) from 
azide 82 were unsuccessful due to the steric hindrance of the corresponding alkynes (2,6-
dimethoxyphenylacetylene and 1-naphthylacetylene) and the electron-withdrawing effects of 
the corresponding alkynes (4-fluorophenylacetylene, 3- and 4-nitrophenylacetylene).  
Under similar reaction conditions to those used for 82, the reactions of the azide 97 
(Scheme 4.3) with the corresponding alkynes (5-methyl-1-hexyne, 2-methoxyphenyl 





nature of the azide 97 (2-Me substituent is more sterically demanding than the 2-OMe group 
of azide 82). 
Under similar reaction conditions to that for 82, the less hindered naphthyl azide 99 
gave the 1,5-triazoles 114 – 116 in yields ranging from 10 – 88% using the alkynes 5-methyl-
1-hexyne, cyclohexylacetylene and 2-methoxyphenylacetylene. The reaction of the azide 99 
with the more hindered 2-methoxyphenylacetylene produced the desired 1,5-triazole 116 in 
a low yield of 10% after heating for an extended time (12 h) (Scheme 4.4). The synthesis of 
the triazole 117 was unsuccessful due to the more sterically hindered nature of the alkyne (1-
naphthylacetylene). 
The Ru-catalysed cycloaddition reaction produced 1,5-phenyl triazoles 119 – 122 in 
yields ranging 7 – 87% from the reaction of the azide 118 with four different alkynes (5-
methyl-1-hexyne, cyclohexylacetylene, 2-methoxyphenylacetylene and 1-naphthyl 
acetylene) at 70 °C for 12 – 48 h (Scheme 4.5). 1-Naphthylacetylene produced a low yield 
of 7% of the corresponding 1,5-triazole 122 after heating for 48 h due to its sterically hindered 
nature.  
The Cu-catalysed cycloaddition reaction produced 1,4-triazoles 123 – 132 in yields 
ranging 60 – 96% from azides 82 and 118 with a variety of sterically hindered alkynes 
(Scheme 4.6). All of the reactions were successful and the effect of steric hindrance was 
observed in the case of three alkynes (5-methyl-1-hexyne, cyclohexylacetylene and 2-
methoxyphenyl acetylene) as they required longer reaction times of 36 h – 48 h.  
The advantages of the Grignard method over the Ru-catalyzed method is the low-cost 
of the reagent and its small in size allowing reactions of more hindered substrates to proceed 





The disadvantages of Ru-method – Cp*RuCl(PPh3)2 catalyst is highly expensive, 
larger in size and failed to produce sterically hindered 1,5-triazoles from sterically hindered 
aryl azide even in a longer period of reaction time.  
The magnesium-promoted ‘click’ reaction may have further applications to sterically 
hindered situations including, drug discovery allowing the attachment of sterically hindered 
chromophores for drug monitoring in biological systems, the synthesis of sterically 
demanding and novel chiral ligands and organocatalysts for asymmetric chemical synthesis 







5.0 – Conclusions and future directions 
A diverse set of twenty-nine novel antibacterial phenyltriazole and naphthyltriazole 
peptidomimetic derivatives were designed and synthesized as part of an ongoing project into 
the development of new antibacterial agents against C. difficile. This range of compounds 
were realized through derivatization of eleven key intermediates 58 – 68 via the incorporation 
of benzyl and alkyl substituents on the 1,2,3-triazole ring at the hydrophobic region. The 
eleven key intermediates 58 – 68 were achieved through implementation of a modular multi-
step synthesis that utilized eight key building block precursors 50 – 57. This modular 
approach should allow for easy diversification and manipulation of future synthesized 
derivatives based upon the resultant SAR data. 
The targeted compounds were designed to incorporate an alkyl substituted naphthyl-
1,2,3-triazole or a phenyl-1,2,3-triazole moiety into the hydrophobic backbone to replace the 
binaphthyl and biphenyl core of the lead compounds 2 and 3 (Figure 5.1); this was to improve 
the solubility of the peptoids, so they could be used as an oral CDI chemotherapeutic and still 
retain antibacterial activity. Following synthesis and spectroscopic characterization, the 
compounds were subjected to antimicrobial and toxicity assays to screen for improved 
activity. The results of these assays were used to explore the SAR trends of the compounds 
and thus, to identify a lead compound or other vital structural components necessary for both 










      Figure 5.1 – The replacement of the biphenyl and binaphthyl core of the lead compounds 2 and 3 with 





All synthesized compounds exhibited some level of antibacterial activity; the least 
potent MIC value observed against Gram-positive bacteria was 128 μg/mL, with most of the 
compounds having MIC values ranging from 4 – 16 μg/mL against Gram-positive bacteria. 
All of the monocationic derivatives failed to exhibit antibacterial activity against C. 
difficile. The dicationic derivatives (41 and 43) exhibited less Gram-positive antibacterial 
efficacy but exhibited antibacterial activity against the C. difficile strains with MIC values of 
8 μg/mL (Figure 5.2). 
 





These dicationic derivatives 41 and 42 exhibited fungal activity against C. 
neoformans. Compound 2 exhibited the strongest broad-spectrum antibacterial efficacy, but 
it had poor water solubility. Compounds 41 and 43 exhibit less broad-spectrum antibacterial 
efficacy than compound 2 but they had five times better water solubility. The replacement of 
the binaphthyl group with a phenyl-1,2,3-triazole or naphthyl-1,2,3-triazole moiety led to 
increased compound solubility which often translated to a decrease in Gram-positive 
antibacterial activity. 
As seen in Figure 5.2, the novel antibacterial molecules 41 and 43, designed from 
compound 2 led to the development of distinct structural derivatives that exhibited an 
increase in desirable properties for an antibacterial chemotherapeutic. Furthermore, 
compound 41 exhibited antibacterial activity against C. difficile. 
Compound 41 was selected as a potential hit compound based upon its in vitro activity 
against C. difficile and good water solubility. It was synthesized on larger scale and used in 
an in vivo CDI mouse model at Monash University. The data of the CDI mouse model trial 
revealed that mice fed compound 41 showed 80% survival rate after 24 h; both mouse weight 
loss and disease progression were significantly slowed by compound 41 during the 
administration of the trial. Compound 41 exhibited selectivity for Gram-positive bacteria – 
it was much less active against all the Gram-negative bacteria that were tested. This 
selectivity could be the reason for the drugs positive performance in the CDI mouse model 
study; by not eliminating the commensal, Gram-negative Bacteroides spp. and E. coli, 
compound 41 was likely quite effective at selectively killing C. difficile without destroying 
the entire enteric microflora. If successful in further antibacterial trials, the compound 41 will 





A solubility assay was also developed and performed on selected compounds to 
ascertain the role of solubility in the efficacy and administration of the phenyl and naphthyl 
peptide derivatives.  
In summary, a total of 29 novel antibacterial compounds were synthesized and fully 
characterized. The synthesis of these derivatives involved the synthesis of 96 intermediate 
compounds in total, i.e., 87 novel intermediate compounds and nine known compounds. A 
modular synthetic route to various novel phenyltriazole and naphthyltriazole peptide 
scaffolds was realized and the resultant synthetic derivatives represent a potential new 
direction for developing novel antibiotics for the treatment of CDI and other bacterial 
infections. The compounds synthesized and identified in this project are the subject of 
ongoing studies into the development of a novel CDI treatment. Therefore, the current and 
future chemical and biological research focused on these phenyl and naphthyl peptide 
derivatives will aim towards the advancement of an effective and potent CDI 
chemotherapeutic. 
Future drug discovery research will likely involve two target areas. One area will 
focus on scale-up of compound 43 for further in vivo mouse model study and the second 
target area will likely focus on modifications of compounds 44 – 46. These modifications 
might produce novel peptidomimetics with good water solubility and increasing antibacterial 
efficacy – this is an important biological study requirement needed for novel medications 
that work against drug-resistant C. difficile and other Gram-positive bacteria. 
During the synthetic part of this project, it was revealed that the synthesis of sterically 
hindered 1,5-disubstituted-1,2,3-triazoles from hindered aryl azides and alkynes was not 
successful using Cp*RuCl(PPh3)2 as a catalyst due to the sterically hindered nature of the 





converted some of the azide to an amine in an undesired reaction. This led to a study of the 
magnesium-promoted click reaction which was initially developed by Sharpless. et al.92 The 
study involved the regioselective synthesis of 1,5-disubstituted-1,2,3-triazole via the addition 
of chloromagnesium acetylides to azides. By applying this methodology, sterically hindered 
1,5-disubstituted-1,2,3-triazoles were prepared by treating chloromagnesium acetylides with 
less and more hindered azides in yields ranging from 52-89%. 
In summary, the lead compound 1 (AVX-13616; Figure 1.11) and its 
derivatives 2 and 3 displayed exceptional in vitro antimicrobial potency (MIC) of 8.0 µg/mL 
against hypervirulent C. difficile (Figure 1.12 and 1.13)54. These compounds had poor water 
solubility making mouse models studies difficult and the results unreliable. In this study 
we have designed and synthesized new compounds having related cationic peptidomimetic 
features to compounds 2 and 3 with modifications of the hydrophobic 1,1'-binaphthyl 
moiety to N-phenyltriazole and N-naphthyltriazole moieties. These modifications produced 
better water-soluble compounds and for compound 41 and 43 retained antimicrobial potency 
(MIC) of 8.0 µg/mL against C. difficile. The data of the CDI mouse model trial revealed that 
mice fed compound 41 showed 80% survival rate after 24 h; both mouse weight loss and 
disease progression were significantly slowed by compound 41 during the administration of 
the trial. Based on analysis of these results, future research will be focused on the scale up of 










6.0 – Experimental 
6.1 – General information 
Synthesis 
Unless otherwise stated, all solvents and chemicals were laboratory or reagent grade 
and were purchased from commercial sources and used as received. Water was purified via 
Millipore filtration prior to use. HOBt was purchased with added stabilizers (10% w/w H2O); 
therefore, the quantities required for reactions were adjusted accordingly and are reflected in 
the reagent masses reported in the experimental (whereas the reported mmol quantities reflect 
the true quantity of a chemical). All reactions were conducted under normal atmosphere and 
cold reaction temperatures were obtained by an ice bath (0 ºC) or ice/salt bath (–10 ºC). 
Heating of reactions was performed with a paraffin oil bath. Small quantities of liquid 
reagents were measured and added to reactions via syringe or autopipette. Unless otherwise 
noted, all filtrations were conducted as vacuum filtration through a sintered glass funnel 
(medium porosity). Vacuum filtration was achieved with the aid of a water aspirator. Solvent 
removal via concentration was performed on a rotary evaporator under reduced pressure. All 
solvent mixtures are expressed in terms of volume ratio (i.e. v/v). Thin layer chromatography 
(TLC) was performed on aluminium-backed SiO2 gel plates (F254 grade - 0.20 mm 
thickness). Visualization was achieved with UV light, ninhydrin stain or cerium ammonium 
molybdate stain. Flash chromatography was performed on SiO2 gel 60 with a positive air 
pressure. All synthesized compounds were dried under high vacuum (< 1 mbar) before 
determination of chemical yields and spectroscopic characterization. Optical rotations of 










Characterization and analysis 
1H NMR spectra were recorded on a Bruker Avance 400 (400 MHz), Avance 500 
(500 MHz), a Varian VNMRS PS54 500 (500 MHz), a Varian Inova 500 (500 MHz) or a 
Varian Mercury 400 (400 MHz) NMR spectrometer. Chemical shifts are reported in ppm and 
were measured relative to the internal standard. Samples were dissolved in CDCl3 (with TMS 
as the internal standard – 0.00 ppm), CD3OD (solvent resonance as internal standard – 3.31 
ppm) or DMSO-d6 (solvent resonance as internal standard – 2.50 ppm). The 1H NMR data 
is reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, dd = doublet of doublet, dt = doublet of triplets, m = multiplet, br = broad), coupling 
constants (Hz), integration and assignment 13C NMR spectra were recorded on a Bruker 
Avance 400 (101 MHz), Avance 500 (126 MHz), a Varian VNMRS PS54 500 (126 MHz), a 
Varian Inova 500 (126 MHz) or a Varian Mercury 400 (101 MHz) NMR spectrometer with 
complete 1H decoupling. Chemical shifts are reported in ppm and were measured relative to 
the internal standard. Samples were dissolved in CDCl3 (solvent resonance as the internal 
standard – 77.16 ppm), CD3OD (solvent resonance as the internal standard – 49.20 ppm) or 
DMSO-d6 (solvent resonance as internal standard – 39.50 ppm). Variable temperature NMR 
experiments were performed at 90 °C on the Bruker Avance 400 NMR spectrometer. 1H and 
13C NMR resonances assignments were confirmed by analysis of NMR experiments: APT, 
gCOSY, gHSQC, gHMBC, zTOCSY and NOESY. Carbon resonances that required 2-D 
NMR analysis for assignment (i.e. not observed via 1-D 13C NMR analysis) are marked with 
the label “observed by gHMBC” or “observed by gHSQC”. Compounds that exhibited non-
observable carbon resonances in both 1-D and 2-D NMR analysis are denoted and explained 
with footnotes. Unassigned aromatic hydrogens are labelled as “Ar”, whereas 





hydrogen atom attached to aromatic carbon #3). NMR spectra were processed and prepared 
with MestReNova (version 6.0) NMR software. Low resolution mass spectra (LRMS) were 
obtained via electrospray ionization (ESI) on a Shimadzu LC-2010 mass spectrometer. 
LRMS data was recorded as the ion mass/charge ratio (m/z). High resolution mass 
spectrometry (HRMS) was performed on a Waters Quadrupole-Time of Flight (QTOF) Xevo 
spectrometer via ESI and with Leucine-Enkephalin as an internal standard. All mass 
spectrometry samples were dissolved in high performance liquid chromatography (HPLC) 
grade MeOH (containing <1% formic acid for ionization). Optical rotations were measured 
on a Jasco P-2000 polarimeter with a 10 cm path length; rotation values (α) are expressed in 
units of “deg cm3 g-1 dm-1” with concentration (c) expressed in units of “g/100 mL”. Solid-
state infrared spectroscopy was performed on a Shimadzu IRAffinity-1 FTIR spectrometer 
in combination with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory 
outfitted with a 1.5 mm round diamond crystal. IR peaks are reported as the wavenumber 
(?̅?max in cm-1) of the maximum absorption. 
 
6.2 – General synthetic procedures 
 General Procedure I: Alkylation of phenols (with ethyl bromoacetate) 
To a stirred solution of the phenol (1 eq) in dry DMF (5 mL/mmol substrate) was 
added K2CO3 (3 eq), followed by ethyl bromoacetate (1.3 eq) at room temperature and the 
reaction was allowed to stir at rt for 12 h. The reaction mixture was diluted with EtOAc (2 x 
50 mL), washed with water (2 x 50 mL), brine (2 x 50 mL) and dried (MgSO4). The solution 
was filtered, concentrated under vacuum and the residue was subjected to silica gel flash 






General Procedure II: Ester hydrolysis (with KOH) 
To a stirred solution of the ester (1 eq) in ethanol (10 mL/mmol substrate) was added 
7% KOH solution (5 mL/mmol) at rt and the reaction was allowed to stir at rt for 2 h. The 
reaction mixture was acidified with 1 M HCl (25 mL) and extracted with EtOAc (2 x 25 mL). 
The combined organic extracts were washed with brine (50 mL) and dried (MgSO4). The 
solution was filtered, concentrated under vacuum to afford the acid product.  
 
General Procedure III: Amide coupling 
The amine (1.0 eq), carboxylic acid (1.0 eq), EDC.HCl (1.2 eq), HOBt (1.1 eq) and 
TEA (1 eq) were combined in a dichloromethane/acetonitrile solution (10 mL/mmol amine) 
and stirred at rt for the specified time. The solvent was removed (not required for ≤ 5.0 mL 
dichloromethane/acetonitrile) and the residue was dissolved in EtOAc (25 mL for reactions 
that contained ≤ 1.0 mmol amine or 25 mL/mmol amine for larger scale reactions). The 
organic solution was washed successively with aqueous HCl (1.0 M – 2 x 25 mL), saturated 
aqueous NaHCO3 (3 x 25 mL) and brine (1 x 25 mL). The EtOAc solution was dried 
(MgSO4), filtered and concentrated. If necessary, the residue was subjected to further 
purification via flash chromatography over SiO2 gel to furnish the targeted amide product. 
 
General Procedure IV: Copper-catalyzed azide-alkyne cycloaddition 
To a stirred solution of the azide (1.0 eq) and alkyne (2.0 – 3.0 eq) in tert-
butanol/water (4:1) at rt was added CuSO4∙5H2O (0.2 eq), followed by sodium ascorbate (0.4 
eq). Stirring was continued at rt (unless noted otherwise) for the specified time. Aqueous 
saturated NH4Cl solution (1 mL), then water (20 mL) was added, and the mixture was 
extracted with EtOAc (20 mL for reactions that contained ≤ 1.0 mmol azide or 20 mL/mmol 





brine (2 x 25 mL) and dried (MgSO4). The solution was filtered, concentrated under vacuum 
and the residue was subjected to flash chromatography over SiO2 gel to afford the desired 
1,4-disubstituted 1,2,3-triazole product. 
 
General Procedure V: Ruthenium-catalyzed azide-alkyne cycloaddition 
To a stirred solution of the azide (1 eq) in dry 1,4-dioxane (2 mL/mmol substrate), in 
a dried flask equipped with a condenser and under an atmosphere of nitrogen at room 
temperature, was added the alkyne (1.1 eq), followed by pentamethylcyclopentadienylbis 
(triphenylphosphine)ruthenium(II) chloride (0.1 eq). The mixture was stirred and heated at 
70 °C for 12 h. The reaction mixture was cooled to room temperature and saturated aqueous 
NH4Cl solution (1 mL), then water (25 mL) was added, and the mixture was extracted with 
EtOAc (2 x 25 mL). The combined extracts were washed with water (2 x 25 mL), brine (2 x 
25 mL) and dried (MgSO4). The solution was filtered, concentrated under vacuum and the 
residue was subjected to flash chromatography over SiO2 gel to afford the desired 1,5-
disubstituted 1,2,3-triazole product.  
 
General Procedure VI: Magnesium-promoted azide-alkyne cycloaddition 
To a dried flask equipped with a condenser and containing a solution of EtMgCl (2 
M in diethyl ether, 1.2 eq) in dry THF (10 mL/mmol) under a nitrogen atmosphere at room 
temperature, was added dropwise, via a syringe, the alkyne (1.1 eq). The mixture was stirred 
and heated at 50 °C for 30 min. The solution was cooled to rt and a solution of the azide (1 
eq) in dry THF (10 mL/mmol) was added dropwise over a period of 5 min at rt. After a further 
10 min, the reaction mixture was stirred and heated at 50 °C for 3-5 h. Aqueous saturated 





EtOAc (2 x 25 mL). The combined extracts were washed with water (2 x 25 mL), brine (2 x 
25 mL) and dried (MgSO4). The solution was filtered, concentrated under vacuum and the 
residue was subjected to silica gel flash column chromatography over SiO2 gel to afford the 
desired 1,5-disubstituted 1,2,3-triazole product.  
 
General Procedure VII: Amine deprotection (N-Boc and/or N-Pbf removal) 
 
The N-protected amine (1.0 eq) was dissolved in a CH2Cl2 (30 mL/mmol substrate) 
with magnetic stirring. If the substrate molecule contained an N-Pbf moiety then H2O (20.0 
eq) was also added to the solution. TFA (30.0 mL/mmol substrate) was then added and the 
reaction mixture was stirred at rt overnight (> 16 h) followed by removal of the solvent. The 
residue was dissolved in CH2Cl2 (30 mL/mmol substrate), an excess amount of anhydrous 
HCl (2.0 M in Et2O, 15 mL/mmol substrate, 30.0 eq) was added and the solvent was then 
removed. The resulting residue was dissolved in a minimal volume of CH2Cl2 (or MeOH) 
and excess Et2O (25 mL for ≤ 0.1 mmol substrate) was added to precipitate the hydrochloride 
salt of the amine. The reaction mixture was filtered, resulting filtrate was collected and 
concentrated, then triturated with Et2O (3 x 20 mL). The product was collected by dissolution 
in MeOH; concentration followed by drying in vacuo gave the final mono or di-hydrochloride 
salt as a thin, translucent film that was routinely scratched with a spatula into a fine 
hygroscopic powder or amorphous gum. 
 
6.3 – Synthesis  
6.3.1 – Precursor Building Blocks (Aromatic Cores) 







Following General Procedure IV, benzyl azide (1.00 g, 7.51 mmol, 0.5 
M in CH2Cl2), 2-ethynylphenol 69 (0.89 g, 7.51 mmol), CuSO4∙5H2O 
(0.37 g, 1.50 mmol) and sodium ascorbate (0.59 g, 3.01 mmol) were 
stirred in t-BuOH (10 mL) and H2O (2.5 mL) at rt for 12 h to give the 
triazole 70 (1.51 g, 80%) as a translucent tan gum after flash chromatography over SiO2 gel 
(EtOAc/n-hexane - 20:80). TLC (EtOAc/n-hexane - 40:60): Rf = 0.6; 
1H NMR (500 MHz, 
CDCl3) δ 10.82 (brs, 1H, -OH), 7.72 (s, 1H, H5), 7.41-7.39 (m, 3H, H6', H3''/H5''), 7.34-7.30 
(m, 3H, H2''/H4''/H6''), 7.23 (apparent t, J = 8.0 Hz, 1H, H4'), 7.04 (d, J = 8.0 Hz, 1H, H3'), 
6.85 (apparent t, J = 8.0 Hz, 1H, H5'), 5.59 (s, 2H, CH2Ph); 
13C NMR (126 MHz, CDCl3) δ 
156.0 (C2'), 148.3 (C4), 134.2 (C1''), 129.9 (C4'), 129.4 (C3''/C5''), 129.2 (C2''/C6''), 128.3 
(C6'), 125.9 (C5), 119.5 (C4''), 118.8 (C5'), 117.8 (C1'), 114.0 (C3'), 54.7 (CH2Bn); IR (neat) 
?̅?max 3021, 3138, 3033, 1617, 1580, 1478, 1449, 1356, 1277, 1247, 1235, 1213, 1157, 1071, 
1056, 1033, 728, 692, 653 cm-1; MS (ESI +ve) m/z 252 ([M + H]
+
, 100%) ; HRMS (ESI +ve 
TOF) calcd for C15H14N3O 252.1137, found 252.1136 ([M+H]
+). 
 
2-(2-(1-Benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetic acid (50) 
To a stirred solution of 2-(1-benzyl-1H-1,2,3-triazol-4-yl)phenol 70 
(1.50 g, 5.97 mmol) in dry THF (10 mL) was added K2CO3 (2.47 g, 
17.92 mmol), followed by bromoacetic acid (1.24 g, 8.95 mmol) at rt 
and the reaction was stirred and heated at 80 °C for 12 h. The reaction 
mixture was cooled to rt, diluted with water (50 mL) and extracted with Et2O (50 mL). The 
aqueous layer was cooled to 0 °C, acidified with 1 M HCl solution (25 mL) and the resultant 





80%) as a white solid. M.P: 138 - 140 °C. TLC (MeOH/CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR 
(500 MHz, CDCl3) δ 8.64 (s, 1H, H5), 8.23 (d, J = 8.0 Hz, 1H, H6'), 7.40-7.33 (m, 5H, 
H2'''/H3'''/H4'''/H5'''/H6'''), 7.30 (apparent t, J = 8.3 Hz, 1H, H4'), 7.11 (apparent t, J = 8.0 
Hz, 1H, H5'), 6.88 (d, J = 8.3 Hz, 1H, H3'), 5.60 (s, 2H, CH2Ph), 4.68 (s, 2H, H1''), COOH 
resonance was not observed; 13C NMR (126 MHz, CDCl3) δ 170.6 (C=O), 153.7 (C2'), 143.3 
(C4), 134.9 (C1'''), 129.0 (C3'''/C5'''), 128.9 (C4'), 128.5 (C2'''/C6'''), 127.9 (C6'), 127.4 (C5), 
124.3 (C4'''), 121.9 (C5'), 119.5 (C1'), 111.8 (C3'), 65.3 (C1''), 54.1 (CH2Ph); IR (neat) ?̅?max 
2950, 1735, 1608, 1586, 1550, 1490, 1438, 1351, 1290, 1224, 1126, 1078, 1047, 835, 756, 
725, 696, 648 cm-1; MS (ESI +ve) m/z 348 ([M + K]
+
, 100%), 310 ([M + H]
+
, 25%); HRMS 
(ESI +ve TOF) calcd for C17H15N3O3Na 332.1011, found 332.1003 ([M + Na]
+). 
 
Ethyl 2-(2-iodophenoxy)acetate (72)78 
Following General Procedure I, 1-iodophenol 71 (5.00 g, 22.72 
mmol), K2CO3 (9.42 g, 68.18 mmol) and ethyl bromoacetate (4.93 g, 
29.54 mmol) were stirred in dry DMF (40 mL) at rt for 16 h to give 
the ester 72 (6.52 g, 93%) as a pale brown oil after flash chromatography over SiO2 gel 
(EtOAc/n-hexane - 10:90). The spectroscopic data was found to be in agreement with those 
previously reported.78 TLC (EtOAc/n-hexane - 20:80): Rf = 0.6; 
1H NMR (500 MHz, CDCl3) 
δ 7.78  (d, J = 8.0 Hz, 1H, H6), 7.28-7.25 (m, 1H, H4), 6.78-6.71 (m, 2H, H3/H5), 4.67 (s, 
2H, H1'), 4.25 (q, J = 7.0 Hz, 2H, OCH2CH3), 1.28 (t, J = 7.0 Hz, 3H, OCH2CH3); 
13C NMR 
(126 MHz, CDCl3) δ 168.3 (C=O), 156.8 (C2), 139.7 (C6), 129.6 (C4), 123.6 (C5), 112.6 
(C3), 86.5 (C1), 66.5 (C1') , 61.6 (OCH2CH3), 14.1 (OCH2CH3); IR (neat) ?̅?max 3480, 2984, 
2940, 1743, 1621, 1501, 1461, 1448, 1379, 1350, 1293, 1209, 1152, 1104, 802, 763 cm-1; 





Ethyl 2-(2-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetate (73) 
To a stirred solution of ethyl 2-(2-iodophenoxy)acetate 72 (1.00 g, 
3.26 mmol), 5-methyl-1-hexyne (0.94 g, 9.80 mmol), CuI (0.12 g, 
0.65 mmol), NaN3 (0.23 g, 3.59 mmol) and sodium ascorbate (0.26 
g, 1.30 mmol) in DMSO (10 mL)/H2O (2 mL) was added racemic 
trans-N,N'-dimethylcyclohexane-1,2-diamine (0.09 g, 0.65 mmol) at 
rt under nitrogen atmosphere. The reaction mixture was stirred and heated at 75 °C for 16 h.  
The reaction was cooled to rt and aqueous saturated NH4Cl solution (10 mL) was added and 
the mixture was extracted with EtOAc (2 x 50 mL). The combined extracts were washed with 
water (50 mL), brine (50 mL) and dried (MgSO4). The solution was filtered, concentrated 
under vacuum and the residue was subjected to silica gel flash column chromatography over 
SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 73 (0.91 g, 87%) as a yellow waxy 
solid. TLC (EtOAc/n-hexane - 20:80); Rf = 0.5; 
1H NMR (500 MHz, CDCl3) δ 8.16 (s, 1H, 
H5), 7.87 (d, J = 7.5 Hz, 1H, H6'), 7.35 (apparent t, J = 7.5 Hz, 1H, H4'), 7.13 (apparent t, J 
= 7.5 Hz, 1H, H5'), 6.96 (d, J = 7.5 Hz, 1H, H3'), 4.68 (s, 2H, H1'''), 4.25 (q, J = 7.0 Hz, 2H, 
OCH2CH3), 2.81 (t, J = 7.5 Hz, 2H, H1''), 1.70-1.61 (m, 3H, H2''/H3''), 1.29 (t, J = 7.5 Hz, 
3H, OCH2CH3), 0.96 (d, J = 6.0 Hz, 6H, H4''/H5''); 
13C NMR (126 MHz, CDCl3) δ 168.0 
(C=O), 149.0 (C2'), 148.1 (C4), 129.4 (C4'), 127.2 (C6'), 125.4 (C5'), 123.1 (C5), 122.4 (C3'), 
113.3 (C1'), 65.9 (C1'''), 61.6 (OCH2CH3), 38.5 (C2''), 27.7 (C1''), 23.7 (C3''), 22.4 (C4''/C5''; 
Observed by gHMBC), 14.1 (OCH2CH3); IR (neat) ?̅?max 2957, 2870, 1755, 1601, 1548, 1509, 
1466, 1379, 1296, 1230, 1203, 1167, 1129, 1073, 977, 758 cm-1; MS (ESI +ve) m/z 318 ([M 







2-(2-(4-Isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic acid (51) 
Following General Procedure II, ethyl 2-(2-(4-isopentyl-1H-1,2,3-
triazol-1-yl)phenoxy) acetate 73 (0.90 g, 2.84 mmol) and 7% KOH 
solution (3 mL) were stirred in ethanol (10 mL) at rt for 2 h to give the 
product acid 51 (0.71 g, 85%) as a white solid. M.P: 118 - 120 °C. TLC 
(EtOAc/n-hexane - 100:0): Rf = 0.2; 
1H NMR (500 MHz, CDCl3) δ      
9.36 (brs, 1H, COOH), 8.19 (s, 1H, H5), 7.77 (d, J = 7.5 Hz, 1H, H6'), 7.39 (apparent t, J = 
7.5 Hz, 1H, H4'), 7.13 (apparent t, J = 7.5 Hz, 1H, H5'), 7.04 (d, J = 7.5 Hz, 1H, H3'), 4.76 
(s, 2H, H1'''), 2.80 (t, J = 7.5 Hz, 2H, H1''), 1.64-1.59 (m, 3H, H2''/H3''), 0.92 (d, J = 5.5 Hz, 
6H, H4''/H5'');  13C NMR (126 MHz, CDCl3) δ 170.8 (C=O), 149.4 (C2'), 147.9 (C4), 130.2 
(C4'), 126.7 (C6'), 125.4 (C5'), 123.7 (C5), 122.5 (C3'), 113.6 (C1'), 65.9 (C1'''), 38.3 (C2''), 
27.7 (C1''), 23.2 (C3''), 22.4 (C4''/5''; Observed by gHMBC); IR (neat) ?̅?max 3160, 2955, 2930, 
1737, 1602, 1505 1471, 1439, 1294, 1219, 1181, 1129, 1065, 835, 753 cm-1; MS (ESI +ve) 
m/z 290 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C15H20N3O3 290.1505, found 
290.1513 ([M + H]+). 
 
Ethyl 2-(2-azidophenoxy)acetate (77) 
To a stirred solution of ethyl 2-(2-iodophenoxy)acetate 72 (1.00 g, 
3.26 mmol), CuI (0.06 g, 0.32 mmol), NaN3 (0.24 g, 3.59 mmol) and 
sodium ascorbate (0.06 g, 0.32 mmol) in DMSO (10 mL)/H2O (2 mL) 
was added racemic trans-N,N'-dimethylcyclohexane-1,2-diamine (0.07 g, 0.49 mmol) at rt 
under nitrogen atmosphere. The reaction mixture was stirred and heated at 80 °C for 5 h.  The 
reaction was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The 





solution was filtered, concentrated under vacuum and the residue was subjected to silica gel 
flash column chromatography over SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 77 
(0.51 g, 70%) as a yellow waxy solid. TLC (EtOAc/CH2Cl2/n-hexane – 10:10:80); Rf = 0.5; 
1H NMR (400 MHz, CDCl3) δ 7.08-6.95 (m, 3H, H4/H5/H6), 6.81 (dd, J = 8.1, 1.3 Hz, 1H, 
H3), 4.67 (s, 2H, H1'), 4.26 (q, J = 7.1 Hz, 2H, OCH2CH3), 1.28 (t, J = 7.1 Hz, 3H, 
OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 168.3 (C=O), 150.2 (C2), 129.1 (C1), 125.4 (C6), 
122.6 (C4), 120.7 (C5), 113.8 (C3), 66.2 (C1'), 61.4 (OCH2CH3), 14.12 (OCH2CH3); IR 
(neat) ?̅?max 2984, 2116, 1756, 1738, 1592, 1495, 1473, 1454, 1379, 1297, 1199, 1106, 1072, 
1020, 749 cm-1; MS (ESI +ve) m/z 194 ([M + H – N2]
+, 100%). 
 
Ethyl 2-(2-(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetate (78) 
Following General Procedure V, ethyl 2-(2-azidophenoxy)acetate 
77 (0.53 g, 2.40 mmol), 5-methyl-1-hexyne (0.46 g, 4.80 mmol) and 
pentamethylcyclopentadienylbis(triphenylphosphine) ruthenium(II) 
chloride (0.19 g, 0.24 mmol) were stirred and heated in 1,4-dioxane 
at 70 °C for 12 h to give the ester 78 (0.28 g, 37%) as a pale-yellow oil after flash 
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80). TLC (EtOAc/n-hexane – 50:50): 
Rf = 0.3;
 1H NMR (400 MHz, CDCl3) δ 7.55 (s, 1H, H4), 7.46 (apparent t, J = 6.8 Hz, 1H, 
H4'), 7.37 (d, J = 6.4 Hz, 1H, H6'), 7.14 (apparent t, J = 6.4 Hz, 1H, H5'), 6.92 (d, J = 6.8 Hz, 
1H, H3'), 4.55 (s, 2H, H1'''), 4.20 (q, J = 5.6 Hz, 2H, OCH2CH3), 2.64-2.56 (m, 2H, H1''), 
1.56-1.42 (m, 3H, H2''/H3''), 1.24 (t, J = 5.6 Hz, 3H, OCH2CH3), 0.81 (d, J = 5.2 Hz, 6H, 
H4''/H5''); 13C NMR (101 MHz, CDCl3) δ 168.1 (C=O), 152.6 (C2'), 140.6 (C5), 131.5 (C4), 
131.5 (C4'), 129.2 (C6'), 125.8 (C1'), 122.2 (C5'), 113.2 (C3'), 65.7 (C1'''), 61.6 (OCH2CH3), 





2935, 2870, 1755, 1602, 1509, 1466, 1445, 1381, 1369, 1295, 1203, 1167, 1129, 1073, 1025, 
977, 757 cm-1; MS (ESI +ve) m/z 340 ([M + Na]+, 100%); HRMS (ESI +ve TOF) calcd for 
C17H23N3O3Na 340.1637, found 340.1638 ([M + Na]
+). 
 
2-(2-(5-Isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic acid (52) 
Following General Procedure II, ethyl 2-(2-(5-isopentyl-1H-1,2,3-
triazol-1-yl)phenoxy)acetate 78 (0.28 g, 0.88 mmol) and 7% KOH 
solution (4 mL) were stirred in ethanol (4 mL) at rt for 2 h to give the 
product acid 52 (0.21 g, 78%) as a pale brown solid. M.P: 128-130 °C. 
TLC (EtOAc/n-hexane - 100:0): Rf = 0.2; 
1H NMR (500 MHz, CDCl3) δ 8.10 (brs, 1H, 
COOH), 7.62 (s, 1H, H4), 7.49 (apparent t, J = 8.0 Hz, 1H, H4'), 7.35 (d, J = 7.5 Hz, 1H, 
H6'), 7.15 (apparent t, J = 7.5 Hz, 1H, H5'), 7.03 (d, J = 8.0 Hz, 1H, H3'), 4.64 (s, 2H, H1'''), 
2.61 (t, J = 7.5 Hz, 2H, H1''), 1.56-1.42 (m, 3H, H2''/H3''), 0.81 (d, J = 6.5 Hz, 6H, H4''/H5''); 
13C NMR (126 MHz, CDCl3) δ 170.6 (C=O), 152.4 (C2'), 140.6 (C5), 131.9 (C4), 131.6 
(C4'), 128.5 (C6'), 125.6 (C1'), 122.6 (C5'), 114.1 (C3'), 66.0 (C1'''), 37.1 (C2''), 27.6 (C1''), 
22.3 (C4''/C5''; Observed by gHMBC), 21.3 (C3''); IR (neat) ?̅?max 2960, 2929, 2871, 1722, 
1602, 1509, 1465, 1371, 1296, 1231, 1164, 1110, 1072, 995, 840, 760 cm-1; MS (ESI +ve) 
m/z 328 ([M + K]+, 100%), 290 ([M + H]+, 60%); HRMS (ESI +ve TOF) calcd for 
C15H19N3O3Na 312.1324, found 312.1329 ([M + Na]
+). 
 
6.3.1.2 – Triazole linked naphthalic acids 
Ethyl 2-((1-iodonaphthalen-2-yl)oxy)acetate (75) 
Following General Procedure I, 1-iodonaphthol 74 (1.00 g, 





bromoacetate (0.80 g, 4.81 mmol) were stirred in DMF (8 mL) at rt for 16 h to give the ester 
75 (0.68 g, 52%) as a pale yellow waxy solid after flash chromatography over SiO2 gel 
(EtOAc/n-hexane - 10:90). TLC (EtOAc/n-hexane - 20:80): Rf = 0.6; 
1H NMR (400 MHz, 
CDCl3) δ 8.16 (d, J = 7.2 Hz, 1H, H8), 7.78 (d, J = 7.2 Hz, 1H, H5), 7.72 (d, J = 8.0 Hz, 1H, 
H4), 7.54 (t, J = 7.2 Hz, 1H, H7), 7.39 (t, J = 7.2 Hz, 1H, H6), 7.08 (d, J = 8.0 Hz, 1H, H3), 
4.80 (s, 2H, H1'), 4.27 (q, J = 5.6 Hz, 2H, OCH2CH3), 1.29 (t, J = 5.6 Hz, 3H, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 168.7 (C=O), 155.6 (C2), 135.8 (C8a), 131.7 (C4a), 130.6 
(C4), 130.5 (C8), 128.4 (C7), 128.3 (C5), 121.1 (C6), 114.4 (C3), 89.47 (C1), 67.6 (C1'), 
61.7 (OCH2CH3) 14.3 (OCH2CH3); IR (neat) ?̅?max 2981, 1756, 1622, 1593, 1502, 1462, 1349, 
1291, 1200, 1151, 1134, 1096, 1028, 801, 764, 747 cm-1; MS (ESI +ve) m/z 379 ([M + Na]+, 
100%); HRMS (ESI +ve TOF) calcd for C14H13O3NaI 378.9807, found 378.9801 ([M + 
Na]+). 
 
Ethyl 2-((1-(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate (76) 
To a stirred solution of ethyl 2-(2-iodophenoxy)acetate 75 (0.20 
g, 0.54 mmol), 5-methyl-1-hexyne (0.16 g, 1.64 mmol), CuI 
(0.02 g, 0.11 mmol), NaN3 (0.04 g, 0.60 mmol) and sodium 
ascorbate (0.04 g, 0.22 mmol) in DMSO (2.5 mL) H2O (0.5 
mL) was added racemic trans-N,N'-dimethyl cyclohexane-1,2-
diamine (0.016 g, 0.11 mmol) at rt under a nitrogen atmosphere. The reaction mixture was 
stirred and heated at 75 °C for 16 h.  The reaction was cooled to rt and aqueous saturated 
NH4Cl solution (3 mL) was added and the mixture was extracted with EtOAc (2 x 25 mL). 
The combined extracts were washed with water (25 mL), brine (25 mL) and dried (MgSO4). 





gel flash column chromatography over SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 
76 (0.05 g, 25%) as a yellow waxy solid. TLC (EtOAc/n-hexane - 33:67); Rf = 0.4; 
1H NMR 
(400 MHz, CDCl3) δ 7.97 (d, J = 7.2 Hz, 1H, H8'), 7.84 (d, J = 6.4 Hz, 1H, H5'), 7.67 (s, 1H, 
H5), 7.49-7.41 (m, 2H, H6'/H7'), 7.27-7.25 (m, 2H, H3'/H4'), 4.67 (s, 2H, H1'''), 4.22 (q, J = 
5.6 Hz, 2H, OCH2CH3), 2.89 (t, J = 5.6 Hz, 2H, H1''), 1.73-1.67 (m, 3H, H2''/H3''), 1.26 (t, J 
= 5.6 Hz, 3H, OCH2OCH3), 0.99 (d, J = 4.0 Hz, 6H, H4''/H5''); 
13C NMR (101 MHz, CDCl3) 
δ 168.5 (C=O), 150.5 (C2'), 148.1 (C8a'), 131.6 (C4), 131.3 (C4a'), 129.5 (C4'), 128.5 (C5'), 
127.9 (C7'), 125.3 (C8'), 124.7 (C6'), 122.1 (C5), 121.3 (C3'), 114.3 (C1'), 66.7 (C1'''), 61.6 
(OCH2CH3), 38.6 (C2''), 27.9 (C1''), 23.8 (C3''), 22.5 (C4''/C5''; Observed by gHMBC), 14.2 
(OCH2CH3); IR (neat) ?̅?max 2954, 2928, 2868, 1748, 1632, 1600, 1513, 1483, 1454, 1430, 
1366, 1288, 1206, 1150, 1117, 1087, 1042, 806, 749 cm-1; MS (ESI +ve) m/z 390 ([M +Na]+, 
100%); HRMS (ESI +ve TOF) calcd for C21H26N3O3 368.1974, found 368.1985 ([M + H]
+). 
 
2-((1-(4-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid (54) 
Following General Procedure II, ethyl 2-((1-(4-isopentyl-1H-
1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate 76 (0.07 g, 0.19 
mmol) and 7% KOH solution (0.5 mL) were stirred in ethanol (2 
mL) at rt for 2 h to give after acidification the acid 54 (0.04 g, 62%) 
as a white solid. M.P: 152 – 154 °C. TLC (EtOAc/n-hexane - 
100:0): Rf = 0.2; 
1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 9.0 Hz, 1H, H8'), 7.88 (d, J = 7.5 
Hz, 1H, H5'), 7.69 (s, 1H, H5), 7.54-7.46 (m, 2H, H6'/H7'), 7.47-7.29 (m, 2H, H3'/H4'), 4.78 
(s, 2H, H1'''), 2.91-2.87 (m, 2H, H1''), 1.71-1.68 (m, 3H, H2''/H3''), 0.98 (d, J = 6.0 Hz, 6H, 
H4''/H5''), COOH resonance was not observed; 13C NMR (126 MHz, CDCl3) δ 170.6 (C=O), 





125.6 (C8'), 124.9 (C6'), 121.7 (C5), 120.9 (C3'), 114.4 (C1'), 66.8 (C1'''), 38.5 (C2''), 28.0 
(C1''), 23.7 (C3''), 22.6 (C4''/C5''; Observed by gHMBC); IR (neat) ?̅?max 3147, 2954, 2929, 
2868, 1731, 1631, 1600, 1514, 1483, 1429, 1366, 1284, 1213, 1151, 1118, 1087, 1062, 923, 
806, 748 cm-1; MS (ESI +ve) m/z 362 ([M + Na]+, 40%), 340 ([M + H]+, 100%); HRMS (ESI 




To an ice-cold solution of 2-methoxynaphthalene 79 (3.00 g, 18.96 mmol) 
in acetic anhydride (35 mL) was added fuming HNO3 (1.32 g, 20.85 
mmol) dropwise at 0 °C. The mixture was stirred at rt for 1 h and placed 
in a freezer for 16 h. The deposited crystals were filtered, washed with acetic anhydride, 
water and dried under vacuum for 3 h to afford nitro compound 80 (0.86 g, 22%) as a yellow 
solid. TLC (EtOAc/n-hexane - 20:80): Rf = 0.5; The spectroscopic data were found to be in 
agreement with that previously reported.80 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.2 Hz, 
1H, H8), 7.84 (d, J = 9.1 Hz, 1H, H4), 7.68 (dd, J = 8.5, 0.8 Hz, 1H, H5), 7.61-7.57 (m, 1H, 
H7), 7.47-7.43 (m, 1H, H6), 7.34 (d, J = 9.1 Hz, 1H, H3), 4.03 (s, 3H, OMe); 13C NMR (101 
MHz, CDCl3) δ 148.6 (C2), 132.1 (C8a), 129.1 (C4), 128.2 (C4a), 128.1 (C7), 128.0 (8), 
125.6 (C6), 125.1 (C1), 120.4 (C5), 113.0 (C3), 57.0 (OMe); IR (neat) ?̅?max 3030, 2944, 2846, 
1636, 1602, 1515, 1459, 1436, 1357, 1280, 1259, 1220, 1155, 1079, 809, 795 cm-1; MS (ESI 
+ve) m/z 204 ([M + H]+, 100%). 
 
2-Methoxynaphthalen-1-amine (81)81 
Iron powder (0.14 g, 0.49 mmol) was added to a stirred solution of 2-





(2 mL : 1 mL : 2 mL) at rt and the mixture was sonicated for 2 h. The reaction was basified 
with aqueous KOH solution (3 mL) and extracted with EtOAc (2 x 25 mL). The combined 
extracts were washed with water (25 mL), brine (25 mL) and dried (MgSO4). The solution 
was filtered, concentrated under vacuum and the residue was subjected to silica gel flash 
column chromatography over SiO2 gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 81 (0.07 
g, 82%) as a brown oil. TLC (EtOAc/n-hexane - 20:80); Rf = 0.5; The spectroscopic data 
were found to be in agreement with those previously reported.81 1H NMR (400 MHz, CDCl3) 
δ 7.76-7.73 (m, 2H, H8/H5), 7.43-7.39 (m, 1H, H7), 7.33-7.29 (m, 2H, H4/H6), 7.22 (d, J = 
8.8 Hz, 1H, H3), 4.22 (brs, 2H, NH2), 3.95 (s, 3H, OMe); 
13C NMR (101 MHz, CDCl3) δ 
142.5 (C2), 129.5 (C4), 129.4 (C4a), 128.3 (C8a), 125.0 (C5), 123.9 (C7), 123.5 (C8), 120.2 
(C1), 118.4 (C6), 113.5 (C3), 56.7 (OMe); IR (neat) ?̅?max 3452, 3366, 2936, 2837, 1683, 
1609, 1513, 1475, 1407, 1268, 1242, 1097, 1047, 794, 744 cm-1; MS (ESI +ve) m/z 174 ([M 
+ H]+, 60%), 142 (60%), 91 (100%). 
 
1-Azido-2-methoxynaphthalene (82) 
A solution of NaNO2 (0.04 g, 0.60 mmol) in H2O (0.5 mL) was added 
dropwise to a stirred suspension of 2-methoxynaphthalen-1-amine 81 
(0.07 g, 0.40 mmol) in 3 N HCl solution (2 mL) at 0 °C and stirring at 
 0 °C was continued for 15 min. Then NaN3 (0.05 g, 0.80 mmol) in H2O (0.5 mL) was 
added at 0 °C and after 10 min the mixture was continued stirring at rt for 3 h. The reaction 
was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The combined 
extracts were washed with water (20 mL), brine (20 mL) and dried (MgSO4). The solution 
was filtered, concentrated under vacuum and the residue was subjected to silica gel flash 





g, 31%) as a brown waxy solid. TLC (EtOAc/n-hexane – 20:80); Rf = 0.7; 
1H NMR (400 
MHz, CDCl3) δ 8.07 (dd, J = 8.5, 1.0 Hz, 1H, H8), 7.72 (d, J = 8.2 Hz, 1H, H5), 7.62 (d, J = 
9.0 Hz, 1H, H4), 7.47-7.43 (m, 1H, H7), 7.37-7.33 (m, 1H, H6), 7.23 (d, J = 9.0 Hz, 1H, H3), 
4.01 (s, 3H, OMe); 13C NMR (101 MHz, CDCl3) δ 150.3 (C2), 129.3 (C8a), 127.7 (C4), 
127.5 (C4a), 126.5 (C5), 125.6 (C8), 124.4 (C7), 122.4 (C1), 121.4 (C6), 114.0 (C3), 57.1 
(OMe); IR (neat) ?̅?max 3058, 3005, 2938, 2841, 2103, 2045, 1591, 1507, 1441, 1375, 1290, 
1146, 1084, 1017, 912, 806, 747 cm-1; MS (ESI +ve) m/z 172 ([M + H – N2]
+, 100%).  
 
5-Isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (83) 
Following General Procedure VI, 1-azido-2-methoxynaphthalene 82 
(0.05 g, 0.25 mmol) was treated with 5-methyl-1-hexyne (0.03 g, 0.27 
mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 
mL) at 50 °C for 3 h to give the triazole 83 (0.06 g, 81%) as a pale 
brown waxy solid after flash chromatography over SiO2 gel (EtOAc/n-hexane - 20:80). TLC 
(EtOAc/n-hexane - 20:80): Rf = 0.3; 
1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 9.1 Hz, 1H, 
H8'), 7.85 (dd, J = 7.4, 2.0 Hz, 1H, H5'), 7.71 (s, 1H, H4), 7.45-7.37 (m, 3H, H6', H7' and 
H4'), 6.97 (d, J = 9.0 Hz, 1H, H3'), 3.87 (s, 3H, OMe), 2.45-2.34 (m, 2H, H1''), 1.47-1.35 (m, 
3H, H2'' and H3''), 0.73 (d, J = 7.9 Hz, 3H, H5''),  0.72 (d, J = 7.9 Hz, 3H, H4''); 13C NMR 
(101 MHz, CDCl3) δ 152.7 (C2'), 140.7 (C5), 132.0 (C8a'), 131.6 (C4), 131.4 (C4a'), 128.7 
(C4'), 128.3 (C5'), 127.9 (C7'), 124.6 (C8'), 121.2 (C6'), 117.9 (C3'), 113.1 (C1'), 56.5 (OMe), 
36.7 (C2''), 27.2 (C1''), 22.08 (C5''), 22.07 (C4''), 20.8 (C3''); IR (neat) ?̅?max 2954, 2868, 1630, 
1599, 1507, 1457, 1275, 1255, 1064, 1040, 809, 748 cm-1; MS (ESI +ve) m/z 318 ([M + Na]+, 
50%), 296 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C18H22N3O 296.1763, found 





              1-(5-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-ol (84) 
BBr3 (0.13 g, 0.51 mmol) was added dropwise to a stirred solution of 
5-isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole 83 (0.05 
g, 0.17 mmol) in CH2Cl2 (1 mL) at -78 °C and after 30 min the mixture 
was allowed to stir at rt for 36 h. The reaction was quenched with 
MeOH (0.5 mL), diluted with EtOAc (25 mL), washed with water (25 mL), brine (25 mL) 
and dried (MgSO4). The solution was filtered, concentrated under vacuum and the residue 
was subjected to silica gel flash column chromatography over SiO2 gel (EtOAc/n-hexane - 
20:80 → 100:0) to afford alcohol 84 (0.04 g, 82%) as a pale brown solid. M.P: 164 - 166 °C. 
TLC (EtOAc/n-hexane – 40:60); Rf = 0.5; 
1H NMR (400 MHz, CDCl3) δ 10.31 (brs, 1H, 
OH), 7.78-7.74 (m, 2H, H8'/H5'), 7.62 (s, 1H, H4), 7.44 (d, J = 8.5 Hz, 1H, H4'), 7.38-7.29 
(m, 2H, H7'/H6'), 6.84 (d, J = 8.5 Hz, 1H, H3'), 2.52-2.32 (m, 2H, H1''), 1.42-1.24 (m, 3H, 
H2''/H3''), 0.69 (d, J = 6.2 Hz, 3H, H5''), 0.65 (d, J = 6.2 Hz, 3H, H4''); 13C NMR (101 MHz, 
CDCl3) δ 151.6 (C2'), 141.5 (C5), 131.9 (C8a'), 131.4 (C4), 131.2 (C4a'), 128.3 (C4'), 128.0 
(C5'), 127.9 (C7'), 123.8 (C8'), 120.4 (C6'), 119.1 (3'), 115.0 (C1'), 36.5 (C2''), 27.2 (C1''), 
22.0 (C4''/C5''), 20.8 (C3''); IR (neat) ?̅?max 3061, 2957, 2869, 1638, 1583, 1512, 1440, 1360, 
1287, 1245, 1149, 997, 951, 818, 749 cm-1; MS (ESI +ve) m/z 304 ([M + Na]+, 100%); HRMS 
(ESI +ve TOF) calcd for C17H20N3O 282.1606, found 282.1602 ([M + H]
+). 
 
Ethyl 2-((1-(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate (85) 
Following General Procedure I, 1-(5-isopentyl-1H-1,2,3-
triazol-1-yl)naphthalen-2-ol 84 (0.04 g, 0.14 mmol), K2CO3 
(0.06 g, 0.42 mmol) and ethyl bromoacetate (0.03 g, 0.18 





ester 85 (0.03 g, 58%) as a pale brown oil after flash chromatography over SiO2 gel 
(EtOAc/n-hexane - 20:80). TLC (EtOAc/n-hexane - 40:60): Rf = 0.6; 
1H NMR (400 MHz, 
CDCl3) δ 8.00 (d, J = 7.2 Hz, 1H, H8'), 7.86 (dd, J = 7.3, 2.0 Hz, 1H, H5'), 7.71 (s, 1H, H4), 
7.46-7.40 (m, 2H, H6'/H7'), 7.24 (d, J = 8.5 Hz, 1H, H4'), 7.02 (d, J = 8.5 Hz, H3'), 4.66 
(ABq, J = 19.0 Hz, 2H, H1'''), 4.22 (q, J = 5.6 Hz, 2H, OCH2CH3), 2.63-2.55 (m, 1H, H1''), 
2.44-2.38 (m, 1H, H1''), 1.48-1.41 (m, 3H, H2''/H3''), 1.24 (t, J = 5.6 Hz, 3H, OCH2CH3), 
0.75 (d, J = 5.1 Hz, 3H, H5''), 0.72 (d, J = 5.0 Hz, 3H, H4''); 3C NMR (101 MHz, CDCl3) δ 
168.2 (C=O), 151.0 (C2'), 141.2 (C5), 131.9 (C8a'), 131.6 (C4), 131.4 (C4'), 129.3 (C4a'), 
128.4 (C5'), 127.9 (C7'), 125.1 (C8'), 121.5 (C6'), 118.9 (C3'), 113.8 (C1'), 66.2 (C1'''), 61.5 
(OCH2CH3), 36.6 (C2''), 27.3 (C1''), 22.1 (C5''), 22.0 (C4''), 20.8 (C3''), 14.1 (OCH2CH3); IR 
(neat) ?̅?max 2956, 2930, 2869, 1752, 1631, 1600, 1512, 1483, 1292, 1202, 1152, 1095, 1025, 
808, 749 cm-1; MS (ESI +ve) m/z 390 ([M + Na]+, 100%); HRMS (ESI +ve TOF) calcd for 
C21H26N3O3 368.2356, found 368.2363 ([M + H]
+). 
 
              2-((1-(5-Isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetic acid (54)  
Following General Procedure II, ethyl 2-((1-(5-isopentyl-1H-
1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetate 85 (0.28 g, 0.76 
mmol) and 7% KOH solution (3 mL) were stirred in ethanol (3 
mL) at rt for 2 h to give the acid 54 (0.22 g, 85%) as a white solid. 
M.P: 148 - 150 °C. TLC (EtOAc/n-hexane - 100:0): Rf = 0.2; 
1H NMR (400 MHz, CDCl3) δ 
8.01 (d, J = 9.0 Hz, 1H, H8'), 7.88-7.86 (m, 1H, H5'), 7.75 (s, 1H, H4), 7.49-7.42 (m, 
H6'/H7'), 7.30 (d, J = 8.5 Hz, 1H, H4'), 7.01 (d, J = 8.5 Hz, 1H, H3'), 4.72 (s, 2H, H1'''), 4.59 
(brs, 1H, COOH), 2.57-2.49 (m, 1H, H1''), 2.44-2.37 (m, 1H, H1''), 1.46-1.33 (m, 3H, 





CDCl3) δ 170.4 (C=O), 151.1 (C2'), 141.6 (C5), 132.3 (C8a'), 131.2 (C4), 131.2 (4'), 129.3 
(C4a'), 128.6 (C5'), 128.1 (C7'), 125.2 (C8'), 121.3 (C6'), 118.6 (3'), 113.9 (C1'), 66.2 (C1'''), 
36.5 (C2''), 27.2 (C1''), 22.0 (C4''/C5''), 20.9 (C3''); IR (neat) ?̅?max 2956, 2935, 2869, 1738, 
1631, 1601, 1513, 1484, 1428, 1277, 1218, 1152, 1093, 811, 751 cm-1; MS (ESI +ve) m/z 
362 ([M + Na]+, 30%), 340 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C19H22N3O3 
340.1661, found 340.1666 ([M + H]+). 
 
6.3.1.3 – Alternate phenyl triazole acids 
2-Azidophenol (87)79 
A solution of NaNO2 (5.06 g, 73.39 mmol) in H2O (5 mL) was added dropwise 
to a stirred suspension of 2-aminophenol 86 (4.00 g, 36.69 mmol) in 3 N HCl 
solution (50 mL) at 0 °C and stirring was continued at 0 °C for 15 min. A 
solution of NaN3 (4.77 g, 73.39 mmol) in H2O (5 mL) was added at 0 °C and after 10 min 
the mixture was stirred at rt for 3 h. The reaction was diluted with water (50 mL) and 
extracted with EtOAc (2 x 100 mL). The combined extracts were washed with water (100 
mL), brine (100 mL) and dried (MgSO4). The solution was filtered, concentrated under 
vacuum and the residue was subjected to silica gel flash column chromatography over SiO2 
gel (EtOAc/n-hexane - 10:90 → 100:0) to afford 87 (3.10 g, 60%) as a brown waxy solid. 
TLC (EtOAc/n-hexane – 20:80); Rf = 0.5; The spectroscopic data were found to be in 
agreement with those previously reported.79 1H NMR (500 MHz, CDCl3) δ 7.07-7.02 (m, 2H, 
H4/H6), 6.94-6.90 (m, 2H, H3/H5), 5.39 (brs, 1H, OH); 13C NMR (126 MHz, CDCl3) δ 147.1 
(C2), 125.8 (C1), 125.8 (C4), 121.1 (C6), 118.2 (C5), 115.9 (C3); IR (neat) ?̅?max 3341, 2121, 







Following General Procedure I, 2-azidophenol 87 (2.00 g, 14.80 
mmol), K2CO3 (6.13 g, 44.40 mmol) and 1-bromo-3-methylbutane 
(2.46 g, 16.28 mmol) were stirred in dry DMF (16 mL) at rt for 48 h 
to give compound 88 (2.56 g, 84%) as a brown oil after flash chromatography over SiO2 gel 
(EtOAc/n-hexane-10:90). TLC (EtOAc/n-hexane-20:80): Rf = 0.6; 
1H NMR (400 MHz, 
CDCl3) δ 7.05-7.02 (m, 1H, H4), 6.92 (dd, J = 8.2, 1.8 Hz, 1H, H6), 6.87-6.84 (m, 2H, 
H3/H5), 4.01 (t, J = 6.7 Hz, 2H, H1'), 1.88-1.82 (m, 1H, H3'), 1.71 (q, J = 6.7 Hz, 2H, H2'), 
0.96 (d, J = 6.6 Hz, 6H, H4'/H5'); 13C NMR (126 MHz, CDCl3) δ 152.0 (C2), 128.3 (C1), 
125.7 (C6), 121.4 (C4), 120.8 (C5), 112.9 (C3), 67.4 (C1'), 37.8 (C2'), 25.1 (C3'), 22.6 
(C4'/C5'); IR (neat) ?̅?max 2956, 2871, 2107, 1592, 1495, 1451, 1386, 1304, 1239, 1149, 1042, 
980, 741 cm-1; MS (ESI +ve) m/z 178 ([M – N2 + H]




Following General Procedure VI, 1-azido-2-(isopentyloxy)benzene 
88 (1.30 g, 6.34 mmol) was treated with tetrahydro-2-(2-
propynyloxy)-2H-pyran (0.98 g, 6.97 mmol) and EtMgCl (0.67 g, 
7.61 mmol; 2 M in Et2O) in dry THF (13 mL) at 50 °C for 48 h to give triazole 89 (1.20 g, 
55%) as a pale brown oil after flash chromatography over SiO2 gel (EtOAc/n-hexane - 10:90). 
TLC (EtOAc/n-hexane - 20:80): Rf = 0.4; 
1H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H, H4), 
7.48-7.44 (m, 1H, H4'), 7.39 (dd, J = 7.9, 1.7 Hz, 1H, H6'), 7.08-7.05 (m, 2H, H3'/H5'), 4.69 
(d, J = 13.1 Hz, 1H, CHAHBOTHP), 4.52 (t, J = 3.2 Hz, 1H, H2'''), 4.46 (d, J = 13.1 Hz, 1H, 





1.69-1.64 (m, 1H, H3''), 1.61-1.37 (m, 8H, H2''/H3'''/H4'''/H5'''), 0.83 (d, J = 6.4 Hz, 6H, 
H4''/H5''); 13C NMR (126 MHz, CDCl3) δ 153.5 (C2'), 136.5 (C5), 132.8 (C4), 131.5 (C4'), 
128.6 (C6'), 125.4 (C1'), 120.7 (C5'), 113.1 (C3'), 97.8 (C2'''), 67.5 (C1''), 61.6 (C6'''), 57.9 
(CHAHBOTHP), 37.6 (C2''), 30.1 (C3'''), 25.3 (C5'''), 25.0 (C3''), 22.5 (C4''), 22.4 (C5''), 18.7 
(C4'''); IR (neat) ?̅?max 2952, 2871, 1602, 1509, 1465, 1387, 1350, 1287, 1261, 1247, 1123, 
1056, 1033, 975, 871, 816, 755 cm-1; MS (ESI +ve) m/z  346 ([M + H]+, 100%); HRMS (ESI 




To a stirred solution of 1-(2-(isopentyloxy)phenyl)-5-(((tetrahydro-
2H-pyran-2-yl)oxy)methyl)-1H-1,2,3-triazole 89 (1.17 g, 3.39 
mmol) in MeOH (15 mL) was added p-toluene sulfonic acid 
monohydrate (0.71 g, 3.73 mmol) at rt and the mixture was allowed to stir at rt for 16 h. The 
reaction mixture was concentrated under vacuum and the residue was subjected to silica gel 
flash column chromatography over SiO2 gel (MeOH/CH2Cl2 - 5:95 → 100:0) to afford 90 
(0.71 g, 80%) as a light brown oil. TLC (MeOH/CH2Cl2 – 10:90); Rf = 0.4; 
1H NMR (500 
MHz, CDCl3) δ 7.71 (s, 1H, H4), 7.50-7.46 (m, 1H, H4'), 7.37-7.35 (m, 1H, H6'), 7.09-7.06 
(m, 2H, H3'/H5'), 4.58 (s, 2H, CH2OH), 3.99 (t, J = 6.6 Hz, 2H, H1''), 3.95 (brs, 1H, OH), 
1.55-1.47 (m, 3H, H2''/H3''), 0.81 (d, J = 6.4 Hz, 6H, H4''/H5''); 13C NMR (126 MHz, CDCl3) 
δ 153.2 (C2'), 139.4 (C5), 132.3 (C4), 131.8 (C4'), 128.7 (C6'), 125.0 (C1'), 121.2 (C5'), 
113.5 (C3'), 67.9 (C1''), 53.9 (CH2OH), 37.5 (C2''), 25.0 (C3''), 22.5 (C4''/C5''); IR (neat) ?̅?max 
2955, 2871, 1602, 1508, 1464, 1387, 1368, 1287, 1244, 1164, 1127, 1099, 1048, 1019, 978, 
831, 756, 660 cm-1; MS (ESI +ve) m/z 262 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd 






Ethyl 2-((1-(2-(isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methoxy)acetate (91) 
To a stirred solution of (1-(2-(isopentyloxy)phenyl)-1H-1,2,3-
triazol-5-yl)methanol 90 (0.25 g, 0.96 mmol) in dry THF (2 mL) 
at 0 °C under a nitrogen atmosphere was added  NaH (0.06 g, 1.43 
mmol; 60 %), followed by ethyl bromoacetate (0.21 g, 1.24 mmol). 
After 10 min the mixture was allowed to stir at rt for 16 h. The reaction was diluted with 
water (10 mL) and extracted with EtOAc (2 x 25 mL). The combined extracts were washed 
with water (2 x 25 mL), brine (2 x 25 mL) and dried (MgSO4). The solution was filtered, 
concentrated under vacuum and the residue was subjected to silica gel flash column 
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0) to afford 91 (0.23 g, 69%) 
as a brown gummy solid. TLC (EtOAc/n-hexane – 40:60); Rf = 0.6; 
1H NMR (400 MHz, 
CDCl3) δ 7.82 (s, 1H, H4), 7.50-7.47 (m, 1H, H6'), 7.41 (ddd, J = 7.7, 7.7, 1.6 Hz, 1H, H4'), 
7.11-7.06 (m, 2H, H3'/H5'), 4.62 (s, 2H, CH2OCOOEt), 4.16 (q, J = 7.1 Hz, 2H, OCH2CH3), 
3.98 (t, J = 6.6 Hz, 2H, H1''), 3.95 (s, 2H, H1'''), 1.56-1.48 (m, 3H, H2''/H3''), 1.24 (t, J = 7.1 
Hz, 3H, OCH2CH3), 0.83 (d, J = 6.4 Hz, 6H, H4''/H5''); 
13C NMR (101 MHz, CDCl3) δ 170.0 
(C=O), 153.6 (C2'), 135.7 (C5), 133.6 (C4), 132.0 (C4'), 128.8 (C6'), 125.2 (C1'), 121.2 (C5'), 
113.4 (C3'), 67.8 (C1'''), 67.5 (C1''), 62.3 (CH2O), 61.4 (OCH2CH3), 37.8 (C2''), 25.2 (C3''), 
22.8 (C4''/C5''), 14.5 (OCH2CH3); IR (neat) ?̅?max 2957, 2872, 1750, 1602, 1509, 1465, 1386, 
1369, 1287, 1265, 1247, 1207, 1135, 1048, 1025, 977, 756 cm-1; MS (ESI +ve) m/z 370 ([M 
+ Na]+, 70%), 348 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C18H26N3O4 348.1923, 








2-((1-(2-(Isopentyloxy)phenyl)-1H-1,2,3-triazol-5-yl)methoxy)acetic acid (55) 
To a stirred solution of ethyl 2-((1-(2-(isopentyloxy)phenyl)-1H-
1,2,3-triazol-5-yl)methoxy)acetate 91 (0.23 g, 0.66 mmol) in 
THF:H2O (3 mL:1mL) was added LiOH.H2O (0.14 g, 3.31 mmol) at 
rt and the reaction was allowed to stir at rt for 16 h. The reaction  
mixture was diluted with water (5 mL), acidified with 1 M HCl (5 mL) and extracted 
with EtOAc (2 x 25 mL). The combined organic extracts were washed with brine (50 mL) 
and dried (MgSO4). The solution was filtered, concentrated under vacuum to afford the acid 
55 (0.17 g, 81%) as a pale brown waxy solid. TLC (EtOAc/n-hexane – 100:0); Rf = 0.2;  
1H NMR (400 MHz, CDCl3) δ 8.76 (brs, 1H, COOH), 7.88 (s, 1H, H4), 7.50-7.46 (m, 1H, 
H4'), 7.40 (d, J = 7.6 Hz, 1H, H6'), 7.10-7.05 (m, 2H, H3'/H5'), 4.63 (s, 2H, H1'''), 4.00 (s, 
2H, CH2O), 3.98-3.97 (m, 2H, H1''), 1.57-1.47 (m, 3H, H2''/H3''), 0.82 (d, J = 6.2 Hz, 6H, 
H4''/H5''); 13C NMR (101 MHz, CDCl3) δ 173.0 (C=O), 153.3 (C2'), 135.7 (C5), 132.7 (C4), 
131.9 (C4'), 128.4 (C6'), 124.6 (C1'), 120.9 (C5'), 113.2 (C3'), 67.6 (C1'''), 67.0 (C1''), 61.9 
(C-C5), 37.5 (C2''), 24.9 (C3''), 22.4 (C4''/C5''); IR (neat) ?̅?max 2955, 2931, 2871, 2533, 1733, 
1602, 1508, 1464, 1429, 1368, 1287, 1246, 1163, 1116, 1049, 994, 846, 755, 662 cm-1; MS 
(ESI +ve) m/z 342 ([M + Na]+, 100%), 320 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd 











6.3.2 – Synthesis of N-protected β-azido-amines  
(9H-Fluoren-9-yl)methyl (R)-(1-hydroxy-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydro 
benzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)carbamate (93)77  
Commercial Fmoc-(D)-Arg(Pbf)-OH 92 (10.00 g, 15.41 
mmol) was dissolved in THF (80 mL) with magnetic 
stirring. The solution was cooled to −10 °C (ice/salt 
bath) followed by sequential dropwise addition of 
isobutyl chloroformate (2.31 g, 16.95 mmol) and N-
methylmorpholine (1.70 g, 16.95 mmol). The mixture 
was stirred at −10 °C for 30 min and filtered through a small pad of Celite, which was rinsed 
with fresh, cold THF (5 x 20 mL) and the combined filtrates were kept cold (ice bath). The 
cold filtrate was added dropwise to a cold aqueous solution of NaBH4 (0.90 g, 23.68 mmol 
in 10 mL H2O) with vigorous magnetic stirring. After the addition was complete, the mixture 
was stirred for 5 min and added to H2O (50 mL) with vigorous stirring. The reaction was 
stirred for 10 min and then the aqueous mixture was extracted with EtOAc (2 x 200 mL). The 
combined organic extracts were washed with H2O (2 x 200 mL), brine (200 mL), dried 
(MgSO4), filtered and concentrated. The residue was subjected to flash chromatography over 
SiO2 gel to afford the alcohol 93 (8.10 g, 82%) as a translucent gum. The spectroscopic data 
were found to be in agreement with those previously reported.77 TLC (MeOH/CH2Cl2 – 
10:90): Rf = 0.7; 
1H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 7.7 Hz, 2H, H4''/H5''), 7.54 (d, J 
= 7.5 Hz, 2H, H1''/H8''), 7.34 (t, J = 7.4 Hz, 2H, H3''/H6''), 7.25-7.20 (m, 2H, H2''/H7''), 6.32-
6.05 (m, 3H, N5-H/NH2 (guanidine)), 5.67-5.51 (brs, 1H, N
2-H), 4.34 (d, J = 7.0 Hz, 2H, 
H10''), 4.13 (t, J = 7.0 Hz, 1H, H9''), 3.71-3.47 (m, 3H, H1/H2), 3.25-3.14 (m, 2H, H5), 2.89 





(m, 4H, H3/H4), 1.41 (s, 6H, C2'-(CH3)2); 
13C NMR (126 MHz, CDCl3) δ 158.9 (C7a'), 157.0 
(C=O), 156.3 (C=N), 143.9 (C1a''/C8a''), 143.8 (C4a''), 141.3 (C5a''), 138.4 (C3a'), 132.6 
(C6'), 132.3 (C4'), 127.7 (C5'), 127.1 (C3''/C6''), 125.1 (C2''/C7''), 124.7 (C4''/C5''), 119.9 
(C1''/ C8''), 117.6 (C7'), 86.5 (C2'), 66.7 (C10''), 64.7 (C1), 52.5 (C2), 47.2 (C9''), 43.2 (C3'), 
40.0 (C5), 28.6 (C3, C2'-(CH3)2), 25.6 (C4), 19.3 (C4'-CH3), 18.0 (C6'-CH3), 12.5 (C7'-CH3); 




A solution of triphenylphosphine (1.82 g, 6.94 mmol), iodine (1.76 
g, 6.94 mmol), imidazole (0.52 g, 7.57 mmol) in CH2Cl2 (15 mL) 
was stirred at rt for 10 min followed by the addition of a solution of 
the alcohol 93 (4.00 g, 6.31 mmol) in CH2Cl2 (5 mL). The reaction 
was stirred at rt for 25 h, diluted with CH2Cl2 (50 mL) and filtered 
to remove the white precipitate. The filtrate was concentrated, and the residue was subjected 
to flash chromatography over SiO2 gel (EtOAc/Et2O – 50:50) to give a mixture of the 
intermediate iodide and triphenylphosphine oxide. The mixture was dissolved in DMF (25 
mL) and NaN3 (2.05 g, 31.51 mmol) was added to the solution followed by vigorous stirring 
at rt for 4 h. After the azidation reaction was shown to be complete by TLC analysis 
(EtOAc/n-hexane. – 80:20), the reaction was heated at 50 °C (oil bath) overnight (12 h) to 
remove the N-Fmoc protecting group. The reaction mixture was cooled to rt and then 
partitioned between EtOAc (200 mL) and aqueous HCl (0.5 M – 200 mL) with magnetic 
stirring for 5 min. The acidic aqueous phase was separated and washed with EtOAc (3 x 100 





w/w) and was extracted with EtOAc (3 x 100 mL). The organic extracts were combined and 
washed with H2O (100 mL), brine (100 mL), dried (MgSO4), filtered and concentrated to 
afford the amine 56 (2.00 g, 73% over two steps) as an off-white foam that collapsed into a 
translucent, pale yellow gum. The spectroscopic data were found to be in agreement with 
those previously reported.47 TLC (MeOH/CH2Cl2 – 10:90): Rf = 0.21; 
1H NMR (500 MHz, 
CDCl3) δ 6.38-6.08 (m, 3H, N
1-H/NH2 (guanidine)), 3.37 (m, 1H, H1A or H1B), 3.27-3.09 
(m, 3H, H5, H1A or H1B), 2.95 (s, 2H, H3'), 2.93-2.87 (m, 1H, H2), 2.58 (s, 3H, C4'-CH3), 
2.51 (s, 3H, C6'-CH3), 2.10 (s, 3H, C7'-CH3), 1.73 (s, 2H, -NH2),  1.71-1.58 (m, 2H, H4), 
1.58-1.48 (m, 1H, H3A or H3B), 1.46 (s, 6H, C2'-(CH3)2), 1.42-1.29 (m, 1H, H3A or H3B); 
13C NMR (126 MHz, CDCl3) δ 158.8 (C7a'); 156.2 (C=N), 138.3 (C3a'), 132.9 (C6'), 132.3 
(C4'), 124.7 (C5'), 117.5 (C7'), 86.4 (C2'), 58.3 (C1), 50.8 (C2), 43.3 (C3'), 41.0 (C5), 31.0 
(C3), 28.6 (C2'-(CH3)2), 25.8 (C4), 19.3 (C4'-CH3), 17.9 (C6'-CH3), 12.5 (C7'-CH3); MS (ESI 
+ve) m/z 460 ([M + Na]+, 20%), 438 ([M + H]+, 100%). 
 
(9H-Fluoren-9-yl)methyl tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2-dimethyl-2,3-dihydro 
benzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexane-1,5-diyl) 
dicarbamate (95). 
To a reaction vessel charged with azide 56 (1.38 
g, 3.16 mmol), Fmoc-L-Lys(Boc)-OH 94 (1.62 
g, 3.50 mmol), EDCI (0.67 g, 3.50 mmol) and 
HOBt (0.53 g, 3.50 mmol) was added CH2Cl2 
(10 mL) and the mixture was stirred at rt for 12 





diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The organic extracts 
were combined and washed with HCl (1 M – 100 mL), aqueous NaHCO3 (100 mL), brine 
(25 mL), dried (MgSO4) and concentrated to give a pale-yellow residue. This residue was 
purified via flash chromatography over SiO2 (MeOH/ CH2Cl2 = 4:96) to afford 95 as an off-
white foam (1.50 g, 54%). TLC (MeOH/CH2Cl2 – 10:90) Rf = 0.52; 
1H-NMR (400 MHz, 
CDCl3) δ 7.77-7.70 (m, 2H, H4''/H5''), 7.55 (d, J = 7.5 Hz, 2H, H1''/H8''), 7.55 (brs, 1H, 
βCONH), 7.41-7.32 (m, 2H, H2''/H7''), 7.29-7.21 (m, 2H, H3''/H6''), 7.17 (brs, 1H, αCONH), 
6.31-6.24 (m, 2H, NH2 (guanidine)), 6.19-6.09 (brs, 1H, N
5-H), 4.82-4.72 (brs, 1H, LysN1-
H), 4.33 (d, J = 7.4 Hz, 2H, H10''), 4.25-4.07 (m, 2H, Lys5/H9''), 4.07-3.97 (m, 1H, H2), 
3.41-3.23 (m, 2H, H1), 3.23-2.98 (m, 4H, H5/Lys1), 2.89 (s, 2H, H3'), 2.55 (s, 3H, C6'-CH3), 
2.48 (s, 3H, C4'-CH3), 2.06 (s, 3H, C7'-CH3), 1.67 (s, 6H, C2'-CH3), 1.55-1.35 (m, 19H, 
H3/H4/Lys2/ Lys3/Lys4/C(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 172.7 (Cβ), 158.8 (C7a'), 
156.7 (Cα), 156.4 (C=N), 156.2 (COOC(CH3)3), 143.85 (C1a''or C8a''), 143.83 (C8a'' or 
C1a''), 143.82 (C4a'' or C5a''), 143.6 (C5a'' or C4a''), 138.3 (C3a'), 132.8 (C6'), 132.2 (C4'), 
127.8 (C3''/C6''), 127.1 (C4''/C5''), 125.0 (C2''/C7''), 124.7 (C5'), 120.0 (C1''/C8''), 117.6 
(C7'), 86.4 (C2'), 79.3 (C(CH3)3), 67.3 (C10''), 55.1 (Lys5), 54.8 (C1), 48.8 (C2), 47.0 (C9''), 
43.2 (C3'), 40.9 (C5), 39.9 (Lys1), 31.9 (Lys2), 29.5 (Lys4), 29.3 (C3), 28.6 (C2'-(CH3)2), 
28.4 (C(CH3)3), 25.5 (C4), 22.5 (Lys3), 19.3 (C6'-CH3), 17.9 (C4'-CH3), 12.5 C7'-CH3); IR 
(neat) ?̅?max 3322, 2101, 1634, 1548, 1450, 1248, 1165, 1092, 739, 567 cm-1; MS (ESI +ve) 
m/z 910 ([M + Na]+, 80%), 888 ([M + H]+, 100%),; HRMS (ESI +ve TOF) calcd for 









To a solution of Fmoc-protected amine 95 (1.50 g, 1.69 mmol) in 
acetonitrile (15 mL) was added piperidine (0.25 mL, 1.5 eq.) and 
the reaction was stirred vigorously at rt for 12 h. The reaction 
mixture was diluted with MeOH (50 mL) and extracted with 
hexane (50 mL) multiple times until TLC analysis showed no 
byproduct (dibenzofulvene piperidine adduct) present in the 
MeOH layer. Then MeOH extract was concentrated under 
reduced pressure to give 57 as an off-white foam (0.80 g, 71%). 
TLC (MeOH/CH2Cl2 – 10:90) Rf =0.2; 
1H-NMR (500 MHz, CDCl3) δ 7.61 (brs, 1H, N
2-H), 
6.42-6.20 (m, 3H, N5-H/ NH2 (guanidine)), 4.82-4.72 (m, 1H, LysN
1-H), 4.12-3.99 (m, 1H, 
Lys5), 3.46-3.29 (m, 3H, H1/H2), 3.29-3.14 (m, 2H, H5), 3.14-3.04 (m, 2H, Lys1), 2.96 (s, 
2H, C3'), 2.58 (s, 3H, C6'-CH3), 2.52 (s, 3H, C4'-CH3), 2.10 (s, 3H, C7'-CH3), 1.62-1.31 (m, 
25H, H3/H4/Lys2/Lys3/Lys4/C(CH3)3/C2'-(CH3)2), N
5H2 resonance was not observed; 
13C-
NMR (126 MHz, CDCl3) δ 158.8 (C7a'), 156.6 (C=O), 156.4 (C=N), 138.5 (C3a'), 133.2 
(C4'), 132.4 (C6'), 124.7 (C5'), 117.6 (C7'), 86.5 (C2'), 79.4 ((C(CH3)3), 55.1 (Lys5), 55.0 
(C1), 46.9 (C2), 43.4 (C3'), 40.9 (C5), 40.4 (Lys1), 34.7 (Lys4), 30.1 (Lys2), 29.8 (C3), 28.8 
(C2'-(CH3)2), 28.6 (C(CH3)3), 25.8 (C4), 22.7 (Lys3), 19.4 (C6'-CH3), 18.1 (C4'-CH3), 12.6 
(C7'-CH3), COO(C(CH3)3) resonance was not observed; IR (neat) ?̅?max 3327, 2101, 1685, 
1620, 1551, 1454, 1366, 1278, 1250, 1168, 1094, 665, 569 cm-1; MS (ESI +ve) m/z 688 ([M 
+ Na]+, 20%), 666 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H52N9O6S 





6.3.3 – Synthesis of the N-protected β-azides  
(R)-N-(1-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl) 
guanidino)pentan-2-yl)-2-(2-(1-benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetamide (58) 
Following General Procedure III, 2-(2-(1-
benzyl-1H-1,2,3-triazol-4-yl)phenoxy)acetic 
acid 50 (0.05 g, 0.16 mmol), (R)-N-(amino ((4-
amino-5-azidopentyl)amino)methylene)-2,2,4, 
6,7-pentamethyl-2,3-dihydrobenzofuran-5-
sulfonamide 56 (0.07 g, 0.16 mmol), EDCI.HCl 
(0.03 g, 0.17 mmol), HOBt (0.03 g, 0.17 mmol) 
and TEA (0.01 g, 0.16 mmol) were stirred in CH2Cl2 (2 mL) at rt for 16 h to give the 
acetamide 58 (0.08 g, 69%) as a yellow waxy solid. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR (400 MHz, CDCl3) δ 7.81 (s, 1H, H5), 7.51 (brs, 1H, CONH), 7.35-7.25 (m, 7H, 
Ar6/Ar4/Ar2'/Ar3'/Ar4'/Ar5'/Ar6'), 7.00 (t, J = 7.5 Hz, 1H, Ar5), 6.88 (d, J = 8.5 Hz, 1H, 
Ar3), 6.28-6.20 (m, 3H, N5'-H/ NH2 (guanidine)), 5.55 (ABq, J = 15.0 Hz, 2H, OCHAHB), 
4.61 (s, 2H, CH2Ph), 4.12-4.08 (m, 1H, H2'), 3.48-3.32 (m, 2H, H1'), 3.24-3.10 (m, 2H, H5'), 
2.88 (s, 2H, H3''), 2.52 (s, 3H, C4''-CH3), 2.45 (s, 3H, C6''-CH3), 2.70 (s, 3H, C7''-CH3), 1.80-
1.66 (m, 1H, H3'), 1.64-1.40 (m, 3H, H3'/H4'), 1.42 (s, 6H, C2''-(CH3)2); 
13C NMR (101 
MHz, CDCl3) δ 169.6 (C=O), 158.7 (C7a''), 156.4 (C=N), 154.3 (Ar2), 145.6 (C4), 138.45 
(Ar1'), 138.44 (C4''/C6''), 134.6 (C7''), 133.1 (C3a''), 132.3 (C5''), 130.0 (C5), 129.2 (Ar4), 
128.9 (Ar3'/Ar5'), 128.2 (Ar2'/Ar6'), 124.7 (Ar6), 122.1 (Ar4'), 119.3 (Ar1), 117.5 (Ar5), 
113.3 (Ar3), 86.5 (C2''), 67.9 (OCHAHB), 60.5 (CH2Ph), 54.5 (C1'), 54.3 (C2'), 49.1 (C5'), 
43.3 (C3''), 41.0 (C3'), 29.7 (C2''-(CH3)2), 25.5 (C4'), 19.4 (C4''-CH3), 18.0 (C6''-CH3), 12.6 





1487, 1454, 1407, 1384, 1370, 1354, 1291, 1262, 1152, 1106, 1093, 1060, 1040, 994, 976, 
852, 784, 757, 664, 642 cm-1; MS (ESI +ve) m/z 767 ([M + K]+, 25%), 751 ([M + Na]+, 






Following General Procedure III, 
2-(2-(1-benzyl-1H-1,2,3-triazol-4-
yl)phenoxy)acetic acid 50 (0.09 g, 





57 (0.20 g, 0.30 mmol), EDCI.HCl (0.06 g, 0.33 mmol), HOBt (0.05 g, 0.33 mmol) and TEA 
(0.03 g, 0.30 mmol) were stirred in CH2Cl2 (3 mL) at rt for 16 h to give the acetamide 59 
(0.14 g, 49%) as a white solid. M.P: 244 - 246 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR (400 MHz, CDCl3) δ 8.98 (brs, 1H, βCONH), 7.93 (s, 1H, H5), 7.69-7.67 (m, 1H, 
αCONH), 7.36-7.26 (m, 7H, Ar6/Ar4/Ar2'/Ar3'/Ar4'/Ar5'/Ar6'), 7.11-7.10 (m, 1H, LysN1-
H), 7.04 (t, J = 7.5 Hz, 1H, Ar5), 6.92 (d, J = 8.5 Hz, 1H, Ar3), 6.28-6.20 (m, 2H, NH2 
(guanidine)), 6.18-6.10 (m, 1H, N5'-H (guanidine)), 5.61 (ABq, J = 15.0 Hz, 2H, OCHAHB), 





H1'), 4.08-3.98 (m, 1H, H2'), 3.32-3.20 (m, 2H, H5'), 3.20-3.06 (m, 2H, Lys1), 2.92 (s, 2H, 
H3''), 2.56 (s, 3H, C4''-CH3), 2.49 (s, 3H, C6''-CH3), 2.07 (s. 3H, C7''-CH3), 2.02-1.80 (m, 
6H, Lys4/H3'/H4'), 1.48-1.42 (m, 4H, Lys2/Lys3), 1.44 (s, 9H, C(CH3)3), 1.40 (s, 6H, C2''-
(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 172.6 (βC=O), 169.5 (αC=O), 158.8 (C7a''), 156.4 
(C=N), 156.3 (Ar2), 154.1 (COOC(CH3)3), 145.0 (C4), 138.4 (Ar1' ), 135.0 (C4''), 133.2 
(C6''), 132.4 (C3a''), 129.9 (Ar4), 129.3 (C5''), 129.2  (C5), 129.1 (C7''), 129.0 (Ar3'), 128.8 
(Ar5'), 128.2 (Ar2'), 124.7 (Ar6'), 122.5 (Ar4'), 122.4 (Ar6), 119.6 (Ar5), 117.6 (Ar3), 113.3 
(Ar1), 86.5 (C2''), 79.2 (C(CH3)3), 67.8 (OCHAHB), 60.6 (Lys5), 55.0 (CH2Ph), 54.3 (C1'), 
53.9 (C2'), 53.6 (C5'), 43.4 (C3''), 40.9 (Lys1), 40.2 (Lys4), 31.6 (C3'), 29.5 (Lys2), 28.7 
(C(CH3)3), 28.6 (C2''-(CH3)2), 25.6 (C4'), 23.1 (Lys3), 19.4 (C4''-CH3), 18.1 (C6''-CH3), 12.6 
(C7''-CH3); IR (neat) ?̅?max 3426, 3322, 3156, 3065, 2973, 2932, 2865, 2100, 1660, 1619, 
1547, 1489, 1454, 1406, 1392, 1366, 1247, 1165, 1105, 1092, 1042, 994, 976, 941, 904, 852, 
783, 756, 698, 642 cm-1; MS (ESI +ve) m/z 979 ([M + Na]+, 100%); HRMS (ESI +ve TOF) 





Following General Procedure III, 2-(2-(4-
isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic 
acid 51 (0.13 g, 0.46 mmol), (R)-N-(amino ((4-
amino-5-azidopentyl)amino)methylene)-
2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-
5-sulfonamide 56 (0.20 g, 0.46 mmol), 





0.50 mmol) and TEA (0.05 g, 0.46 mmol) were stirred in CH2Cl2 (3 mL) at rt for 14 h to give 
the acetamide 60 (0.19 g, 58%) as a pale-yellow solid. M.P: 234 - 236 °C. TLC (MeOH/ 
CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H, H5), 7.42 (t, J = 7.5 
Hz, 1H, Ar4), 7.39 (d, J = 8.0 MHz, 1H, Ar6), 7.22 (brs, 1H, CONH), 7.16 (t, J = 7.5 Hz, 
1H, Ar5), 7.09 (d, J = 8.0 Hz, 1H, Ar3), 6.36 (brs, 1H, N5'-H (guanidine)), 6.29 (brs, 2H, 
NH2, (guanidine)), 4.61 (ABq, J = 9.5 Hz, 2H, OCHAHB), 4.08-3.94 (m, 1H, H2'), 3.40-3.30 
(m, 2H, H1'), 3.30-3.20 (m, 2H, H5'), 2.94 (s, 2H, H3''), 2.80 (t, J = 8.0 Hz, 2H, H1'''), 2.57 
(s, 3H, C4''-CH3), 2.51 (s, 3H, C6''-CH3), 2.07 (s, 3H, C7''-CH3), 1.70-1.44 (m, 7H, 
H2'''/H3'''/H3'/H4'), 1.44 (s, 6H, C2''-(CH3)2), 0.95 (d, J = 6.0 Hz, 6H, H5'''/H4'''); 
13C NMR 
(126 MHz, CDCl3) δ 168.1 (C=O), 158.3 (C7a''), 156.3 (C=N), 151.8 (Ar2), 140.5 (C4''), 
138.0 (C6''), 133.1 (C4), 133.0 (C3a''), 132.6 (C5''), 131.4 (Ar4), 127.8 (Ar6), 125.2 (C7''), 
124.4 (Ar5), 122.2 (C5), 117.5 (Ar3), 113.3 (Ar1), 86.4 (C2''), 67.8 (OCHAHB), 55.2 (C1'), 
47.6 (C2'), 43.8 (C2'''), 40.1 (C5'), 36.1 (C3''), 29.9 (C1'''), 29.6 (C3'), 26.1 (C2''-(CH3)2), 24.5 
(C3'''), 22.5 (C4'), 22.4 (C4'''/C5'''), 20.9 (C4''-CH3), 18.6 (C6''-CH3), 12.8 (C7''-CH3); IR 
(neat) ?̅?max 3430, 3419, 3338, 3332, 3152, 3076, 2956, 2869, 2101, 1680, 1618, 1550, 1508, 
1457, 1407, 1385, 1369, 1288, 1252, 1162, 1153, 1106, 1093, 1056, 1038, 994, 978, 852, 
815, 784, 760, 667, 642 cm-1; MS (ESI +ve) m/z 731 ([M + Na]+, 100%), 709 ([M + H]+, 














Following General Procedure III, 
2-(2-(4-isopentyl-1H-1,2,3-triazol-
1-yl)phenoxy)acetic acid 51 (0.10 g, 





(0.23 g, 0.34 mmol), EDCI.HCl 
(0.07 g, 0.38 mmol), HOBt (0.06 g, 0.38 mmol) and TEA (0.03 g, 0.34 mmol) were stirred 
in CH2Cl2 (5 mL) at rt for 16 h to give the acetamide 61 (0.25 g, 78%) as an off-white solid. 
M.P: 256 - 258 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR (400 MHz, CDCl3) δ 
7.78-7.74 (m, 1H, Ar6), 7.70 (s, 1H, H5), 7.54-7.36 (m, 3H, Ar4/Ar5/βCONH), 7.20-7.04 
(m, 2H, αCONH/Ar3), 6.40-6.10 (m, 3H, N5'-H/NH2 (guanidine)), 5.04-4.96 (m, 1H, LysN
1-
H), 4.65-4.56 (m, 2H, OCHAHB), 4.44-4.38 (m, 1H, Lys5), 4.04-3.96 (m, 1H, H2'), 3.32-3.24 
(m, 2H, H1'), 3.22-2.98 (m, 4H, H5'/Lys1), 2.92 (s, 2H, H3''), 2.84-2.74 (m, 2H, H1'''), 2.54 
(s, 3H, C4''-CH3), 2.48 (s, 3H, C6''-CH3), 2.06 (s, 3H, C7''-CH3), 1.90-1.70 (m, 2H, Lys4), 
1.64-1.58 (m, 4H, H4'/Lys2), 1.56-1.26 (m, 7H, H3'/ Lys3/H2'''/ H3'''), 1.46 (s, 9H, C(CH3)3), 
1.44 (s, 6H, C2''-(CH3)2), 0.33 (d, J = 5.5 Hz, 6H, H4'''/H5'''); 
13C NMR (101 MHz, CDCl3) 
δ 168.5 (βC=O), 168.1 (αC=O), 158.1 (C7a''), 156.4 (C=N), 150.4 (COO(CH3)3), 145.9 





(C7''), 124.7 (Ar6), 122.6 (Ar5), 117.5 (C5), 117.3 (Ar3), 111.3 (Ar1), 86.4 (C2''), 79.1 
(C(CH3)3), 67.4 (OCHAHB), 54.9 (Lys5), 53.7 (C1'), 43.4 (C2'), 40.9 (C2'''), 38.5 (C5'), 31.5 
(C3''), 31.3 (Lys1), 29.8 (Lys4), 29.4 (C3'), 28.7 (Lys2), 28.5 (C1'''), 27.85 (C(CH3)3), 27.83 
(C2''-(CH3)2), 25.5 (C4'), 23.5 (C3'''), 22.9 (Lys3), 22.5 (C4'''/C5'''), 19.3 (C4''-CH3), 18.0 
(C6''-CH3), 12.5 (C7''-CH3); IR (neat) ?̅?max 3316, 3071, 2953, 2932, 2868, 2100, 1662, 1619, 
1602, 1546, 1508, 1459, 1420, 1389, 1365, 1250, 1195, 1165, 1109, 1056, 1026, 982, 913, 
834, 816, 755, 665, 644, 622 cm-1; MS (ESI +ve) m/z 959 ([M + Na]+, 100%); HRMS (ESI 





Following General Procedure III, 2-(2-(5-
isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetic 
acid 52 (0.14 g, 0.48 mmol), (R)-N-(amino((4-
amino-5-azidopentyl)amino)methylene)-
2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-
5-sulfonamide 56 (0.21 g, 0.48 mmol), 
EDCI.HCl (0.10 g, 0.53 mmol), HOBt (0.08 g, 
0.53 mmol) and TEA (0.05 g, 0.48 mmol) were stirred in CH2Cl2 (3 mL) at rt for 16 h to give 
the acetamide 62 (0.22 g, 65%) as an off-white solid. M.P: 228 - 230 °C. TLC (MeOH/ 
CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H, H4), 7.60-7.55 (m, 1H, 
Ar4), 7.33 (dd, J = 7.7, 1.5 Hz, 1H, Ar6), 7.24-7.20 (m, 1H, Ar5), 7.13 (d, J = 8.2 Hz, 1H, 
Ar3), 6.60 (brs, 1H, CONH), 6.36 (brs, 1H, N5'-H (guanidine)), 6.28 (brs, 2H, NH2 





4H, H1'/H5'), 2.95 (s, 2H, H3''), 2.60 (s, 3H, C4''-CH3), 2.58-2.54 (m, 2H, H1'''), 2.53 (s, 3H, 
C6''-CH3), 2.08 (s, 3H, C7''-CH3), 1.92-1.82 (m, 2H, H3'), 1.56-1.52 (m, 1H, H3'''), 1.52-1.42 
(m, 4H, H2'''/H4'), 1.45 (s, 6H, C2''-(CH3)2), 0.83 (d, J = 6.3 Hz, 6H, H5'''/H4'''); 
13C NMR 
(101 MHz, CDCl3) δ 167.4 (C=O), 158.5 (C7a''), 156.3 (C=N), 152.1 (Ar2), 140.7 (C5), 
138.3 (C3a''), 133.3 (C4), 132.35 (C4''), 132.30 (C6''), 131.7 (C5''), 128.0 (Ar4), 124.8 (Ar6), 
124.4 (C7''), 122.4 (Ar1), 117.3 (Ar5), 113.6 (Ar3), 86.2 (C2''), 67.1 (OCHAHB), 54.6 (C1'), 
48.9 (C2'), 43.2 (C2'''), 40.7 (C5'), 37.0 (C3''), 29.1 (C3'), 28.6 (C2''-(CH3)2), 27.4 (C1'''), 25.3 
(C4'), 22.1 (C4'''/C5'''), 22.0 (C3'''), 21.1 (C4''-CH3), 19.2 (C6''-CH3), 12.4 (C7''-CH3); IR 
(neat) ?̅?max 3448, 3419, 3153, 3076, 2957, 2869, 2101, 1680, 1619, 1550, 1508, 1456, 1407, 
1385, 1369, 1288, 1256, 1163, 1153, 1107, 1092, 1056, 1037, 994, 978, 852, 783, 734, 669, 
642 cm-1; MS (ESI +ve) m/z 731 ([M + Na]+, 100%); HRMS (ESI +ve TOF) calcd for 






Following General Procedure III, 
2-(2-(5-isopentyl-1H-1,2,3-triazol-
1-yl)phenoxy)acetic acid 52 (0.03 g, 









(0.07 g, 0.10 mmol), EDCI.HCl (0.02 g, 0.11 mmol), HOBt (0.02 g, 0.11 mmol) and TEA 
(0.01 g, 0.10 mmol) were stirred in CH2Cl2 (2 mL) at rt for 12 h to give the acetamide 63 
(0.07 g, 74%) as an off-white solid. M.P: 242 - 244 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 
0.5; 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H, H4), 7.54 (t, J = 8.1 Hz, 1H, Ar4), 7.52 (brs, 
1H, βCONH), 7.34-7.14 (m, 3H, Ar6/Ar5/Ar3), 7.04-6.98 (brs, 1H, αCONH), 6.12-6.08 (m, 
3H, N5'-H/NH2 (guanidine)), 5.20-5.14 (m, 1H, LysN
1-H), 4.65-4.53 (m, 2H, OCHAHB), 
4.38-4.31 (m, 1H, Lys5), 3.99-3.96 (m, 1H, H2'), 3.30-3.24 (m, 2H, H1'), 3.10-3.01 (m, 4H, 
H5'/Lys1), 2.94 (s, 2H, H3''), 2.56 (s, 3H, C4''-CH3), 2.49 (s, 3H, C6''-CH3), 2.49-2.45 (m, 
2H, H1'''), 2.07 (s, 3H, C7''-CH3), 1.80-1.70 (m, 2H, Lys4), 1.54-1.40 (m, 9H, 
H3'/H4'/Lys2/H2'''/H3'''), 1.45 (s, 9H, C(CH3)3), 1.42 (s, 6H, C2''-(CH3)2), 1.30-1.26 (m, 2H, 
Lys3), 0.83 (d, J = 6.4 Hz, 3H, H4'''), 0.81 (d, J = 6.4 Hz, 3H, H5'''); 13C NMR (101 MHz, 
CDCl3) δ 171.8 (βC=O), 168.4 (αC=O), 158.6 (C7a''), 156.2 (C=N), 152.1 (COOC(CH3)3), 
140.2 (Ar2), 138.2 (C5), 133.1 (C4''), 132.1 (C6''), 132.0 (C3a''), 131.9 (C5''), 128.1 (C4), 
128.0 (Ar4), 124.9 (C7''), 124.5 (Ar6), 122.4 (Ar1), 117.3 (Ar5), 113.8 (Ar3), 86.3 (C2''), 
78.9 (C(CH3)3), 67.3 (OCHAHB), 54.6 (Lys5), 53.4 (C1'), 53.4 (C2'), 48.7 (C2'''), 43.2 (C5'), 
40.6 (C3''), 40.1 (Lys1), 37.0 (Lys4), 31.5 (C3'), 29.2 (Lys2), 28.5 (C(CH3)3), 28.4 (C2''-
(CH3)2), 28.2 (C1'''), 27.4 (C4'), 25.4 (C3'''), 22.8 (C4'''), 22.7 (C5'''), 22.1 (Lys3), 19.2 (C4''-
CH3), 17.9 (C6''-CH3), 12.4 (C7''-CH3); IR (neat) ?̅?max 3319, 3073, 2953, 2933, 2869, 2101, 
1662, 1602, 1546, 1508, 1459, 1420, 1390, 1366, 1251, 1195, 1165, 1109, 1057, 1024, 984, 
913, 882, 833, 755, 665, 622, 580 cm-1; MS (ESI +ve) m/z 959 ([M + Na]+, 100%), 937 ([M 










Following General Procedure III, 2-((1-
(4-isopentyl-1H-1,2,3-triazol-1-yl) 
naphthalen-2-yl)oxy)acetic acid 53 (0.14 
g, 0.41 mmol), (R)-N-(amino((4-amino-5-
azidopentyl)amino)methylene)-2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-
sulfonamide 56 (0.18 g, 0.41 mmol), 
EDCI.HCl (0.09 g, 0.45 mmol), HOBt (0.07 g, 0.45 mmol) and TEA (0.04 g, 0.41 mmol) 
were stirred in CH2Cl2 (5 mL) at rt for 12 h to give the acetamide 64 (0.21 g, 67%) as an off-
white solid. M.P: 238 - 240 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR (400 MHz, 
CDCl3) δ 8.08 (d, J = 9.2 Hz, 1H, Ar8), 7.92 (d, J = 8.2 Hz, 1H, Ar5), 7.66 (s, 1H, H5), 7.56-
7.47 (m, 2H, Ar6/Ar7), 7.35 (d, J = 8.2 Hz, 1H, Ar4), 7.19 (d, J = 8.2 Hz, 1H, Ar3), 6.66 
(brs, 1H, CONH), 6.54-6.58 (m, 3H, N5'-H/ NH2 (guanidine)), 4.69 (ABq, 14.8 Hz, 2H, 
OCHAHB), 3.99-3.94 (m, 1H, H2'), 3.55-3.20 (m, 4H, H1'/H5'), 2.93 (s, 2H, H3''), 2.91-2.88 
(m, 2H, H1'''), 2.58 (s, 3H, C4''-CH3), 2.52 (s, 3H, C6''-CH3), 2.07 (s, 3H, C7''-CH3), 1.78-
1.76 (m, 2H, H3'), 1.74-1.58 (m, 3H, H2'''/H3'''), 1.52-1.46 (m, 2H, H4'), 1.44 (s, 6H, C2''-
(CH3)2), 1.00 (d, J = 6.2 Hz, 6H, H4'''/H5'''); 
13C NMR (101 MHz, CDCl3) δ 167.5 (C=O), 
158.5 (C7a''), 156.3 (Ar2), 149.9 (C=N), 149.1 (Ar8a), 138.3 (C3a''), 133.4 (C4''), 132.7 
(C6''), 132.3 (C4), 130.3 (C5''), 129.2 (Ar4), 129.1 (Ar4a), 128.4 (C7''), 125.6 (Ar5), 124.9 
(Ar7), 124.4 (Ar8), 120.6 (C5), 119.7 (Ar6), 117.3 (Ar3), 113.0 (Ar1), 86.2 (C2''), 67.6 





(CH3)2), 27.8 (C1'''), 25.3 (C4'), 23.5 (C3'''), 22.4 (C4'''/C5'''), 19.2 (C4''-CH3), 17.9 (C6''-
CH3), 12.4 (C7''-CH3); IR (neat) ?̅?max 3435, 3418, 3332, 3141, 2954, 2869, 2100, 1677, 1627, 
1600, 1548, 1483, 1452, 1407, 1383, 1369, 1278, 1254, 1150, 1107, 1091, 1044, 809, 782, 
734, 664, 642, 619, cm-1; MS (ESI +ve) m/z 781 ([M + Na]+, 60%), 759 ([M + H]+, 100%); 















guanidino)pentan-2-yl)amino)-6-oxohexyl) carbamate 57 (0.24 g, 0.35 mmol), EDCI.HCl 
(0.08 g, 0.39 mmol), HOBt (0.06 g, 0.39 mmol) and TEA (0.03 g, 0.35 mmol) were stirred in 
CH2Cl2 (5 mL) at rt for 12 h to give the acetamide 65 (0.22 g, 64%) as an off-white solid. M.P: 
236 – 238 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR (400 MHz, CDCl3) δ 8.05 
(d, J = 8.5 Hz, 1H, Ar8), 7.89 (d, J = 8.5 Hz, 1H, Ar5), 7.65 (s, 1H, H5), 7.54-7.47 (m, 2H, 





αCONH), 6.36-6.08 (m, 3H, N5'-H/NH2 (guanidine)), 5.00 (brs, 1H, LysN
1-H), 4.69 (ABq, J 
= 16.5 Hz, 2H, OCHAHB), 4.42-4.36 (m, 1H, Lys5), 4.02-3.96 (m, 1H, H2'), 3.44-2.94 (m, 
6H, H1'/H5'/Lys1), 2.88 (s, 2H, H3''), 2.88-2.84 (m, 2H, H1'''), 2.55 (s, 3H, C4''-CH3), 2.48 (s, 
3H, C6''-CH3), 2.06 (s, 3H, C7''-CH3), 2.00-1.86 (m, 4H, H4'/Lys4), 1.84-1.60 (m, 7H, 
H3'/Lys3/H2'''/H3'''), 1.44 (s, 6H, C2''(CH3)2), 1.39 (s, 9H, C(CH3)3), 1.32-1.22 (m, 2H, Lys2), 
0.9 (d, J = 5.0 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CDCl3) δ 171.9 (βC=O), 168.1 
(αC=O), 158.7 (C7a''), 156.4 (C=N), 150.1 (Ar2), 149.1 (COOC(CH3)3), 138.4 (Ar8a), 133.4 
(C4), 132.6 (C4''), 132.46 (C6''), 132.44 (C3a''), 130.6 (C5''), 129.4 (Ar4), 129.1 (Ar4a), 
128.48 (C7''), 128.47 (Ar5), 125.7 (Ar7), 124.7 (Ar8), 121.1 (C5), 120.3 (Ar6), 117.5 (Ar3), 
113.8 (Ar1), 86.5 (C2''), 79.2 (C(CH3)3), 68.0 (OCHAHB), 54.8 (Lys5), 53.6 (C1'), 43.4 (C2'), 
40.8 (C2'''), 40.2 (C5'), 38.6 (C3''), 38.5 (Lys1), 31.79 (Lys4), 31.74 (C3'), 29.4 (Lys2), 28.7 
(C2''-(CH3)2), 28.6 ((CH3)3), 28.0 (C1'''), 25.5 (C4'), 23.8 (C3'''), 22.8 (C4'''/C5'''), 22.6 (Lys3), 
19.4 (C4''-CH3), 18.1 (C6''-CH3), 12.6 (C7''-CH3); IR (neat) ?̅?max 3405, 3317, 3415, 3057, 
2953, 2868, 2100, 1664, 1631, 1600, 1546, 1514, 1484, 1452, 1406, 1390, 1366, 1265, 1247, 
1165, 1106, 1090, 1044, 994, 970, 852, 781, 733, 661, 641 cm-1; MS (ESI +ve) m/z 987 ([M 














Following General Procedure III, 2-((1-
(5-isopentyl-1H-1,2,3-triazol-1-yl)naph- 




sulfonamide 56 (0.19 g, 0.44 mmol), 
EDCI.HCl (0.09 g, 0.48 mmol), HOBt (0.07 g, 0.48 mmol) and TEA (0.04 g, 0.44 mmol) 
were stirred in CH2Cl2 (5 mL) at rt for 16 h to give the acetamide 66 (0.22 g, 66%) as an off-
white solid. M.P: 248 - 250 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.6; 
1H NMR (400 MHz, 
CDCl3) δ 8.11 (d, J = 7.3 Hz, 1H, Ar8), 7.94-7.92 (m, 1H, Ar5), 7.78 (s, 1H, H4), 7.55-7.49 
(m, 2H, Ar6/Ar7), 7.41 (d, J = 7.4 Hz, 1H, Ar4), 7.04-7.02 (m, 1H, Ar3), 6.48 (brs, 1H, 
CONH), 6.35 (brs, 2H, NH2 (guanidine)), 6.29 (brs, 1H, N
5'-H (guanidine)), 4.65 (ABq, J = 
11.8 Hz, 2H, OCHAHB), 3.96-3.93 (m, 1H, H2'), 3.44-3.21 (m, 2H, H1'), 3.20-3.10 (m, 2H, 
H5'), 2.94 (s, 2H, H3''), 2.61 (s, 3H, C4''-CH3), 2.54 (s, 3H, C6''-CH3), 2.50-2.37 (m, 2H, 
H1'''), 2.08 (s, 3H, C7''-CH3), 1.58-1.34 (m, 7H, H3'/H4'/H2'''/H3'''), 1.46 (s, 6H, C2''-(CH3)2), 
0.73 (d, J = 5.0 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CDCl3, major rotamer) δ 167.9 
(C=O), 158.5 (C7a''), 156.4 (Ar2), 150.5 (C=N), 150.4 (C5), 141.8 (Ar8a), 138.3 (C4''), 133.3 
(C6''), 133.1 (C4), 132.3 (C3a''), 131.9 (C5''), 130.5 (Ar4), 129.3 (Ar4a), 129.1 (C7''), 128.5 
(Ar5), 125.6 (Ar7), 124.4 (Ar8), 120.7 (Ar6), 118.3 (Ar3), 113.2 (Ar1),  86.2 (C2''), 67.3 





(CH3)2), 28.6 (C1'''), 27.2 (C4'), 25.4 (C3'''), 22.0 (C4'''/C5'''), 19.2 (C4''-CH3), 17.9 (C6''-
CH3), 12.4 (C7''-CH3); IR (neat) ?̅?max 3435, 3332, 3141, 3076, 2954, 2868, 2100, 1677, 1627, 
1600, 1548, 1483, 1452, 1407, 1369, 1278, 1254, 1150, 1107, 1091, 1044, 994, 852, 809, 
782, 749, 734, 664, 619 cm-1; MS (ESI +ve) m/z 803 ([M + HCOO-], 100%), 757 ([M - H], 













furan-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexyl)carbamate 57 (0.26 g, 0.38 
mmol), EDCI.HCl (0.08 g, 0.42 mmol), HOBt (0.06 g, 0.42 mmol) and TEA (0.04 g, 0.38 
mmol) were stirred in CH2Cl2 (5 mL) at rt for 16 h to give the acetamide 67 (0.25 g, 67%) as 
a pale brown solid. M.P: 242 - 244 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.5; 
1H NMR 
(400 MHz, CDCl3) δ 8.14-8.09 (m, 1H, Ar8), 7.93 (d, J = 7.3 Hz, 1H, Ar5), 7.83 (s, 1H, H4), 
7.66-7.36 (m, 3H, Ar4/βCONH/Ar7), 7.08-6.95 (m, 2H, Ar6/Ar3), 6.54-6.52 (m, 1H, 
αCONH), 6.34-6.24 (m, 3H, N5'-H/NH2 (guanidine)), 5.13 (brs, 1H, LysN





= 16.5 Hz, 2H, OCHAHB), 4.42-4.36 (m, 1H, Lys5), 4.02-3.96 (m, 1H, H2'), 3.30-2.94 (m, 
6H, H1'/H5'/Lys1), 2.94 (s, 2H, H3''), 2.57 (s, 3H, C4''-CH3), 2.51 (s, 3H, C6''-CH3), 2.48-
2.32 (m, 2H, H1'''), 2.08 (s, 3H, C7''-CH3), 1.82-1.76 (m, 2H, H4'), 1.58-1.16 (m, 11H, 
H3'/Lys2/Lys3/Lys4/H2'''/H3'''), 1.44 (s, 6H, C2''-(CH3)2), 1.40 (s, 9H, C(CH3)3), 0.74 (d, J 
= 5.5 Hz, 3H, H4'''), 0.71 (d, J = 6.0 Hz, 3H, H5'''); 13C NMR (101 MHz, CDCl3, major 
rotamer) δ 171.4 (βC=O), 167.6 (αC=O), 158.5 (C7a''), 156.2 (C=N), 150.6 (Ar2), 150.5 
(COOC(CH3)3), 141.4 (C5), 138.2 (Ar8a), 133.2 (C4), 133.0 (C4''), 132.2 (C6''), 130.6 
(C3a''), 129.3 (C5''), 129.0 (Ar4), 128.8 (Ar4a), 128.4 (C7''), 125.6 (Ar5), 124.5 (Ar7), 120.8 
(Ar8), 118.2 (Ar6), 117.3 (Ar3), 113.5 (Ar1), 86.3 (C2''), 78.9 (C(CH3)3), 67.7 (OCHAHB), 
54.5 (Lys5), 53.4 (C1'), 43.2 (C2'), 40.7 (C2'''), 40.2 (C5'), 36.7 (C3''), 31.8 (Lys1), 29.3 
(Lys4), 29.1 (C3'), 28.5 (Lys2), 28.4 (C2''-(CH3)2), 28.4 ((CH3)3), 27.2 (C1'''), 25.4 (C4'), 
22.9 (C3'''), 22.0 (C4'''/C5'''), 20.9 (Lys3), 19.2 (C4''-CH3), 17.9 (C6''-CH3), 12.4 (C7''-CH3); 
IR (neat) ?̅?max 3406, 3317, 3144, 3057, 2953, 2868, 2100, 1664, 1631, 1600, 1545, 1514, 
1484, 1452, 1406, 1390, 1366, 1265, 1165, 1151, 1090, 1044, 1024, 994, 913, 852, 807, 781, 
733, 660, 641, 566 cm-1; MS (ESI +ve) m/z 988 ([M + H]+, 100%); HRMS (ESI +ve TOF) 















Following General Procedure 
III, 2-((1-(2-(isopentyloxy) 
phenyl)-1H-1,2,3-triazol-5-yl) 
methoxy)acetic acid 55 




sulfonyl)guanidino)pentan-2-yl)amino)-6-oxohexyl) carbamate 57 (0.25 g, 0.37 mmol), 
EDCI.HCl (0.08 g, 0.41 mmol), HOBt (0.06 g, 0.41 mmol) and TEA (0.04 g, 0.37 mmol) 
were stirred in CH2Cl2 (3 mL) at rt for 16 h to give the acetamide 68 (0.25 g, 70%) as a pale 
brown solid. M.P: 220 - 222 °C. TLC (MeOH/ CH2Cl2 - 10:90): Rf = 0.6; 
1H NMR (400 
MHz, CDCl3) δ 7.82 (s, 1H, H4), 7.49 (ddd, J = 8.2, 1.6 Hz, 1H, Ar4), 7.40 (dd, J = 8.0, 1.6 
Hz, 1H, Ar6), 7.11-7.0 (m, 3H, Ar5/Ar3/βCONH), 6.97 (brs, 1H, αCONH), 6.34-6.24 (m, 
3H, N5'-H/NH2 (guanidine)), 4.75 (t, J = 5.8 Hz, 1H, LysN
1-H), 4.63-4.55 (m, 2H, C5-CH2), 
4.35 (t, J = 6.5 Hz, 1H, Lys5), 4.01-3.74 (m, 3H, H2'/H1'''), 3.89-3.74 (m, 2H, OCHAHB), 
3.38-3.28 (m, 2H, H1'), 3.44-3.40 (m, 2H, H5'), 3.07-3.00 (m, 2H, Lys1), 2.94 (s, 2H, H3''), 
2.56 (s, 3H, C4''-CH3), 2.50 (s, 3H, C6''-CH3), 2.08 (s. 3H, C7''-CH3), 1.85-1.80 (m, 2H, 
Lys4), 1.64-1.45 (m, 9H, H2'''/H3'''/Lys2/H3'/H4'), 1.45 (s, 6H, C2''(CH3)2), 1.41 (s, 9H, 
C(CH3)3), 1.36-1.20 (m, 2H, Lys3), 0.82 (d, J = 6.3 Hz, 6H, H4'''/H5'''); 
13C NMR (101 MHz, 





138.3 (Ar2), 135.0 (C5), 133.1 (C4''), 132.9 (C6''), 132.2 (C3a''), 131.8 (C4), 128.3 (C5''), 
124.9 (C7''), 124.8 (Ar4), 124.6 (Ar6), 121.1 (Ar1), 117.4 (Ar5), 113.3 (Ar3), 86.4 (C2''), 
79.2 (C(CH3)3), 69.1 (OCHAHB), 67.7 (C1'''), 62.1 (C5-CH2), 54.6 (Lys5), 52.7 (C1'), 43.2 
(C2'), 40.7 (C5'), 39.9 (C3''), 37.5 (Lys1), 32.0 (C2'''), 29.7 (Lys4), 29.3 (Lys2), 29.2 (C3'), 
28.6 (C2''-(CH3)2), 28.4 ((CH3)3), 25.5 (C4'), 24.9 (C3'''), 22.5 (C4'''/C5'''), 22.4 (Lys3), 19.2 
(C4''-CH3), 17.9 (C6''-CH3), 12.4 (C7''-CH3); IR (neat) ?̅?max 3325, 3147, 3076, 2963, 2930, 
2869, 2100, 1661, 1620, 1549, 1510, 1459, 1404, 1390, 1367, 1286, 1250, 1166, 1107, 1050, 
1036, 996, 978, 852, 808, 783, 757, 734, 663, 642, 569 cm-1; MS (ESI +ve) m/z 989 ([M + 
Na]+, 100%); HRMS (ESI +ve TOF) calcd for C46H70N12O9SNa 989.5007, found 989.5029 
([M + Na]+). 
 
6.3.4 – Synthesis of the derivatives 21 – 49  
(R)-2-(2-(1-Benzyl-1H-1,2,3-triazol-4-yl)phenoxy)-N-(1-(4-(cyclohexylmethyl)-1H-
1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)acetamide hydrochloride (21) 
Following General Procedure IV, azide 58 (0.08 g, 
0.11 mmol), 3-cyclohexyl-1-propyne (0.04 g, 0.33 
mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol) and 
sodium ascorbate (0.009 g, 0.04 mmol) were stirred 
in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give 
the intermediate 133 as an off-white gum after flash chromatography over SiO2 gel 
(MeOH/CH2Cl2 – 0:100 → 4:96). Following General Procedure VII, the intermediate 133 
(0.07 g, 0.08 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.6 mmol) 
and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the amine salt 






23 +63.1 (c 0.0053, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.59 (s, 1H, H5), 7.98 
(s, 1H, Hα), 7.80 (apparent t, J = 7.5 Hz, 1H, Ar4), 7.44-7.30 (m, 6H, Ar6/Ar2'/Ar3'/Ar4'/Ar5' 
/Ar6'), 7.09 (apparent t, J = 7.5 Hz, 1H, Ar5), 6.99 (d, J = 7.5 Hz, 1H, Ar3), 4.88-4.72 (m, 
3H, OCHAHB/H1'), 4.66-4.52 (m, 3H, H1'/CH2Ph), 4.48-4.42 (m, 1H, H2'), 3.22-3.12 (m, 
2H, H5'), 2.36-2.24 (m, 3H, βC-CH2/H1''), 1.84-1.40 (m, 9H, H3'/H4'/H2''/H3''/H4''/ 
H5''/H6''), 1.16-1.02 (m, 3H, H2''/H4''/H6''), 0.88-0.78 (m, 2H, H3''/H5''); 13C NMR (101 
MHz, CD3OD) δ 171.7 (C=O), 158.7 (C=N), 155.9 (Ar2), 145.8 (C4), 145.6 (Ar1'), 136.8 
(Ar6), 131.3 (Cβ), 131.2 (C5), 130.2 (Ar4), 129.7 (Ar3'), 129.6 (Ar5'), 129.5 (Ar2'), 129.3 
(Ar6'), 127.4 (Ar4'), 125.4 (Cα), 123.4 (Ar5), 120.2 (Ar1), 114.4 (Ar3), 68.8 (OCHAHB), 56.2 
(C1'), 55.4 (CH2Ph), 50.7 (C2'), 42.0 (C5'), 39.0 (C1''), 33.8 (βC-CH2), 32.7 (C2''/C6''), 29.9 
(C3'), 27.3 (C4''), 27.1 (C3''/C5''), 26.4 (C4'); IR (neat) ?̅?max 3343, 3272, 3184, 3072, 2926, 
2853, 2475, 1900, 1667, 1585, 1549, 1489, 1449, 1351, 1289, 1224, 1179, 1167, 1127, 1079, 
1049, 978, 936, 858, 759, 723, 696, 672, 648, 584 cm-1; MS (ESI +ve) m/z 599 ([M – HCl + 
H]+, 100%), 300 ([M – HCl + H]2+, 70%); HRMS (ESI +ve TOF) calcd for C32H43N10O2 
599.3565, found 599.3562 ([M – HCl + H]+). 
 
(R)-N-(1-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(4-
isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (22) 
Following General Procedure IV, azide 60 
(0.07 g, 0.09 mmol), cyclohexylacetylene (0.03 
g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02 
mmol) and sodium ascorbate (0.008 g, 0.04 
mmol) were stirred in t-BuOH (2 mL) and H2O 





chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General 
Procedure VII, the intermediate 134 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.03 g, 1.46 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (2 mL) to give the amine salt 22 (0.03 g, 55% over two steps) as a pale brown 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +68.1 (c 0.0047, MeOH). 1H NMR (400 
MHz, CD3OD) δ 8.46 (s, 1H, H5), 8.36 (s, 1H, Hα), 7.65 (apparent t, J = 7.5 Hz, 1H, Ar4), 
7.55 (d, J = 7.3 Hz, 1H, Ar6), 7.28-7.18 (m, 2H, Ar5/Ar3), 4.84-4.78 (m, 1H, H1'), 4.72-4.58 
(m, 3H, OCHAHB/H1'), 4.50-4.40 (m, 1H, H2'), 3.30-3.20 (m, 2H, H5'), 2.90-2.80 (m, 2H, 
H1'''), 2.04-1.94 (m, 2H, H3'), 1.86-1.50 (m, 11H, H4'/H2'''/H3'''/H1''/H2''/H3''/H4''/H5''/ 
H6''), 1.48-1.20 (m, 5H, H2''/H3''/H4''/H5''/H6''), 0.99 (d, J = 5.0 Hz, 6H, H4'''/H5'''); 13C 
NMR (101 MHz, CD3OD) δ 170.9 (C=O), 158.7 (C=N), 152.1 (Ar2), 147.9 (Cβ), 132.8 (C4), 
127.7 (Ar4), 127.3 (Ar6), 125.9 (C5), 125.3 (Cα), 123.8 (Ar5), 122.3 (Ar3), 115.7 (Ar1), 
69.1 (C1'), 67.0 (OCHAHB), 57.2 (C2'), 50.7 (C2'''), 42.1 (C5'), 39.6 (C1''), 33.3 (C2''), 33.2 
(C6''), 29.8 (C3'), 29.0 (C1'''), 26.8 (C4''), 26.7 (C3''), 26.5 (C5''), 24.1 (C3'''), 23.6 (C4'), 22.9 
(C4'''/C5'''); IR (neat) ?̅?max 3339, 3276, 3180, 2931, 2857, 2481, 1906, 1670, 1603, 1549, 
1507, 1465, 1451, 1386, 1368, 1289, 1230, 1168, 1130, 1048, 981, 937, 855, 821, 800, 761, 
701, 669 cm-1; MS (ESI +ve) m/z 565 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd 












isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (23) 
Following General Procedure IV, azide 60 (0.07 
g, 0.09 mmol), cyclopentylacetylene (0.03 g, 0.29 
mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol) and 
sodium ascorbate (0.008 g, 0.04 mmol) were 
stirred in t-BuOH (2 mL) and H2O (0.5 mL) for 
16 h to give the intermediate 135 as an off-white solid after flash chromatography over SiO2 
gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General Procedure VII, the intermediate 
135 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.4 
mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the 
amine salt 23 (0.025 g, 57% over two steps) as a brown solid that rapidly transitioned to a 
sticky gum. [𝛼]𝐷
23 +58.0 (c 0.0052, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.58 (s, 1H, H5), 
8.45 (brs, 1H, Hα), 7.68-7.58 (m, 1H, Ar6), 7.56-7.46 (m, 1H, Ar4), 7.22-7.06 (m, 2H, 
Ar5/Ar3), 4.70-4.56 (m, 2H, OCHAHB), 4.50-4.40 (m, 1H, H1'), 4.38-4.30 (m, 1H, H1'), 4.20-
4.12 (m, 1H, H2'), 3.14-3.02 (m, 3H, H5'/H1''), 2.76-2.62 (m, 2H, H1'''), 1.96-1.84 (m, 2H, 
H3'), 1.68-1.38 (m, 13H, H4'/H2'''/H3'''/H2''/H3''/H4''/H5''), 0.90 (d, J = 5.6 Hz, 6H, H4'''/ 
H5'''); 13C NMR (101 MHz, CD3OD) δ 167.2 (C=O), 156.7 (C=N), 150.6 (Ar2), 149.6 (Cβ), 
146.7 (C4), 129.9 (Ar4), 125.9 (Ar6), 125.1 (Cα), 123.5 (C5), 121.6 (Ar5), 121.5 (Ar3), 113.9 
(Ar1), 69.7 (C1'), 58.4 (OCHAHB), 50.7 (C2'), 42.3 (C2'''), 39.2 (C5'), 36.1 (C1''), 33.9 (C3'), 
29.8 (C1'''), 28.9 (C2''/C5''), 26.7 (C3''/C4''), 26.2 (C3'''), 24.0 (C4'), 22.9 (C4'''/C5'''); IR 
(neat) ?̅?max 3344, 3276, 3184, 2957, 2871, 2478, 2110, 1895, 1722, 1668, 1603, 1551, 1505, 





586 cm-1; MS (ESI +ve) m/z 551 ([M – HCl + H]+, 100%), 276 ([M – HCl + H]2+, 80%); 




isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (24) 
Following General Procedure IV, azide 60 
(0.06 g, 0.09 mmol), 1-ethynyl-4-fluoro 
benzene (0.03 g, 0.27 mmol), CuSO4∙5H2O 
(0.005 g, 0.02 mmol) and sodium ascorbate 
(0.008 g, 0.04 mmol) were stirred in t-BuOH (2 
mL) and H2O (0.5 mL) for 16 h to give the intermediate 136 as an off-white solid after flash 
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General 
Procedure VII, the intermediate 136 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.03 g, 1.4 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (2 mL) to give the amine salt 24 (0.03 g, 54% over two steps) as an off-white 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +74.2 (c 0.0051, MeOH). 1H NMR (400 
MHz, DMSO-d6) δ 8.51 (s, 1H, H5), 8.39 (brs, 2H, N
5-H/C=NH), 7.86-7.78 (m, 3H, 
NH2.HCl), 7.59 (d, J = 7.5 Hz, 1H, Ar6), 7.50-7.38 (m, 1H, CONH), 7.32-7.22 (m, 4H, 
Hα/Ar4/H2''/H6''), 7.08 (t, J = 7.5 Hz, 1H, Ar3), 7.02 (d, JH-F = 8.5 Hz, 2H, H3''/H5''), 7.02-
6.90 (m, 1H, Ar5), 4.65 (ABq, J = 15.8 Hz, 2H, OCHAHB), 4.54-4.40 (m, 2H, H1'), 4.28-
4.18 (m, 1H, H2'), 3.12-3.02 (m, 2H, H5'), 2.64 (t, J = 7.5 Hz, 2H, H1'''), 1.62-1.40 (m, 7H, 
H3'/H4'/H2'''/H3'''), 0.88 (d, J = 6.5 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, DMSO-d6) δ 
167.5 (C=O), 161.7 (d, JC-F = 196.4 Hz, C4''), 156.9 (C=N), 149.7 (Ar2), 146.9 (Cβ), 145.3 





(Ar5), 123.7 (Ar3), 121.8 (d, JC-F = 22.3 Hz, C2''/C6''), 115.8 (d, JC-F = 16.9 Hz, C3''/C5''), 
114.0 (Ar1), 67.3 (C1'), 64.9 (OCHAHB), 52.7 (C2'), 48.7 (C2'''), 40.3 (C5'), 28.3 (C3'), 27.1 
(C1'''), 25.0 (C3'''), 22.9 (C4'), 22.3 (C4'''/C5'''); IR (neat) ?̅?max 3342, 3273, 3182, 2957, 2871, 
2489, 1895, 1667, 1559, 1501, 1469, 1414, 1387, 1367, 1286, 1230, 1191, 1166, 1132, 1081, 
1049, 993, 975, 941, 843, 816, 759, 666, 654, 600, 585 cm-1; MS (ESI +ve) m/z 577 ([M – 
HCl + H]+, 100%), 289 ([M – HCl + H]2+, 20%); HRMS (ESI +ve TOF) calcd for 




1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (25) 
Following General Procedure IV, azide 60 (0.07 
g, 0.09 mmol), 3-phenyl-1-propyne (0.03 g, 0.27 
mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol) and 
sodium ascorbate (0.008 g, 0.04 mmol) were 
stirred in t-BuOH (2 mL) and H2O (0.5 mL) for 
16 h to give the intermediate 137 as an off-white gum after flash chromatography over SiO2 
gel (MeOH/CH2Cl2 – 0:100 → 3:97). Following General Procedure VII, the intermediate 
137 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.4 
mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the 
amine salt 25 (0.029 g, 53% over two steps) as a brown solid that rapidly transitioned to a 
sticky gum. [𝛼]𝐷
23 +68.1 (c 0.0042, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.76 (brs, 1H, 
H5), 8.38 (brs, 1H, Hα), 7.68 (d, J = 7.5 Hz, 1H, Ar6), 7.55 (t, J = 8.0 Hz, 1H, Ar4), 7.32-
7.20 (m, 6H, Ar5/H2''/H3''/H4''/H5''/H6''), 7.15 (d, J = 8.0 Hz, 1H, Ar3), 4.82-4.76 (m, 1H, 





3.28-3.16 (m, 2H, H5'), 2.92-2.84 (m, 2H, H1'''), 1.84-1.50 (m, 7H, H3'/H4'/H2'''/H3'''), 0.99 
(d, J = 4.0 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 170.4 (C=O), 158.6 (C=N), 
151.8 (Ar2), 137.6 (Cβ), 133.1 (C4), 131.1 (C1''), 130.8 (Ar4), 130.0 (C2''/C6''), 129.8 (Ar6), 
129.7 (C3''/C5''), 128.34 (C5), 128.33 (C4''), 127.2 (Cα), 123.64 (Ar5), 123.63 (Ar3), 115.4 
(Ar1), 68.7 (C1'), 66.8 (OCHAHB), 56.8 (C2'), 50.5 (C2'''), 41.9 (C5'), 38.8 (C3'), 29.5 
(CH2Ph), 28.8 (C1'''), 26.2 (C3'''), 23.4 (C4'), 22.6 (C4'''/C5'''); IR (neat) ?̅?max 3338, 3274, 
3182, 3073, 2957, 2934, 2870, 2470, 1902, 1669, 1603, 1549, 1507, 1465, 1386, 1368, 1288, 
1230, 1167, 1132, 1049, 983, 936, 855, 799, 760, 721, 697, 669, 644 cm-1; MS (ESI +ve) m/z 
573 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H41N10O2 573.3414, found 
573.3434 ([M – HCl + H]+). 
 
(R)-N-(1-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(5-
isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (26) 
Following General Procedure IV, azide 62 
(0.07 g, 0.09 mmol), cyclohexylacetylene (0.03 
g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02 
mmol) and sodium ascorbate (0.008 g, 0.04 
mmol) were stirred in t-BuOH (2 mL) and H2O 
(0.5 mL) for 16 h to give the intermediate 138 as a pale brown solid after flash 
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General 
Procedure VII, the intermediate 138 (0.06 g, 0.07 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.03 g, 1.46 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (3 mL) to give the amine salt 26 (0.03 g, 56% over two steps) as a pale brown 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷





MHz, CD3OD) δ 7.98 (d, J = 8.4 Hz, 1H, Ar4), 7.75 (s, 1H, H4), 7.74 (s, 1H, Hα), 7.63-7.57 
(m, 1H, Ar6), 7.48 (dd, J = 7.7, 1.6 Hz, 1H, Ar5), 7.09 (d, J = 8.4 Hz, 1H, Ar3), 4.59 (ABq, 
J = 15.1 Hz, 2H, OCHAHB), 4.51-4.46 (m, 1H, H1'), 4.40-4.33 (m, 1H, H1'), 4.26-4.16 (m, 
1H, H2'), 3.18-3.08 (m, 2H, H1'''), 2.72-2.62 (m, 2H, H5'), 2.00-1.88 (m, 2H, H3'), 1.84-1.68 
(m, 3H, H1''/H2'''), 1.62-1.18 (m, 13H, H3'''/H2''/H3''/ H4''/H5''/H6''/H4'), 0.82 (d, J = 6.4 Hz, 
6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 167.4 (C=O), 157.3 (C=N), 152.8 (Ar2), 
152.0 (Cβ), 140.4 (C5), 133.4 (C4), 132.0 (Ar4), 131.6 (Ar6), 128.9 (Ar1), 125.0 (Cα), 121.8 
(Ar5), 114.0 (Ar3), 67.1 (OCHAHB), 53.0 (C1'), 49.0 (C2'), 36.8 (C5'), 34.8 (C2'''), 32.89 
(C1''), 32.85 (C2''/C6''), 28.9 (C3'), 27.3 (C3'''), 26.0 (C1'''), 25.9 (C4''), 25.3 (C3''/C5''), 22.4 
(C4'), 20.7 (C4'''/C5'''); IR (neat) ?̅?max 3339, 3276, 3185, 2932, 2858, 2476, 1907, 1670, 1603, 
1549, 1507, 1465, 1451, 1386, 1368, 1289, 1230, 1169, 1131, 1048, 983, 954, 938, 855, 822, 
800, 762, 700, 669, 643 cm-1; MS (ESI +ve) m/z 565 ([M – HCl + H]+, 100%); HRMS (ESI 




(5-isopentyl-1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (27) 
Following General Procedure IV, azide 62 (0.07 
g, 0.09 mmol), 3-cyclohexyl-1-propyne (0.03 g, 
0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02 mmol) 
and sodium ascorbate (0.008 g, 0.04 mmol) were 
stirred in t-BuOH (2 mL) and H2O (0.5 mL) for 16 
h to give the intermediate 139 as a white solid after flash chromatography over SiO2 gel 
(MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the intermediate 139 





and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to give the amine salt 
27 (0.03 g, 54% over two steps) as a pale-yellow solid that rapidly transitioned to a sticky 
gum. [𝛼]𝐷
23 +62.1 (c 0.0051, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.27 (brs, 1H, H4), 
7.95 (brs, 1H, Hα), 7.63 (t, J = 7.4 Hz, 1H, Ar4), 7.47 (d, J = 7.4 Hz, 1H, Ar6), 7.30-7.22 (m, 
2H, Ar5/Ar3), 4.79-4.69 (m, 1H, H1'), 4.63-4.49 (m, 3H, OCHAHB/H1'), 4.47-4.39 (m, 1H, 
H2'), 3.22-3.10 (m, 2H, H1'''), 2.77-2.61 (m, 4H, βC-CH2/H5'), 1.84-1.36 (m, 13H, 
H3'/H4'/H2'''/H3'''/H1''/H2''/H3''/H4''/H5''/H6''), 1.34-1.09 (m, 3H, H2''/H4''/H6''), 1.04-0.90 
(m, 2H, H3''/H5''), 0.81 (d, J = 6.1 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 168.7 
(C=O), 157.2 (C=N), 152.5 (Ar2), 145.6 (Cβ), 140.8 (C5), 140.1 (Ar4), 132.6 (C4), 131.7 
(Ar6), 128.5 (Ar1), 123.8 (Cα), 122.2 (Ar5), 113.9 (Ar3), 67.1 (OCHAHB), 56.1 (C1'), 49.1 
(C2'), 40.5 (C5'), 37.3 (C2'''), 36.6 (C1''), 32.2 (βC-CH2), 30.6 (C2''/C6''), 28.2 (C3'), 27.2 
(C3'''), 25.7 (C1'''), 25.6 (C4''), 24.9 (C3''/C5''), 21.1 (C4'), 20.9 (C4'''/C5'''); IR (neat) ?̅?max 
3345, 3275, 3186, 2953, 2927, 2854, 2482, 1909, 1670, 1603, 1550, 1507, 1465, 1450, 1386, 
1368, 1288, 1229, 1168, 1130, 1084, 1049, 983, 958, 935, 854, 761, 669, 648, 585 cm-1; MS 
(ESI +ve) m/z 579 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H47N10O2 
579.3877, found 579.3876 ([M – HCl + H]+).  
 
(R)-N-(1-(4-Benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(2-(5-isopentyl-
1H-1,2,3-triazol-1-yl)phenoxy)acetamide hydrochloride (28) 
Following General Procedure IV, azide 62 
(0.07 g, 0.09 mmol), 3-phenyl-1-propyne (0.03 
g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 0.02 
mmol) and sodium ascorbate (0.008 g, 0.04 





(0.5 mL) for 16 h to give the intermediate 140 as an off-white gum after flash chromatography 
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the 
intermediate 140 (0.07 g, 0.08 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O 
(0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to 
give the amine salt 28 (0.03 g, 55% over two steps) as a pale brown solid that rapidly 
transitioned to a sticky gum. [𝛼]𝐷
23 +73.6 (c 0.0046, MeOH). 1H NMR (400 MHz, CD3OD) 
δ 8.22 (brs, 1H, H4), 8.11 (brs, 1H, Hα), 7.62 (t, J = 7.7 Hz, 1H, Ar4), 7.48 (d, J = 7.3 Hz, 
1H, Ar6), 7.31-7.22 (m, 6H, Ar5/H2''/H3''/H4''/H5''/H6''), 7.17 (d, J = 7.7 Hz, 1H, Ar3), 4.80-
4.70 (m, 1H, H1'), 4.52-4.44 (m, 3H, OCHAHB/H1'), 4.42-4.32 (m, 1H, H2'), 4.16 (s, 2H, 
CH2Ph), 3.24-3.12 (m, 2H, H1'''), 2.72-2.62 (m, 2H, H5'), 1.83-1.42 (m, 7H, H3'/H4'/ 
H2'''/H3'''), 0.81 (d, J = 5.6 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 167.4 (C=O), 
157.3 (C=N), 152.8 (Ar2), 146.1 (Cβ), 140.4 (C5), 139.9 (C1''), 132.0 (C4), 131.6 (Ar4), 
128.9 (C2''/C6''), 128.8 (C3''/C5''), 128.7 (Ar6), 126.5 (C4''), 125.0 (Ar1), 123.6 (Cα), 121.9 
(Ar5), 114.0 (Ar3), 67.0 (OCHAHB), 55.3 (C1'), 52.9 (C2'), 40.5 (C5'), 36.7 (C2'''), 31.6 
(CH2Ph), 28.9 (C3'), 27.3 (C3'''), 25.3 (C1'''), 22.4 (C4'), 20.7 (C4'''/C5'''); IR (neat) ?̅?max 3341, 
3276, 3181, 3088, 3075, 2956, 2934, 2870, 2470, 1914, 1669, 1603, 1549, 1507, 1465, 1385, 
1368, 1288, 1229, 1168, 1131, 1049, 982, 936, 855, 799, 759, 721, 698, 669, 645 cm-1; MS 
(ESI +ve) m/z 573 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C30H41N10O2 










isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (29) 
Following General Procedure IV, azide 
64 (0.07 g, 0.09 mmol), cyclohexyl 
acetylene (0.03 g, 0.27 mmol), 
CuSO4∙5H2O (0.005 g, 0.01 mmol) and 
sodium ascorbate (0.008 g, 0.03 mmol) 
were stirred in t-BuOH (2.0 mL) and H2O 
(0.5 mL) for 16 h to give the intermediate 141 as an off-white gum after flash chromatography 
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following General Procedure VII, the 
intermediate 141 (0.06 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O 
(0.03 g, 1.26 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) 
to give the amine salt 29 (0.03 g, 72% over two steps) as a pale brown solid that rapidly 
transitioned to a sticky gum. [𝛼]𝐷
23 +58.1 (c 0.0061, MeOH); 1H NMR (400 MHz, CD3OD) 
δ 8.36 (brs, 1H, H5), 8.18 (s, 1H, Hα), 8.19 (d, J = 8.9 Hz, 1H, Ar8), 8.00 (d, J = 7.9 Hz, 1H, 
Ar5), 7.59-7.46 (m, 3H, Ar4/Ar6/Ar7), 7.16 (d, J = 8.1 Hz, 1H, Ar3), 4.80-4.68 (m, 3H, 
OCHAHB/H1'), 4.62-4.60 (m, 1H, H1'), 4.58-4.42 (m, 1H, H2'), 3.15-3.14 (m, 2H, H5'), 2.94-
2.91 (m, 2H, H1'''), 2.72 (brs, 1H, H1''), 1.91-1.88 (m, 2H, H3'), 1.79-1.57 (m, 10H, 
H4'/H2'''/H3'''/H2''/H3''/H4''/H5''/H6''), 1.20-1.16 (m, 5H, H2''/H3''/H4''/H5''/H6''), 1.01 (d, J 
= 5.8 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 169.2 (C=O), 157.1 (C=N), 150.6 
(Ar2), 149.3 (C4), 147.6 (Cβ), 132.7 (Ar8a), 130.2 (Ar4), 129.3 (Ar4a), 128.2 (Ar5), 128.1 
(Ar7), 127.0 (Ar8), 125.7 (C5), 125.2 (Cα), 120.2 (Ar6), 119.3 (Ar3), 113.8 (Ar1), 67.7 
(OCHAHB), 55.7 (C1'), 49.1 (C2'), 40.4 (C5'), 37.9 (C2'''), 33.3 (C1''), 31.5 (C2''), 31.4 (C6''), 





(C4'''/C5'''); IR (neat) ?̅?max 3342, 3275, 3181, 2931, 2856, 1669, 1633, 1601, 1550, 1513, 
1483, 1451, 1384, 1367, 1280, 1231, 1172, 1152, 1118, 1081, 1049, 860, 812, 778, 749, 668, 
648, 588 cm-1; MS (ESI +ve) m/z 615 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd 




(4-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (30) 
Following General Procedure IV, azide 64 
(0.07 g, 0.09 mmol), 3-cyclohexyl-1-propyne 
(0.03 g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 
0.02 mmol) and sodium ascorbate (0.008 g, 
0.04 mmol) were stirred in t-BuOH (2 mL) 
and H2O (0.5 mL) for 16 h to give the 
intermediate 142 as an off-white gum after flash chromatography over SiO2 gel 
(MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the intermediate 142 
(0.06 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.36 mmol) 
and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to give the amine salt 
30 (0.03 g, 66% over two steps) as a pale-yellow solid that rapidly transitioned to a sticky 
gum. [𝛼]𝐷
23 +74.1 (c 0.0056, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.19 (s, 1H, H5), 8.14 
(d, J = 8.0 Hz, 1H, Ar8), 8.00 (t, J = 8.9 Hz, 1H, Ar5), 7.70-7.62 (m, 1H, Ar6), 7.61 (s, 1H, 
Hα), 7.58-7.45 (m, 1H, Ar7), 7.39 (d, J = 8.1 Hz, 1H, Ar4),  6.99 (d, J = 8.1 Hz, 1H, Ar3), 
4.62 (s, 2H, OCHAHB), 4.48-4.36 (m, 1H, H1'), 4.36-4.24 (m, 1H, H1'), 4.22-4.08 (m, 1H, 
H2'), 3.08-2.96 (m, 2H, H5'), 2.80-2.70 (m, 2H, H1'''), 2.37 (d, J = 6.2 Hz, 2H, βC-CH2), 





H4''/H6''), 0.92 (d, J = 2.4 Hz, 6H, H4'''/H5'''), 0.81-0.78 (m, 2H, H3''/H5''); 13C NMR (101 
MHz, CD3OD) δ 167.8 (C=O), 157.4 (C=N), 150.9 (Ar2), 147.4 (C4), 145.2 (Cβ), 132.1 
(Ar8a), 130.7 (Ar4), 128.96 (Ar4a), 128.93 (Ar5), 128.5 (Ar7), 125.9 (Ar8), 125.3 (C5), 
123.7 (Cα), 121.3 (Ar6), 119.9 (Ar3), 115.2 (Ar1), 68.1 (OCHAHB), 53.1 (C1'), 49.1 (C2'), 
40.7 (C5', Observed by gHMBC), 38.5 (C2'''), 37.8 (βC-CH2), 33.0 (C1'', Observed by 
gHMBC), 32.9 (C2''), 32.7 (C6''), 28.9 (C1'''), 27.6 (C3'), 26.4 (C3'''), 26.4 (C4'', Observed 
by gHMBC), 26.0 (C3''), 25.4 (C5''), 23.5 (C4'), 22.8 (C4'''/C5'''); IR (neat) ?̅?max 3339, 3273, 
3177, 2953, 2927, 2854, 1907, 1668, 1634, 1601, 1549, 1514, 1483, 1450, 1383, 1367, 1350, 
1281, 1231, 1221, 1153, 1117, 1083, 1052, 1025, 964, 919, 862, 811, 778, 750, 647, 608 cm-
1; MS (ESI +ve) m/z 629 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for 




1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (31) 
Following General Procedure IV, azide 
64 (0.07 g, 0.09 mmol), 3-phenyl-1-
propyne (0.03 g, 0.27 mmol), CuSO4∙5H2O 
(0.005 g, 0.02 mmol) and sodium ascorbate 
(0.008 g, 0.04 mmol) were stirred in t-
BuOH (2 mL) and H2O (0.5 mL) for 16 h 
to give the intermediate 143 as a pale-yellow solid gum after flash chromatography over SiO2 
gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General Procedure VII, the intermediate 
143 (0.06 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.2 





amine salt 31 (0.028 g, 68% over two step) as a pale brown solid that rapidly transitioned to 
a sticky gum. [𝛼]𝐷
23 +66.1 (c 0.0048, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.42 (s, 1H, 
H5), 8.21 (s, 1H, Hα), 8.16 (d, J = 8.9 Hz, 1H, Ar8), 7.99 (d, J = 7.9 Hz, 1H, Ar5), 7.60-7.48 
(m, 2H, Ar6/Ar7), 7.41 (d, J = 9.0 Hz, 1H, Ar4), 7.27-7.15 (m, 6H, Ar3/H2''/H3''/H4''/H5''/ 
H6''), 4.78-4.72 (m, 1H, H1'), 4.67 (ABq, J = 17.6 Hz, 2H, OCHAHB), 4.60-4.52 (m, 1H, 
H1'), 4.42-4.34 (m, 1H, H2'), 4.08 (s, 2H, CH2Ph), 3.22-3.08 (m, 2H, H5'), 3.00-2.88 (m, 2H, 
H1'''), 1.84-1.46 (m, 7H, H3'/H4'/H2'''/H3'''), 0.99 (d, J = 5.7 Hz, 6H, H4'''/H5'''); 13C NMR 
(101 MHz, CD3OD) δ 169.1 (C=O), 157.1 (C=N), 150.6 (Ar2), 147.0 (C4), 144.4 (Cβ), 136.0 
(C1''), 132.9 (Ar8a), 130.0 (Ar4), 129.2 (Ar4a), 128.9 (Ar5), 128.68 (C2''), 128.65 (C6''), 
128.3 (C3''/C5''), 128.1 (Ar7), 127.8 (C4''), 127.0 (Ar8), 126.8 (C5), 125.3 (Cα), 120.1 (Ar6), 
118.8 (Ar3), 113.7 (Ar1), 67.7 (OCHAHB), 55.4 (C1'), 49.2 (C2'), 40.5 (C5'), 37.6 (C2'''), 
34.9 (CH2Ph, Observed by gHMBC), 29.3 (C1'''), 28.1 (C3'), 27.5 (C3'''), 24.8 (C4'), 22.3 
(C4'''/C5'''); IR (neat) ?̅?max 3339, 3272, 3182, 3067, 2956, 2869, 1901, 1669, 1634, 1601, 
1550, 1513, 1496, 1482, 1454, 1433, 1382, 1367, 1281, 1232, 1221, 1153, 1120, 1080, 1049, 
967, 931, 863, 811, 778, 750, 721, 698, 674, 648 cm-1; MS (ESI +ve) m/z 623 ([M – HCl + 
H]+, 100%); HRMS (ESI +ve TOF) calcd for C34H43N10O2 623.3564, found 623.3561 ([M – 












isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (32) 
Following General Procedure IV, azide 
66 (0.07 g, 0.09 mmol), cyclohexyl 
acetylene (0.03 g, 0.27 mmol), 
CuSO4∙5H2O (0.005 g, 0.02 mmol) and 
sodium ascorbate (0.008 g, 0.04 mmol) 
were stirred in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 144 as a 
brown gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96). 
Following General Procedure VII, the intermediate 144 (0.07 g, 0.08 mmol) was dissolved 
in CH2Cl2 (2 mL), treated with H2O (0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by 
work-up with ethereal HCl (3 mL) to give the amine salt 32 (0.036 g, 52% over two steps) 
as a pale brown solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23  +65.6 (c 0.0062, 
MeOH). 1H NMR (400 MHz, CD3OD) δ 8.41 (brs, 1H, H4), 8.34-8.16 (m, 2H, Hα/HAr8), 
8.08-8.00 (m, 2H, Ar5/Ar4), 7.60-7.50 (m, 2H, Ar6/Ar7), 6.99 (d, J = 9.6 Hz, 1H, Ar3), 4.86-
4.78 (m, 2H, OCHAHB), 4.70-4.56 (m, 2H, H1'), 4.44-4.32 (m, 1H, H2'), 3.05 (t, J = 7.0 Hz, 
2H, H5'), 2.66-2.58 (m, 1H, H1''), 2.56-2.44 (m, 2H, H1'''), 2.04-1.50 (m, 10H,  
H4'/H2'''/H3'''/H2''/H3''/H4''/H5''/H6''), 1.48-1.06 (m, 7H, H3'/H2''/H3''/H4''/H5''/H6''), 0.69 
(d, J = 7.0 Hz, 3H, H4'''), 0.67 (d, J = 7.1 Hz, 3H, H5'''); 13C NMR (101 MHz, CD3OD) δ 
169.1 (C=O), 157.2 (C=N), 151.3 (Ar2), 142.9 (Cβ), 133.1 (C5), 131.7 (Ar8a), 130.5 (C4), 
129.3 (Ar4), 128.9 (Ar4a), 128.3 (Ar5), 126.2 (Ar7), 125.3 (Ar8), 120.26 (Ar6), 120.23 (Cα), 
117.7 (Ar3), 113.8 (Ar1),  67.6 (OCHAHB), 55.9 (C1'), 49.3 (C2'), 40.6 (C5'), 36.5 (C2'''), 
33.3 (C1''), 31.5 (C2''), 31.4 (C6''), 28.3 (C1'''), 27.0 (C3'), 25.2 (C3'''), 25.1 (C4''), 25.0 (C3''), 





2481, 1903, 1669, 1632, 1601, 1549, 1512, 1482, 1451, 1385, 1367, 1351, 1272, 1234, 1224, 
1170, 1154, 1132, 1090, 1048, 990, 972, 941, 920, 858, 816, 750, 652 cm-1; MS (ESI +ve) 
m/z 616 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C33H47N10O2 615.3883, 
found 615.3873 ([M – HCl + H]+). 
 
N-((R)-1-(4-(Cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-((1-
(5-isopentyl-1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (33) 
Following General Procedure IV, azide 66 
(0.07 g, 0.09 mmol), 3-cyclohexyl-1-propyne 
(0.03 g, 0.27 mmol), CuSO4∙5H2O (0.005 g, 
0.02 mmol) and sodium ascorbate (0.008 g, 
0.04 mmol) were stirred in t-BuOH (2 mL) and 
H2O (0.5 mL) for 16 h to give the intermediate 145 as an off-white gum after flash 
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General 
Procedure VII, the intermediate 145 (0.07 g, 0.08 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (3 mL) to give the amine salt 33 (0.03 g, 51% over two steps) as a pale brown 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +58.1 (c 0.0044, MeOH). 1H NMR (400 
MHz, CD3OD) δ 8.35 (s, 1H, H4), 8.19 (s, 1H, Hα), 8.08-8.00 (m, 2H, Ar8/Ar5), 7.58-7.50 
(m, 3H, Ar4/Ar6/Ar7), 6.99 (d, J = 9.6 Hz, 1H, Ar3), 4.78 (ABq, J = 19.0 Hz, 2H, OCHAHB), 
4.67-4.54 (m, 2H, H1'/H2'), 4.44-4.30 (m, 1H, H1'), 3.26-3.20 (m, 1H, H1'''), 3.11-2.93 (m, 
1H, H1'''), 2.67 (d, J = 12.8 Hz, 1H, βC-CH2), 2.54-2.44 (m, 3H, H5'/βC-CH2), 1.85-1.30 (m, 
13H, H3'/H4'/H2'''/H3'''/H1''/H2''/H3''/H4''/H5''/H6''), 1.29-1.04 (m, 3H, H2''/H4''/H6''), 1.02-





(C=O), 157.0 (C=N), 151.0 (Ar2), 142.9 (C5), 132.9 (Ar8a), 131.6 (C4), 130.6 (Cβ), 129.4 
(Ar4), 128.9 (Ar4a), 128.3 (Ar5), 126.8 (Ar7), 125.3 (Ar8), 120.3 (Ar6), 120.2 (Cα), 117.7 
(Ar3), 113.8 (Ar1), 67.6 (OCHAHB), 55.5 (C1'), 49.3 (C2'), 37.5 (C2'''), 36.5 (C5'), 33.9 
(C1''), 33.0 (Cβ-CH2), 32.3 (C2''), 32.2 (C6''), 30.9 (C3'), 30.7 (3'''), 28.3 (C1'''), 28.1 (C4''), 
27.0 (C3''), 25.7 (C5''), 25.7 (C4'), 25.6 (C4'''/5'''); IR (neat) ?̅?max 3341, 3271, 3180, 3082, 
2953, 2927, 2854, 2468, 1916, 1670, 1632, 1601, 1549, 1512, 1483, 1450, 1384, 1368, 1349, 
1223, 1169, 1154, 1132, 1091, 1049, 1025, 991, 973, 935, 918, 863, 814, 780, 750, 678, 651 
cm-1; MS (ESI +ve) m/z 630 ([M – HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for 




1H-1,2,3-triazol-1-yl)naphthalen-2-yl)oxy)acetamide hydrochloride (34) 
Following General Procedure IV, azide 
66 (0.07 g, 0.09 mmol), 3-phenyl-1-
propyne (0.03 g, 0.27 mmol), CuSO4∙5H2O 
(0.005 g, 0.02 mmol) and sodium ascorbate 
(0.008 g, 0.04 mmol) were stirred in t-
BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 146 as an off-white gum 
after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following 
General Procedure VII, the intermediate 146 (0.07 g, 0.08 mmol) was dissolved in CH2Cl2 
(2 mL), treated with H2O (0.03 g, 1.6 mmol) and CF3COOH (1 mL) followed by work-up 
with ethereal HCl (3 mL) to give the amine salt 34 (0.034 g, 57% over two steps) as a brown 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +73.7 (c 0.0051, MeOH). 1H NMR (400 





(m, 3H, Ar4/Ar6/Ar7), 7.31-7.13 (m, 5H, H2''/H3''/H4''/H5''/H6''), 7.00 (d, J = 8.5 Hz, 1H, 
Ar3), 4.71 (ABq, J = 18.2 Hz, 2H, OCHAHB), 4.64-4.56 (m, 1H, H1'), 4.56-4.46 (m, 1H, 
H2'), 4.42-4.28 (m, 1H, H1'), 4.15 (s, 1H, CH2Ph), 4.01 (s, 1H, CH2Ph), 3.21-3.15 (m, 1H, 
H1'''), 3.10-2.99 (m, 1H, H1'''), 2.51 (m, 2H, H5'), 1.82-1.52 (m, 3H, H2'''/H3'''), 1.50-1.29 
(m, 4H, H3'/H4'), 0.69 (d, J = 5.7 Hz, 3H, H4'''), 0.66 (d, J = 7.2 Hz, 3H, H5'''); 13C NMR 
(101 MHz, CD3OD) δ 167.5 (C=O), 157.8 (C=N), 151.8 (Ar2), 149.6 (C5), 140.4 (Ar8a), 
138.5 (C1''), 133.3 (C4), 132.5 (Cβ), 130.3 (Ar4), 129.2 (Ar4a), 128.86 (C2''/C6''), 128.82 
(Ar5), 128.74 (C3''/C5''), 128.71 (C4''), 128.6 (Ar7), 126.5 (Ar8), 125.3 (Ar6), 121.1 (Cα), 
115.5 (Ar3), 115.4 (Ar1), 68.3 (OCHAHB), 62.7 (C1'), 53.0 (C2'), 41.1 (C2'''), 40.8 (C5'), 
36.8 (CH2Ph), 31.8 (C3'), 31.7 (3'''), 29.1 (C1'''), 25.3 (C4'), 22.1 (C4'''/5'''); IR (neat) ?̅?max 
3343, 3273, 3181, 3065, 2956, 2934, 2869, 2469, 1906, 1669, 1633, 1601, 1549, 1512, 1497, 
1482, 1454, 1384, 1367, 1351, 1277, 1234, 1223, 1169, 1153, 1132, 1086, 1049, 992, 972, 
934, 919, 863, 813, 780, 751, 722, 698, 652 cm-1; MS (ESI +ve) m/z 624 ([M – HCl + H]+, 
















Following General Procedure IV, 
azide 59 (0.07 g, 0.07 mmol), 3-phenyl-
1-propyne (0.03 g, 0.22 mmol), 
CuSO4∙5H2O (0.004 g, 0.01 mmol) and 
sodium ascorbate (0.006 g, 0.03 mmol) 
were stirred in t-BuOH (2 mL) and H2O 
(0.5 mL) for 16 h to give the intermediate 147 as an off-white solid after flash 
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following General 
Procedure VII, the intermediate 147 (0.06 g, 0.056 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.02 g, 1.11 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (2 mL) to give the amine salt 35 (0.03 g, 55% over two steps) as a pale brown 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +65.3 (c 0.0052, MeOH). 1H NMR (400 
MHz, CD3OD) δ 8.74 (s, 1H, H5), 8.23-7.83 (m, 2H, Hγ/Ar4), 7.50-7.14 (m, 13H, 
Ar6/Ar5/Ar3/Ar2'/Ar3'/Ar4'/Ar5'/Ar6'/H2''/H3''/H4''/H5''/H6''), 5.69 (s, 2H, CH2Ph), 4.92-
4.76 (m, 2H, OCHAHB), 4.84-4.70 (m, 2H, H1'), 4.40-4.32 (m, 1H, Lys5), 4.30-4.22 ((m, 1H, 
H2'), 4.03 (s, 2H, δC-CH2), 3.23-3.07 (m, 2H, H5'), 2.95-2.78 (m, 2H, Lys1), 1.80-1.50 (m, 
8H, Lys4/H3'/Lys2 /H4'), 1.36-1.20 (m, 2H, Lys3); 13C NMR (101 MHz, CD3OD) δ 174.5 
(βC=O), 169.7 (αC=O), 158.7 (C=N), 156.0 (Ar2), 143.1 (C4), 139.0 (Ar1'), 136.5 (C1''), 
131.7 (Ar6), 130.3 (Cδ), 130.0 (C5), 129.9 (Ar4), 129.8 (C2''/C6''), 129.5 (Ar3'/Ar5'/C3''/ 
C5''), 129.4 (Ar2'/Ar6'), 128.9 (Ar4'/C4''), 128.1 (Cγ), 123.4 (Ar5), 119.3 (Ar1), 114.4 (Ar3), 





32.5 (δC-CH2), 31.8 (Lys4), 30.0 (C3'), 28.1 (Lys2), 26.4 (C4'), 24.0 (Lys3); IR (neat) ?̅?max 
3351, 3265, 3203, 3065, 2950, 2870, 1658, 1585, 1546, 1490, 1455, 1441, 1360, 1290, 1229, 
1181, 1165, 1125, 1075, 1053, 978, 907, 840, 804, 758, 725, 698, 670, 644, 586 cm-1; MS 
(ESI +ve) m/z 721 ([M – 2HCl + H]+, 10%), 361 ([M – 2HCl + H]2+, 100%); HRMS (ESI 






Following General Procedure IV, azide 59 
(0.09 g, 0.09 mmol), 3-cyclohexyl-1-
propyne (0.03 g, 0.28 mmol), CuSO4∙5H2O 
(0.005 g, 0.02 mmol) and sodium ascorbate 
(0.007 g, 0.04 mmol) were stirred in t-BuOH 
(2 mL) and H2O (0.5 mL) for 16 h to give the 
intermediate 148 as an off-white gum after flash chromatography over SiO2 gel 
(MeOH/CH2Cl2 – 0:100 → 6:94). Following General Procedure VII, the intermediate 148 
(0.06 g, 0.055 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.10 mmol) 
and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the amine salt 
36 (0.025 g, 35% over two steps) as a pale-yellow solid that rapidly transitioned to a sticky 
gum. [𝛼]𝐷
23 +57.6 (c 0.0054, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.82 (s, 1H, H5), 8.25 
(s, 1H, Hγ), 7.91 (apparent t, J = 7.0 Hz, 1H, Ar4), 7.44-7.36 (m, 6H, Ar6/Ar5/Ar2'/Ar3'/Ar5'/ 
Ar6'), 7.16-7.10 (m, 2H, Ar4'/Ar3), 5.75 (s, 2H, CH2Ph), 4.88-4.70 (m, 3H, OCHAHB/H1'), 





δC-CH2), 2.92-2.84 (m, 2H, H5'), 2.66-2.60 (m, 2H, Lys1), 1.82-1.58 (m, 14H, Lys4/H3'/ 
Lys2/H4'/H1''/H2''/H3''/H4''/H5''/H6''), 1.44-1.28 (m, 2H, H2''/H6''), 1.26-1.12 (m, 3H, 
H3''/H4''/ H5''), 0.94-0.86 (m, 2H, Lys3); 13C NMR (101 MHz, CD3OD) δ 174.5 (βC=O), 
171.6 (αC=O), 158.7 (C=N), 156.1 (Ar2), 145.1 (C4), 144.3 (Ar1'), 136.5 (Cδ), 131.8 (Ar6), 
130.3 (C5/Ar4), 130.0 (Ar3'/Ar5'), 129.5 (Ar4'), 128.5 (Ar2'/Ar6'), 126.4 (Cγ), 123.3 (Ar5), 
119.1 (Ar1), 114.4 (Ar3), 68.8 (OCHAHB), 57.2 (C1'), 55.9 (Lys5), 55.3 (CH2Ph), 50.9 (C2'), 
42.1 (C5'), 40.7 (Lys1), 38.9 (C1''), 33.9 (C2''/C6''), 33.8 (δC-CH2), 32.4 (Lys4), 32.3 (C4''), 
29.7 (C3'), 28.1 (Lys2), 27.3 (C3''), 27.1 (C5''), 26.4 (C4'), 24.3 (Lys3); IR (neat) ?̅?max 3348, 
3266, 3192, 3066, 2927, 2854, 2667, 1659, 1586, 1545, 1490, 1450, 1382, 1351, 1227, 1167, 
1126, 1076, 1050, 977, 937, 911, 846, 805, 760, 725, 696, 675, 647, 585 cm-1; MS (ESI +ve) 
m/z 727 ([M – 2HCl + H]+, 20%), 364 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) 






Following General Procedure IV, azide 
61 (0.07 g, 0.07 mmol), 3-phenyl-1-
propyne (0.03 g, 0.21 mmol), 
CuSO4∙5H2O (0.004 g, 0.01 mmol) and 
sodium ascorbate (0.006 g, 0.02 mmol) 
were stirred in t-BuOH (2 mL) and H2O 
(0.5 mL) for 16 h to give the intermediate 





→ 5:95). Following General Procedure VII, the intermediate 149 (0.06 g, 0.06 mmol) was 
dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.10 mmol) and CF3COOH (1 mL) 
followed by work-up with ethereal HCl (3 mL) to give the amine salt 37 (0.030 g, 56% over 
two steps) as a pale-yellow solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +68.1 (c 
0.0052, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.54 (s, 1H, H5), 8.12 (s, 1H, Hγ), 7.65 (t, 
J = 7.5 Hz, 1H, Ar4), 7.54 (d, J = 8.0 Hz, 1H, Ar6), 7.32-7.20 (m, 7H, Ar5/Ar3/H2''/H3''/ 
H4''/H5''/H6''), 4.84-4.74 (m, 2H, OCHAHB), 4.68-4.62 (m, 1H, H1'), 4.58-4.48 (m, 1H, H1'), 
4.36-4.28 (m, 1H, Lys5), 4.20-4.12 (m, 1H, H2'), 4.12 (s, 2H, δC-CH2), 3.24-3.10 (m, 2H, 
H5'), 2.94-2.80 (m, 4H, Lys1/H1'''), 1.82-1.50 (m, 11H, H2'''/H3'''/H3'/Lys4/H4'/Lys2), 1.36-
1.24 (m, 2H, Lys3), 0.96 (d, J = 5.0 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 
173.9 (βC=O), 170.4 (αC=O), 158.4 (C=N), 152.0 (Ar2), 137.5 (Cδ), 133.5 (C4), 131.1 
(C1''), 130.2 (C2''/C6''), 129.9 (C3''/C5''), 127.6 (C4''/Ar4), 127.4 (Ar6), 126.2 (C5), 125.9 
(Cγ), 123.9 (Ar5), 123.3 (Ar1), 115.7 (Ar3), 69.7 (OCHAHB), 57.6 (C1'), 54.9 (Lys5), 49.6 
(C2'), 42.6 (C2'''), 40.7 (C5'), 38.5 (Lys1), 32.8 (δC-CH2), 31.6 (C3'), 29.8 (Lys4), 29.6 
(C1'''), 28.6 (Lys2), 28.2 (C3'''), 25.8 (C4'), 23.2 (C4'''/C5'''), 22.8 (Lys3); IR (neat) ?̅?max 3375, 
2956, 2932, 2870, 1653, 1572, 1548, 1508, 1462, 1381, 1367, 1288, 1254, 1228, 1150, 1113, 
1058, 1005, 914, 883, 837, 793, 759, 721, 697, 670, 657 cm-1; MS (ESI +ve) m/z 701 ([M –
2HCl + H]+, 100%), 351 ([M – 2HCl + H]2+, 40%); HRMS (ESI +ve TOF) calcd for 












Following General Procedure IV, 
azide 63 (0.02 g, 0.02 mmol), 
cyclohexylacetylene (0.007 g, 0.06 
mmol), CuSO4∙5H2O (0.001 g, 0.004 
mmol) and sodium ascorbate (0.002 g, 
0.008 mmol) were stirred in t-BuOH 
(1.2 mL) and H2O (0.3 mL) for 16 h to give the intermediate 150 as an off-white gum after 
flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General 
Procedure VII, the intermediate 150 (0.02 g, 0.02 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.01 g, 0.40 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (2 mL) to give the amine salt 38 (0.015 g, 98% over two steps) as an off-white 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +65.8 (c 0.0026, MeOH). 1H NMR (400 
MHz, CD3OD) δ 8.35 (s, 1H, H4), 7.93 (s, 1H, Hγ), 7.68-7.60 (m, 1H, Ar4), 7.47 (d, J = 7.0 
Hz, 1H, Ar6), 7.33 (t, J = 7.0 Hz, 1H, Ar5), 7.28-7.20 (m, 1H, Ar3), 4.80-4.68 (m, 3H, 
OCHAHB/H1'), 4.60-4.50 (m, 1H, H1'), 4.42-4.32 (m, 1H, Lys5), 4.16-4.08 (m, 1H, H2'), 
3.28-3.14 (m, 2H, H1'''), 3.00-2.84 (m, 3H, H5'/H1''), 2.70-2.62 (m, 2H, Lys1), 1.88-1.56 (m, 
13H, H2'''/H3'''/H3'/Lys4/H4'/Lys2/Lys3), 1.54-1.38 (m, 8H, H2''/H3''/H4''/H5''/H6''), 1.38-
1.24 (m, 2H, H3''/H5''), 0.81 (d, J = 6.0 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 
174.4 (βC=O), 170.2 (αC=O), 158.8 (C=N), 154.2 (Ar2), 143.4 (Cδ), 139.4 (C5), 134.0 (C4), 
129.8 (Ar4), 127.1 (Ar6), 125.8 (Ar1), 123.56 (Cγ), 123.52 (Ar5), 115.5 (Ar3), 68.6 





(C1''), 33.3 (C3'), 32.6 (C2''/C6''), 29.7 (Lys4), 29.6 (Lys2), 28.8 (C3'''), 28.1 (C1'''), 26.9 
(C4''), 26.7 (C3''/C5''), 24.2 (C4'), 23.6 (C4'''/C5'''), 22.7 (Lys3); IR (neat) ?̅?max 3378, 3350, 
3265, 3066, 2932, 2864, 1915, 1664, 1603, 1548, 1508, 1464, 1452, 1384, 1367, 1286, 1272, 
1250, 1230, 1167, 1114, 1090, 1057, 983, 956, 915, 892, 882, 837, 819, 802, 794, 761, 720, 
667, 645, 628, 581 cm-1; MS (ESI +ve) m/z 693 ([M – 2HCl + H]+, 10%), 347 ([M – 2HCl + 
H]2+, 100%); HRMS (ESI +ve TOF) calcd for C35H59N12O3Cl2 765.4210, found 765.4248 





Following General Procedure IV, azide 63 
(0.10 g, 0.10 mmol), 3-cyclohexyl-1-
propyne (0.04 g, 0.32 mmol), CuSO4∙5H2O 
(0.005 g, 0.02 mmol) and sodium ascorbate 
(0.008 g, 0.04 mmol) were stirred in t-
BuOH (2 mL) and H2O (0.5 mL) for 16 h to 
give the intermediate 151 as an off-white solid after flash chromatography over SiO2 gel 
(MeOH/CH2Cl2 – 0:100 → 4:96). Following General Procedure VII, the intermediate 151 
(0.07 g, 0.06 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 1.32 mmol) 
and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) to give the amine salt 
39 (0.050 g, 64% over two steps) as an off-white solid that rapidly transitioned to a sticky 
gum. [𝛼]𝐷
23 +61.4 (c 0.0048, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.43 (s, 1H, H4), 8.18 





= 9.1 Hz, 1H, Ar5), 7.26 (t, J = 8.9 Hz, 1H, Ar3), 4.74-4.60 (m, 3H, OCHAHB/H1'), 4.51-
4.43 (m, 1H, H1'), 4.38-4.30 (m, 1H, Lys5), 4.14-4.08 (m, 1H, H2'), 3.22-3.13 (m, 2H, H1'''), 
2.96-2.87 (m, 2H, H5'), 2.66-2.60 (m, 4H, δC-CH2/Lys1), 1.78-1.54 (m, 14H, H1''/Lys4/Lys2 
/Lys3/H3'/H4'/H2'''/H3'''), 1.50-1.36 (m, 5H, H2''/H3''/H4''/H5''/H6''), 1.33-1.12 (m, 3H, 
H2''/H4''/ H6''), 1.05-0.91 (m, 2H, H3''/H5''), 0.80 (d, J = 6.4 Hz, 6H, H4'''/H5'''); 13C NMR 
(101 MHz, CD3OD) δ 172.9 (βC=O), 168.5 (αC=O), 157.2 (C=N), 152.5 (Ar2), 152.4 (Cδ), 
142.9 (C5), 132.9 (C4), 129.3 (Ar4), 128.3 (Ar6), 127.8 (Ar1), 123.7 (Cγ), 121.9 (Ar5), 114.0 
(Ar3), 67.1 (OCHAHB), 56.3 (C1'), 53.4 (Lys5), 49.4 (C2'), 40.5 (C2'''), 39.2 (C5'), 37.3 
(Lys1), 36.4 (C1''), 32.3 (δC-CH2), 32.2 (C2''), 31.0 (C6''), 30.4 (C3'), 28.1 (Lys4), 27.2 
(Lys2), 26.5 (C3'''), 25.7 (C1'''), 25.6 (C4''), 24.8 (C3''/C5''), 22.6 (C4'), 21.1 (C4'''/C5'''), 20.9 
(Lys3); IR (neat) ?̅?max 3351, 3268, 3195, 3066, 2927, 2856, 2667, 2067, 1916, 1662, 1543, 
1508, 1465, 1451, 1386, 1368, 1290, 1229, 1168, 1129, 1051, 985, 958, 936, 916, 846, 762, 
668, 646, 585 cm-1; MS (ESI +ve) m/z 707 ([M – 2HCl + H]+, 100%); HRMS (ESI +ve TOF) 






Following General Procedure IV, 
azide 63 (0.03 g, 0.03 mmol), 3-phenyl-
1-propyne (0.01 g, 0.09 mmol), 
CuSO4∙5H2O (0.002 g, 0.006 mmol) and 
sodium ascorbate (0.003 g, 0.012 mmol) 





H2O (0.3 mL) for 16 h to give the intermediate 152 as an off-white gum after flash 
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 4:96). Following General 
Procedure VII, the intermediate 152 (0.03 g, 0.03 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.01 g, 0.56 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (2 mL) to give the amine salt 40 (0.012 g, 52% over two steps) as an off-white 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +66.5 (c 0.0028, MeOH). 1H NMR (400 
MHz, CD3OD) δ 8.16 (s, 1H, H4), 7.64 (s, 1H, Hγ), 7.63 (apparent t, J = 7.0 Hz, 1H, Ar4), 
7.48-7.41 (m, 1H, Ar6), 7.36-7.20 (m, 7H, Ar5/Ar3/H2''/H3''/H4''/H5''/H6''), 4.80-4.58 (m, 
3H, OCHAHB/H1'), 4.57-4.44 (m, 1H, H1'), 4.36-4.28 (m, 1H, Lys5), 4.20-4.08 (m, 3H, 
H2'/H1'''), 3.26-3.14 (m, 2H, H5'), 2.92-2.82 (m, 2H, CH2Ph), 2.68-2.60 (m, 2H, Lys1), 1.80-
1.36 (m, 11H, Lys4/Lys2/H3'/H4'/H2'''/H3'''), 1.30-1.20 (m, 2H, Lys3), 0.79 (d, J = 5.5 Hz, 
3H, H4'''), 0.76 (d, J = 6.0 Hz, 3H, H5'''); 13C NMR (101 MHz, CD3OD) δ 174.2 (βC=O), 
170.0 (αC=O), 158.7 (C=N), 154.1 (Ar2), 154.0 (Cδ), 138.4 (C5), 134.1 (C1''), 130.1 (C4), 
130.0 (Ar4), 129.9 (C2''/C6''), 129.89 (Ar6), 129.86 (C3''/C5''), 128.3 (C4''), 125.7 (Ar1), 
123.5 (Cγ), 115.4 (Ar5), 111.5 (Ar3), 68.6 (OCHAHB), 56.4 (C1'), 54.8 (Lys5), 50.8 (C2'), 
42.1 (C2'''), 40.6 (C5'), 38.1 (Lys1), 32.5 (CH2Ph), 31.4 (C3'), 29.9 (Lys4), 29.8 (Lys2), 28.7 
(C3'''), 28.1 (C1'''), 26.4 (C4'), 23.9 (Lys3), 22.7 (C4'''/C5'''); IR (neat) ?̅?max 3374, 3075, 2956, 
2932, 2870, 1654, 1572, 1548, 1508, 1462, 1381, 1367, 1288, 1253, 1229, 1150, 1113, 1058, 
1005, 914, 883, 838, 793, 759, 720, 697, 670, 657 cm-1; MS (ESI +ve) m/z 701 ([M – 2HCl 
+ H]+, 70%), 351 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) calcd for 











Following General Procedure 
IV, azide 65 (0.08 g, 0.08mmol), 
cyclohexylacetylene (0.03 g, 0.24 
mmol), CuSO4∙5H2O (0.004 g, 
0.01 mmol) and sodium ascorbate 
(0.006 g, 0.03 mmol) were stirred 
in t-BuOH (2.0 mL) and H2O (0.5 
mL) for 16 h to give the intermediate 153 as an off-white gum after flash chromatography 
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 8:92). Following General Procedure VII, the 
intermediate 153 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O 
(0.02 g, 1.00 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) 
to give the amine salt 41 (0.03 g, 46% over two steps) as an off-white solid that rapidly 
transitioned to a sticky gum. [𝛼]𝐷
23 +59.1 (c 0.0052, MeOH); 1H NMR (400 MHz, CD3OD) 
δ 8.30 (s, 1H, H5), 8.29 (s, 1H, Hγ), 8.18 (d, J = 9.2 Hz, 1H, Ar8), 7.98 (d, J = 7.5 Hz, 1H, 
Ar5), 7.61 (ddd, J = 9.2, 9.2, 1.7 Hz, 1H, Ar7), 7.57-7.49 (m, 2H, Ar6/Ar4), 7.14 (d, J = 8.3 
Hz, 1H, Ar3), 4.93-4.89 (m, 2H, OCHAHB), 4.77-4.72 (m, 1H, H1'), 4.59-4.53 (m, 1H, H1'), 
4.37-4.32 (m, 1H, Lys5), 4.12-4.09 (m, 1H, H2'), 3.18-3.14 (m, 2H, H5'), 2.95-2.91 (m, 2H, 
Lys1), 2.84-2.78 (m, 3H, H1'''/H1''), 2.00-1.96 (m, 2H, Lys4), 1.74-1.60 (m, 14H, 
H2'''/H3'''/Lys2/H3'/H4'/H2''/H3''/H4''/H5''/H6''), 1.48-1.21 (m, 7H, Lys3/H2''/H3''/H4''/H5''/ 
H6''), 1.01 (d, J = 6.2 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 173.0 (βC=O), 





129.1 (Ar4a), 128.6 (Ar5), 128.0 (Ar7), 126.9 (Ar8), 125.5 (C5), 125.1 (Cγ), 120.2 (Ar6), 
119.1 (Ar3), 113.9 (Ar1), 67.4 (OCHAHB), 55.7 (C1'), 53.5 (Lys5), 49.3 (C2'), 40.4 (C5'), 
39.0 (Lys1), 37.9 (C2'''), 33.4 (C1''), 31.6 (C2''), 31.5 (C6''), 30.9 (Lys4), 28.1 (Lys2), 27.5 
(C1'''), 26.5 (C3'), 25.2 (C4''), 25.0 (C3''/C5''), 24.8 (C3'''), 22.6 (C4'), 22.5 (C4'''/C5'''), 21.3 
(Lys3); IR (neat) ?̅?max 3348, 3265, 3202, 3066, 2932, 2860, 1662, 1544, 1514, 1483, 1451, 
1384, 1366, 1349, 1279, 1220, 1168, 1117, 1081, 1049, 816, 749, 668, 585 cm-1; MS (ESI 
+ve) m/z 743 ([M – 2HCl + H]+, 60%), 372 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve 





hexanamide dihydrochloride (42) 
Following General Procedure IV, 
azide 65 (0.07 g, 0.07 mmol), 3-
cyclohexyl-1-propyne (0.03 g, 0.21 
mmol), CuSO4∙5H2O (0.004 g, 0.01 
mmol) and sodium ascorbate (0.006 g, 
0.02 mmol) were stirred in t-BuOH (2 
mL) and H2O (0.5 mL) for 16 h to give 
the intermediate 154 as a light brown waxy solid after flash chromatography over SiO2 gel 
(MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the intermediate 154 
(0.05 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O (0.02 g, 0.10 mmol) 
and CF3COOH (1 mL) followed by work-up with ethereal HCl (2 mL) to give the amine salt 






23 +65.3 (c 0.0052, MeOH). 1H NMR (400 MHz, CD3OD) δ 8.23 (s, 2H, H5/Hγ), 
8.13 (d, J = 8.2 Hz, 1H, Ar8), 7.90 (d, J = 7.5 Hz, 1H, Ar5), 7.55 (ddd, J = 8.2, 8.2, 1.6 Hz, 
1H, Ar7), 7.52-7.40 (m, 2H, Ar6/Ar4), 7.08 (d, J = 7.5 Hz, 1H, Ar3), 4.88-4.80 (m, 2H, 
OCHAHB), 4.76-4.66 (m, 1H, H1'), 4.56-4.46 (m, 1H, H1'), 4.34-4.26 (m, 1H, Lys5), 4.10-
4.02 (m, 1H, H2'), 3.16-3.06 (m, 2H, H5'), 2.90-2.82 (m, 2H, Lys1), 2.78-2.74 (m, 2H, H1'''), 
2.62-2.56 (m, 3H, H1''/δC-CH2), 1.80-1.50 (m, 18H, Lys4/Lys2/Lys3/H2'''/H3'''/H3'/H4'/ 
H2''/H3''/H4''/ H5''/H6''), 1.26-1.08 (m, 5H, H2''/H3''/H4''/H5''/H6''), 0.95 (d, J = 4.0 Hz, 6H, 
H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 172.9 (βC=O), 169.1 (αC=O), 157.1 (C=N), 
150.8 (Ar2), 147.6 (C4), 143.4 (Cδ), 132.5 (Ar8a), 130.4 (Ar4), 129.1 (Ar4a), 128.6 (Ar5), 
128.0 (Ar7), 127.0 (Ar8), 126.8 (C5), 125.1 (Cγ), 120.3 (Ar6), 119.1 (Ar3), 113.9 (Ar1), 67.5 
(OCHAHB), 65.5 (C1'), 55.7 (Lys5), 53.5 (C2'), 49.3 (C5'), 40.5 (Lys1), 39.0 (C2'''), 38.0 
(C1''), 37.3 (δC-CH2), 32.3 (C2''), 32.2 (C6''), 30.8 (Lys4), 30.7 (Lys2), 28.1 (C4''), 27.5 
(C1'''), 26.5 (C3'), 25.7 (C3''), 25.6 (C5''), 24.8 (C3'''), 22.7 (C4'), 22.6 (C4'''/C5'''), 21.4 
(Lys3); IR (neat) ?̅?max 3346, 3266, 3193, 3063, 2950, 2927, 2855, 1664, 1602, 1543, 1514, 
1483, 1451, 1383, 1367, 1349, 1280, 1219, 1168, 1154, 1117, 1080, 1050, 963, 933, 916, 
863, 815, 779, 749, 673, 648, 586 cm-1; MS (ESI +ve) m/z 757 ([M – 2HCl + H]+, 50%), 379 
([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) calcd for C40H61N12O3 757.4990, found 













Following General Procedure IV, 
azide 65 (0.07 g, 0.07 mmol), 3-
phenyl-1-propyne (0.02 g, 0.21 
mmol), CuSO4∙5H2O (0.004 g, 
0.01 mmol) and sodium ascorbate 
(0.006 g, 0.02 mmol) were stirred 
in t-BuOH (2 mL) and H2O (0.5 
mL) for 16 h to give the intermediate 155 as a pale brown solid after flash chromatography 
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following General Procedure VII, the 
intermediate 155 (0.060 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O 
(0.02 g, 1.08 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) 
to give the amine salt 43 (0.03 g, 52% over two steps) as a brown solid that rapidly 
transitioned to a sticky gum. [𝛼]𝐷
23 +57.3 (c 0.0042, MeOH). 1H NMR (400 MHz, CD3OD) 
δ 8.41 (brs, 1H, H5), 8.28-8.16 (m, 2H, H2''/H6''), 7.99 (brs, 1H, Hγ), 7.66-7.48 (m, 4H, Ar8/ 
Ar5/Ar7/Ar6), 7.34-7.22 (m, 4H, H3''/H5''/Ar4/Ar3), 7.20-7.14 (m, 1H, H4''), 4.92-4.80 (m, 
2H, OCHAHB), 4.74-4.66 (m, 1H, H1'), 4.60-4.52 (m, 1H, H1'), 4.42-4.32 (m, 1H, Lys5), 
4.28-4.14 (m, 3H, CH2Ph/H2'), 3.22-3.12 (m, 2H, H5'), 3.02-2.84 (m, 2H, Lys1), 2.84-2.76 
(m, 2H, H1'''), 1.82-1.52 (m, 10H, Lys4/Lys2/H3'/H4'/H2'''), 1.50-1.42 (m, 1H, H3'''), 1.34-
1.20 (m, 2H, Lys3), 1.01 (d, J = 4.8 Hz, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 
172.0 (βC=O), 168.1 (αC=O), 156.3 (C=N), 150.0 (Ar2), 149.9 (C4), 143.7 (Cδ), 135.5 





127.6 (C3''/C5''), 127.2 (Ar8), 126.1 (C5), 125.8 (C4''), 124.3 (Cγ), 119.3 (Ar6), 118.0 (Ar3), 
113.1 (Ar1), 66.8 (OCHAHB), 64.7 (C1'), 54.5 (Lys5), 52.6 (C2'), 48.5 (C5'), 39.7 (Lys1), 
38.2 (C2'''), 36.9 (CH2Ph), 30.1 (Lys4), 28.7 (Lys2), 27.4 (C1'''), 26.7 (C3'), 25.7 (C3'''), 24.0 
(C4'), 21.6 (C4'''/C5'''), 20.6 (Lys3); IR (neat) ?̅?max 3349, 3266, 3195, 3063, 2954, 2869, 1662, 
1602, 1545, 1515, 1497, 1484, 1454, 1382, 1367, 1347, 1279, 1232, 1221, 1166, 1153, 1116, 
1079, 1050, 969, 926, 909, 865, 812, 779, 750, 722, 699, 675, 667, 647 cm-1; MS (ESI +ve) 
m/z 751 ([M – 2HCl + H]+, 20%), 376 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) 






Following General Procedure 
IV, azide 67 (0.08 g, 0.08 mmol), 
cyclohexylacetylene (0.03 g, 0.24 
mmol), CuSO4∙5H2O (0.004 g, 
0.02 mmol) and sodium ascorbate 
(0.006 g, 0.04 mmol) were stirred 
in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 156 as an off-white 
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following 
General Procedure VII, the intermediate 156 (0.07 g, 0.06 mmol) was dissolved in CH2Cl2 
(2 mL), treated with H2O (0.02 g, 1.27 mmol) and CF3COOH (1 mL) followed by work-up 
with ethereal HCl (3 mL) to give the amine salt 44 (0.036 g, 55% over two steps) as a pale 
brown solid that rapidly transitioned to a sticky gum. [𝛼]𝐷





NMR (400 MHz, CD3OD) δ 8.25 (s, 1H, H4), 8.25-8.21 (m, 1H, Ar8), 7.99 (s, 1H, Hγ), 8.03-
7.97 (m, 1H, Ar5), 7.64 (ddd, J = 9.2, 2.3 Hz, 1H, Ar7), 7.56-7.50 (m, 2H, Ar6/Ar4), 6.99-
6.95 (m, 1H, Ar3), 5.01-4.65 (m, 3H, OCHAHB/H1'), 4.58-4.48 (m, 1H, H1'), 4.40-4.28 (m, 
1H, Lys5), 4.12-4.04 (m, 1H, H2'), 3.23-3.12 (m, 2H, H5'), 3.00-2.76 (m, 2H, H1'''), 2.72-
2.63 (m, 1H, H1''), 2.54-2.44 (m, 2H, Lys1), 2.08-1.91 (m, 2H, Lys4), 1.90-1.08 (m, 21H, 
H2'''/H3'''/H3'/H4'/Lys2/Lys3/H2''/H3''/H4''/H5''/H6''), 0.71-0.66 (m, 6H, H4'''/H5'''); 13C 
NMR (101 MHz, CD3OD) δ 176.7 (βC=O), 172.6 (αC=O), 161.0 (C=N), 155.3 (Ar2), 146.0 
(Cδ), 136.7 (C5), 136.6 (Ar8a), 135.3 (C4), 134.7 (Ar4), 133.3 (Ar4a), 132.5 (Ar5), 132.1 
(Ar7), 129.0 (Ar8), 128.1 (Ar6), 124.2 (Cγ), 121.2 (Ar3), 118.0 (Ar1), 71.3 (OCHAHB), 58.8 
(C1'), 57.4 (Lys5), 53.2 (C2'), 44.4 (C2'''), 43.0 (C5'), 40.5 (Lys1), 37.9 (C1''), 36.0 (Lys4), 
35.9 (C3'), 34.9 (Lys2), 30.9 (C2''), 30.5 (C6''), 29.4 (C4''), 29.3 (C3''), 29.2 (C5''), 28.7 
(C3'''), 26.4 (1'''), 26.3 (C4'), 24.9 (C4'''/C5'''), 24.4 (Lys3); IR (neat) ?̅?max 3343, 3264, 3185, 
3063, 2931, 2860, 1663, 1601, 1541, 1513, 1483, 1451, 1385, 1367, 1347, 1278, 1220, 1170, 
1154, 1131, 1082, 1049, 990, 973, 931, 919, 859, 818, 779, 750, 678, 652 cm-1; MS (ESI 
+ve) m/z 744 ([M – 2HCl + H]+, 100%); HRMS (ESI +ve TOF) calcd for C39H59N12O3 














hexanamide dihydrochloride (45) 
Following General Procedure IV, 
azide 67 (0.08 g, 0.08 mmol), 3-
cyclohexyl-1-propyne (0.03 g, 0.24 
mmol), CuSO4∙5H2O (0.004 g, 0.02 
mmol) and sodium ascorbate (0.006 g, 
0.04 mmol) were stirred in t-BuOH (2 
mL) and H2O (0.5 mL) for 16 h to give the intermediate 157 as an off-white gum after flash 
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General 
Procedure VII, the intermediate 157 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.02 g, 1.05 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (3 mL) to give the amine salt 45 (0.036 g, 54% over two steps) as a brown solid 
that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +66.1 (c 0.0050, MeOH). 1H NMR (400 MHz, 
CD3OD) δ 8.33 (s, 1H, H4), 8.29 (s, 1H, Hγ), 8.25-8.21 (m, 1H, Ar8), 8.06-8.00 (m, 1H, 
Ar5), 7.64 (ddd, J = 9.2, 9.2, 2.3 Hz, 1H, Ar7), 7.58-7.49 (m, 2H, Ar6/Ar4), 7.00-6.94 (m, 
1H, Ar3), 5.04-4.68 (m, 3H, OCHAHB/H1'), 4.62-4.48 (m, 1H, H1'), 4.40-4.28 (m, 1H, Lys5), 
4.12-4.04 (m, 1H, H2'), 3.23-3.10 (m, 2H, H5'), 3.01-2.85 (m, 1H, H1'''), 2.77-2.58 (m, 3H, 
H1'''/Lys1), 2.54-2.44 (m, 2H, δC-CH2), 1.85-1.49 (m, 14H, H2'''/H3'''/H3'/H4'/Lys2/Lys3/ 
Lys4/H1''), 1.46-1.08 (m, 8H, H2''/H3''/H4''/H5''/H6''), 1.03-0.80 (m, 2H, H3''/H5''), 0.74-
0.64 (m, 6H, H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 171.5 (βC=O), 167.3 (αC=O), 
157.9 (C=N), 151.9 (Ar2), 145.5 (Cδ), 141.1 (C5), 132.4 (Ar8a), 131.7 (C4), 131.4 (Ar4), 





115.5 (Ar1), 68.4 (OCHAHB), 53.1 (C1'), 49.5 (Lys5), 39.1 (C2'), 37.86 (C2'''), 37.83 (C5'), 
36.9 (Lys1), 32.99 (δC-CH2), 32.92 (C1''), 31.8 (Lys4), 29.1 (C3'), 27.1 (Lys2), 26.98 (C2''), 
26.95 (C6''), 26.4 (C4''), 26.03 (C3''), 26.01 (C5''), 25.3 (C3'''), 22.5 (C1'''), 22.4 (C4'), 22.2 
(C4'''/C5'''), 20.7 (Lys3); IR (neat) ?̅?max 3345, 3264, 3187, 3061, 2952, 2927, 2855, 2666, 
1663, 1634, 1602, 1542, 1513, 1483, 1450, 1385, 1368, 1347, 1279, 1220, 1168, 1154, 1131, 
1082, 1050, 1025, 992, 972, 932, 863, 818, 780, 749, 680, 651 cm-1; MS (ESI +ve) m/z 758 
([M – 2HCl + H]+, 70%), 380 ([M – 2HCl + H]2+, 100%); HRMS (ESI +ve TOF) calcd for 






Following General Procedure IV, 
azide 67 (0.08 g, 0.08 mmol), 3-
phenyl-1-propyne (0.03 g, 0.24 
mmol), CuSO4∙5H2O (0.004 g, 
0.02 mmol) and sodium ascorbate 
(0.006 g, 0.04 mmol) were stirred 
in t-BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 158 as an off-white 
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following 
General Procedure VII, the intermediate 158 (0.07 g, 0.06 mmol) was dissolved in CH2Cl2 
(2 mL), treated with H2O (0.02 g, 1.27 mmol) and CF3COOH (1 mL) followed by work-up 
with ethereal HCl (3 mL) to give the amine salt 46 (0.035 g, 53% over two steps) as a white 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷





MHz, CD3OD) δ 8.25-8.18 (m, 1H, Ar8), 8.03-7.93 (m, 2H, Ar5/Ar7), 7.95 (s, 1H, H4), 7.63-
7.50 (m, 3H, Ar6/Ar4/Hγ), 7.33-7.17 (m, 5H, H2''/H3''/H4''/H5''/H6''), 6.99-6.95 (m, 1H, Ar3), 
4.99-4.68 (m, 2H, OCHAHB), 4.62-4.55 (m, 1H, H1'), 4.49-4.39 (m, 1H, H1'), 4.36-4.27 (m, 
1H, Lys5), 4.17-4.02 (m, 3H, H2'/δC-CH2), 3.18-3.12 (m, 2H, H5'), 2.92-2.84 (m, 1H, H1'''), 
2.77-2.67 (m, 1H, H1'''), 2.58-2.42 (m, 2H, Lys1), 1.77-1.44 (m, 8H, H3'/H4'/Lys2/Lys4), 
1.43-1.30 (m, 3H, H2'''/H3'''), 1.28-1.00 (m, 2H, Lys3), 0.71-0.66 (m, 6H, H4'''/H5'''); 13C 
NMR (101 MHz, CD3OD) δ 171.5 (βC=O), 167.2 (αC=O), 157.9 (C=N), 151.8 (Ar2), 146.0 
(Cδ), 141.2 (C5), 141.1 (Ar8a), 140.0 (C4), 132.0 (C1''), 131.7 (Ar4), 131.4 (Ar4a), 129.2 
(C2''), 128.9 (C6''), 128.79 (C3''), 128.74 (C5''), 128.5 (Ar5), 126.48 (Ar7), 126.46 (Ar8), 
125.3 (Ar6), 125.2 (C4''), 123.4 (Cγ), 121.1 (Ar3), 115.5 (Ar1), 68.4 (OCHAHB), 53.0 (C1'), 
49.5 (Lys5), 39.1 (C2'), 36.9 (C2'''), 31.8 (δC-CH2), 29.1 (C5'), 27.1 (Lys1), 26.99 (Lys4), 
26.96 (C3'), 25.3 (Lys2), 22.5 (C3'''), 22.4 (1'''), 22.23 (C4'), 22.20 (C4'''/C5'''), 20.7 (Lys3); 
IR (neat) ?̅?max 3342, 3264, 3190, 3064, 2955, 2935, 2869, 1662, 1601, 1543, 1513, 1483, 1455, 
1384, 1367, 1346, 1279, 1221, 1170, 1154, 1131, 1080, 1049, 991, 972, 930, 864, 815, 780, 
750, 723, 698, 678, 652 cm-1; MS (ESI +ve) m/z 752 ([M – 2HCl + H]+, 100%); HRMS (ESI 















Following General Procedure IV, 
azide 68 (0.07 g, 0.07 mmol), 
cyclohexylacetylene (0.02 g, 0.21 
mmol), CuSO4∙5H2O (0.003 g, 0.01 
mmol) and sodium ascorbate (0.006 
g, 0.02 mmol) were stirred in t-
BuOH (2 mL) and H2O (0.5 mL) for 16 h to give the intermediate 159 as an off-white gum 
after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 6:94). Following 
General Procedure VII, the intermediate 159 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 
(2 mL), treated with H2O (0.02 g, 1.11 mmol) and CF3COOH (1 mL) followed by work-up 
with ethereal HCl (3 mL) to give the amine salt 47 (0.034 g, 61% over two steps) as a light 
brown solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +57.1 (c 0.0052, MeOH). 1H 
NMR (400 MHz, CD3OD) δ 8.05 (s, 2H, H4/Hγ), 7.57 (ddd, J = 8.0, 8.0, 3.0 Hz, 1H, Ar4), 
7.45-7.42 (m, 1H, Ar6), 7.27-7.25 (m, 1H, Ar5), 7.16-7.11 (m, 1H, Ar3), 4.66 (m, 3H, C5-
CH2/H1'), 4.46 (apparent t, J = 10.5 Hz, 1H, H1'), 4.40-4.31 (m, 1H, Lys5), 4.19-4.15 (m, 
1H, H2'), 4.06 (t, J = 6.0 Hz, 2H, H1'''), 3.88 (s, 2H, OCHAHB), 3.20-3.17 (m, 2H, H5'), 2.93-
2.90 (m, 2H, Lys1), 2.84-2.74 (m, 1H, H1''), 2.08-1.96 (m, 2H, H3'), 1.86-1.79 (m, 2H, Lys4), 
1.78-1.55 (m, 9H, Lys2/H4'/H2''/H3''/H4''/H5''/H6''), 1.54-1.37 (m, 8H, H2'''/H3'''/H2''/H3''/ 
H4''/H5''/H6''), 1.35-1.18 (m, 2H, Lys3), 0.82 (d, J = 6.2 Hz, 6H, H4'''/H5'''); 13C NMR (101 
MHz, CD3OD) δ 172.6 (βC=O), 170.2 (αC=O), 157.2 (C=N), 153.5 (Ar2), 132.06 (C5), 





111.8 (Ar3), 68.8 (OCHAHB), 67.2 (C1'''), 61.5 (C5-CH2), 54.2 (C1'), 52.8 (Lys5), 49.1 (C2'), 
40.5 (C5'), 39.1 (Lys1), 37.3 (C2'''), 34.5 (C1''), 32.3 (C2''/C6''), 31.3 (Lys4), 28.5 (C3'), 26.6 
(Lys2), 25.6 (C4''), 25.4 (C3''/C5''), 24.8 (C3'''), 24.7 (C4'), 22.3 (C4'''/C5'''), 21.3 (Lys3); IR 
(neat) ?̅?max 3396, 3372, 3358, 3285, 3274, 3263, 3212, 3198, 3067, 2931, 2865, 2162, 2126, 
1978, 1965, 1659, 1533, 1509, 1464, 1386, 1368, 1345, 1288, 1247, 1229, 1161, 1129, 1052, 
979, 759, 672, 618, 572 cm-1; MS (ESI +ve) m/z 723 ([M – 2HCl + H]+, 100%); HRMS (ESI 





hexanamide dihydrochloride (48) 
Following General Procedure IV, azide 
68 (0.07 g, 0.07 mmol), 3-cyclohexyl-1-
propyne (0.03 g, 0.21 mmol), 
CuSO4∙5H2O (0.003 g, 0.01 mmol) and 
sodium ascorbate (0.006 g, 0.02 mmol) 
were stirred in t-BuOH (2 mL) and H2O 
(0.5 mL) for 16 h to give the intermediate 160 as an off-white gum after flash chromatography 
over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General Procedure VII, the 
intermediate 160 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), treated with H2O 
(0.02 g, 1.10 mmol) and CF3COOH (1 mL) followed by work-up with ethereal HCl (3 mL) 
to give the amine salt 48 (0.037 g, 83% over two steps) as a pale brown solid that rapidly 
transitioned to a sticky gum. [𝛼]𝐷
23 +62.3 (c 0.0052, MeOH). 1H NMR (400 MHz, CD3OD) 





7.25 (m, 1H, Ar5), 7.15-7.11 (m, 1H, Ar3), 4.72-4.44 (m, 4H, C5-CH2/H1'), 4.42-4.26 (m, 
1H, Lys5), 4.22-4.12 (m, 1H, H2'), 4.06 (t, J = 7.6 Hz, 2H, H1'''), 3.91 (s, 2H, OCHAHB), 
3.24-3.16 (m, 2H, H5'), 2.97-2.87 (m, 2H, Lys1), 2.70-2.62 (m, 2H, δC-CH2), 1.78-1.54 (m, 
14H, H3'/Lys2/Lys4/H4'/H1''/H2''/H3''/H4''/H5''/H6''), 1.58-1.44 (m, 3H, H2''/H4''/H6''), 
1.38-1.10 (m, 5H, H2'''/H3'''/Lys3), 1.06-0.91 (m, 2H, H3''/H5''), 0.82 (d, J = 7.7 Hz, 6H, 
H4'''/H5'''); 13C NMR (101 MHz, CD3OD) δ 172.7 (βC=O), 170.2 (αC=O), 157.2 (C=N), 
153.6 (Ar2), 132.0 (C5), 128.1 (Cδ), 125.9 (C4), 124.5 (Ar4), 120.67 (Ar6), 120.64 (Cγ), 
115.5 (Ar1, Observed by gHMBC), 113.39 (Ar5), 113.36 (Ar3), 68.9 (OCHAHB), 67.3 (C1'''), 
61.4 (C5-CH2), 55.0 (C1'), 53.1 (Lys5), 52.9 (C2'), 49.3 (δC-CH2), 40.5 (C5'), 39.1 (Lys1), 
37.6 (C2'''), 37.3 (C1''), 32.4 (C2''), 32.3 (C6''), 31.2 (Lys4), 28.3 (C3'), 26.5 (Lys2), 25.8 
(C4''), 25.7 (C3''), 25.6 (C5''), 24.8 (C3'''), 24.7 (C4'), 22.4 (C4'''/C5'''), 21.4 (Lys3); IR (neat) 
?̅?max 3381, 3359, 3352, 3333, 3284, 3270, 3260, 3250, 3202, 3074, 3063, 2926, 2869, 2176, 
2123, 2061, 1999, 1659, 1529, 1509, 1465, 1450, 1386, 1369, 1288, 1246, 1229, 1137, 1056, 
998, 981, 849, 756, 667, 638, 619, 588, 572 cm-1; MS (ESI +ve) m/z 737  ([M – 2HCl + H]+, 















Following General Procedure IV, 
azide 68 (0.08 g, 0.08 mmol), 3-
phenyl-1-propyne (0.03 g, 0.24 
mmol), CuSO4∙5H2O (0.004 g, 0.01 
mmol) and sodium ascorbate (0.006 g, 
0.03 mmol) were stirred in t-BuOH (2 
mL) and H2O (0.5 mL) for 16 h to give the intermediate 161 as an off-white gum after flash 
chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 → 5:95). Following General 
Procedure VII, the intermediate 161 (0.06 g, 0.05 mmol) was dissolved in CH2Cl2 (2 mL), 
treated with H2O (0.02 g, 1.10 mmol) and CF3COOH (1 mL) followed by work-up with 
ethereal HCl (3 mL) to give the amine salt 49 (0.033 g, 51% over two steps) as a pale brown 
solid that rapidly transitioned to a sticky gum. [𝛼]𝐷
23 +68.1 (c 0.0048, MeOH). 1H NMR (400 
MHz, CD3OD) δ 8.15 (s, 1H, H4), 8.05 (s, 1H, Hγ), 7.58 (t, J = 7.7 Hz, 1H, Ar4), 7.45 (d, J 
= 7.6 Hz, 1H, Ar6), 7.33-7.20 (m, 6H, Ar5/H2''/H3''/H4''/ H5''/H6''), 7.13 (d, J = 7.5 Hz, 1H, 
Ar3), 4.73-4.54 (m, 3H, C5-CH2/H1'), 4.56-4.4.45 (m, 1H, H1'), 4.40-4.26 (m, 1H, Lys5), 
4.22-4.10 (m, 3H, H2'/OCHAHB), 4.10-4.02 (m, 2H, H5'), 3.91 (t, J = 5.9 Hz, 2H, H1'''), 3.25-
3.11 (m, 2H, Lys1), 2.98-2.81 (m, 2H, δC-CH2), 1.73-1.34 (m, 11H, H3'/Lys2/Lys4/ 
H4'/H2'''/H3'''), 1.31-1.16 (m, 2H, Lys3), 0.82 (d, J = 6.1 Hz, 6H, H4'''/H5'''); 13C NMR (101 
MHz, CD3OD) δ 172.7 (βC=O), 170.1 (αC=O), 157.2 (C=N), 153.5 (Ar2), 137.09 (C5), 
137.03 (Cδ), 132.2 (C1''), 128.67 (C2''), 128.65 (C6''), 128.5 (C3''), 128.4 (C5''), 128.1 (C4), 





68.9 (OCHAHB), 67.3 (C1'''), 61.4 (C5-CH2), 54.9 (C1'), 52.8 (Lys5), 49.2 (C2'), 40.5 (C5'), 
39.1 (Lys1), 37.3 (C2'''), 31.2 (δC-CH2), 29.9 (Lys4), 28.3 (C3'), 26.5 (Lys2), 24.8 (C3'''), 
24.7 (C4'), 22.5 (C4'''/C5'''), 21.4 (Lys3); IR (neat) ?̅?max 3358, 3273, 3195, 3068, 2955, 2871, 
2165, 2101, 2063, 1658, 1533, 1509, 1464, 1386, 1368, 1288, 1245, 1227, 1164, 1137, 1050, 
999, 979, 875, 850, 757, 724, 699667, 621, 590 cm-1; MS (ESI +ve) m/z 731 ([M – 2HCl + 
H]+, 100%); HRMS (ESI +ve TOF) calcd for C37H55N12O4 731.4469, found 731.4444 ([M – 
2HCl + H]+). 
 
6.4 – Experimental-Click chemistry  
6.4.1 – Magnesium promoted click reactions 
5-Isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (83)  
This compound was prepared according to the General procedure 
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with 5-methyl-1-hexyne (0.03 g, 0.27 mmol) and EtMgCl 
(0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 3 h 
to give 83 (0.06 g, 81%) as a pale brown waxy solid after purification by column 
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0). TLC (EtOAc/n-hexane 
1:4): Rf = 0.2; 
1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 9.1 Hz, 1H, H8''), 7.85 (dd, J = 7.4, 
2.0 Hz, 1H, H5''), 7.71 (s, 1H, H4), 7.45-7.37 (m, 3H, H6'', H7'' and H4''), 6.99-6.96 (m, 1H, 
H3''), 3.87 (s, 3H, OMe), 2.45-2.34 (m, 2H, H1'), 1.47-1.35 (m, 3H, H2' and H3'), 0.73 (d, J 
= 7.9 Hz, 3H,  H5'), 0.72 (d, J = 7.9 Hz, 3H,  H4'); 13C NMR (101 MHz, CDCl3) δ 152.7 
(C2''), 140.7 (C5), 132.0 (C8a''), 131.6 (C4), 131.4 (C4a''), 128.7 (C4''), 128.3 (C5''), 127.9 
(C7''), 124.6 (C8''), 121.2 (C6''), 117.9 (C3''), 113.1 (C1''), 56.5 (OMe), 36.7 (C2'), 27.2 (C1'), 





1255, 1064, 1040, 809, 748 cm-1; MS (ESI +ve) m/z 296 ([M + H]+, 100%); HRMS (ESI +ve 




This compound was prepared according to the General procedure 
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with ethynylcyclohexane (0.03 g, 0.27 mmol) and EtMgCl 
(0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 5 h to give 100 (0.06 g, 78%) 
as a cream white solid after purification by column chromatography over SiO2 gel (EtOAc/n-
hexane - 30:70 → 100:0). M.P: 104-106 °C; TLC (EtOAc/n-hexane 1:4): Rf = 0.1; 
1H NMR 
(500 MHz, CDCl3) δ 8.03 (d, J = 9.1 Hz, 1H, H8"), 7.87-7.85 (m, 1H, H5"), 7.71 (s, 1H, H4), 
7.44-7.38 (m, 3H, H6", H7" and H4"), 6.95 (dd, J = 8.2, 1.2 Hz, 1H, H3"), 3.87 (s, 3H, OMe), 
2.31-2.24 (m, 1H, H1'), 1.91-1.88 (m, 1H, H5'), 1.74-1.70 (m, 1H, H4'), 1.60-1.56 (m, 3H, 
H6', H2' and H3'), 1.43-1.40 (m, 1H, H5'), 1.32-1.29 (m, 1H, H4'), 1.19-1.10 (m, 2H, H6' and 
H3'), 1.01-0.97 (m, 1H, H2'); 13C NMR (126 MHz, CDCl3) δ 152.7 (C2"), 145.7 (C5), 132.0 
(C8a"), 131.8 (C4), 130.1 (C4"), 128.7 (C4a"), 128.3 (C5"), 127.9 (C7"), 124.6 (C8"), 121.3 
(C6"), 118.1 (C3"), 113.1 (C1"), 56.6 (OMe), 33.3 (C6'), 32.9 (C2'), 32.4 (C1'), 25.9 (C4'), 
25.8 (C5'), 25.6 (C3'); IR (neat) νmax 2927, 2852, 1628, 1599, 1510, 1482, 1276, 1245, 1151, 
1067, 818, 751 cm-1; MS (ESI +ve) m/z 308 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd 











This compound was prepared according to the General 
procedure VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 
mmol) was treated with 1-ethynyl-4-methoxybenzene (0.04 g, 
0.27 mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 4 
h to give 101 (0.072 g, 86%) as a waxy solid after purification by column chromatography 
over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 
1H 
NMR (500 MHz, CDCl3) δ 7.97 (s, 1H, H4), 7.96 (d, J = 9.6 Hz, 1H, H8"), 7.81 (d, J = 8.0 
Hz, 1H, H5"), 7.43-7.35 (m, 2H, H6" and H7"), 7.28 (d, J = 9.1 Hz, 1H, H4" ), 7.16 (d, J = 
8.3 Hz, 1H, H3"), 7.09-7.06 (m, 2H, H2' and H6'), 6.69-6.66 (m, 2H, H3' and H5'), 3.69 (s, 
3H, OMe), 3.66 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ 160.0 (C4'), 152.6 (C2"), 140.2 
(C8a"), 132.0 (C4), 131.65 (C4"), 131.63 (C4a"), 128.7 (C2' and C6'), 128.4 (C5"), 127.9 
(C7"), 127.8 (C8"), 124.6 (C6"), 121.3 (C3"), 119.2 (C5), 118.6 (C1'), 114.0 (C3' and C5'), 
113.2 (C1"), 56.5 (OMe), 55.1 (C7'); IR (neat) νmax 2940, 2839, 1616, 1558, 1507, 1495, 
1457, 1276, 1249, 1179, 1067, 1020, 810, 750 cm-1. MS (ESI +ve) m/z 332 ([M + H]+, 100%); 
HRMS (ESI +ve TOF) calcd for C20H18N3O2 332.1399, found 332.1386 ([M + H]
+). 
 
1-(2-Methoxynaphthalen-1-yl)-5-(2-methoxyphenyl)-1H-1,2,3-triazole (102)  
This compound was prepared according to the General procedure 
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with 1-ethynyl-2-methoxybenzene (0.04 g, 0.27 mmol) and 
EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C 
for 4 h to give 102 (0.074 g, 89%) as an off-white waxy solid after purification by column 





2:3): Rf = 0.1; 
1H NMR (500 MHz, CDCl3) δ 8.01 (s, 1H, H4), 7.89 (d, J = 9.1 Hz, 1H, H6'), 
7.79 (d, J = 8.1 Hz, 1H, H8"), 7.46-7.43 (m, 1H, H5"), 7.39-7.35 (m, 2H, H6" and H7"), 7.21-
7.17 (m, 2H, H4' and H5'), 7.06 (dd, J = 8.0, 1.7 Hz, 1H, H4"), 6.75 (d, J = 7.5 Hz, 1H, H3'), 
6.70 (d, J = 8.0 Hz, 1H, H3"), 3.59 (s, 3H, OMe), 3.26 (s, 3H, H7'); 13C NMR (126 MHz, 
CDCl3) δ 156.6 (C2'), 151.9 (C2"), 137.2 (C8a"), 133.7 (C4), 131.48 (C6'), 131.46 (C4"), 
130.5 (C4'), 130.3 (C4a"), 128.7 (C5"), 127.8 (C7"), 127.6 (C8"), 124.3 (C6"), 122.3 (C5'), 
120.1 (C5), 119.3 (C3"), 116.2 (C1'), 113.0 (C1"), 110.7 (C3'), 56.3 (C7'), 54.7 (OMe); IR 
(neat) νmax 2938, 2840, 1507, 1486, 1465, 1264, 1150, 1104, 1067, 1020, 806, 749 cm
-1. MS 
(ESI +ve) m/z 332 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C20H18N3O2 332.1399, 
found 332.1388 ([M + H]+). 
 
1-(2-Methoxynaphthalen-1-yl)-5-(o-tolyl)-1H-1,2,3-triazole (103) 
This compound was prepared according to the General procedure 
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with 1-ethynyl-2-methylbenzene (0.03 g, 0.27 mmol) and 
EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (3 mL) at 50 °C 
for 3 h to give 103 (0.06 g, 76%) as a cream waxy solid after purification by column 
chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 
1:4): Rf = 0.2; 
1H NMR (500 MHz, CDCl3) δ 7.92 (s, 1H, H4), 7.90 (d, J = 9.1 Hz, 1H, H8"), 
7.80 (d, J = 8.2 Hz, 1H, H5"), 7.50-7.46 (m, 1H, H6"), 7.40-7.37 (m, 1H, H7"), 7.33 (dd, J = 
8.8, 0.6 Hz, 1H, H4"), 7.18 (d, J = 8.8 Hz, 1H, H3"), 7.15-7.11 (m, 2H, H3' and H6' ), 6.87-
6.86 (m, 2H, H4' and H5'), 3.67 (s, 3H, OMe), 2.27 (s, 3H, Me); 13C NMR (126 MHz, CDCl3) 
δ 152.1 (C2"), 139.5 (C8a"), 137.1 (C2'), 133.5 (C4), 131.8 (C4a"), 131.6 (C4"), 130.1 (C1'), 





124.5 (C3"), 121.5 (C6'), 118.2 (C5), 112.7 (C1"), 56.1 (OMe), 20.1 (Me); IR (neat) νmax 
3140, 2929, 2847, 1599, 1510, 1274, 1109, 1244, 1058, 1021, 815, 760 cm-1. MS (ESI +ve) 
m/z 316 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C20H18N3O 316.1450, found 
316.1448 ([M + H]+). 
 
5-(3-Fluorophenyl)-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (104) 
This compound was prepared according to the General procedure 
VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with 1-ethynyl-3-fluorobenzene (0.03 g, 0.27 mmol) and 
EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C 
for 5 h to give 104 (0.069 g, 86%) as a light-yellow solid after purification by column 
chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). M.P: 148-150 °C. TLC 
(EtOAc/n-hexane 1:4): Rf  = 0.3; 
1H NMR (500 MHz, CDCl3) δ 8.05 (s, 1H, H4), 8.00 (d, J 
= 9.1 Hz, 1H, H8"), 7.84 (d, J = 8.1 Hz, 1H, H5"), 7.46-7.43 (m, 1H, H6"), 7.41-7.37 (m, 1H, 
H7"), 7.30 (d, J = 9.1 Hz, 1H, H4"), 7.16-7.11 (m, 2H, H3" and H2'), 6.95-6.86 (m, 3H, H4', 
H5' and H6'), 3.72 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ 162.6 (d, 1JC-F = 198.3 Hz, 
C3'), 152.7 (C2''), 139.3 (C8a''), 132.56 (C4a''), 132.52 (C4), 131.6 (C8''), 130.4 (d, 2JC-F = 
7.0, C1'), 129.1 (d, 3JC-F = 10.1, C5'), 128.79 (C4''), 128.77 (C5''), 128.2 (C3''), 124.8 (C6''), 
123.3 (C7''), 121.2 (C6'), 118.3 (C5), 116.1 (d, 4JC-F = 16.9 Hz, C2'), 114.5 (d, 5JC-F = 18.6 
Hz, C4'), 113.2 (C1''), 56.6 (OMe); IR (neat) νmax 2937, 2842, 1558, 1507, 1457, 1273, 1149, 
1110, 1069, 862, 807, 798, 690 cm-1. MS (ESI +ve) m/z 320 ([M + H]+, 100%); HRMS (ESI 









This compound was prepared according to the General 
procedure VI, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 
mmol) was treated with 2-ethynyl-1,3,5-trimethylbenzene (0.04 
g, 0.27 mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in Et2O) in 
dry THF (2 mL) at 50 °C for 6 h to give 105 (0.045 g, 52%) as a brown waxy solid after 
purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). 
TLC (EtOAc/n-hexane 2:3): Rf = 0.1; 
1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 7.3 Hz, 1H, 
H8"), 7.83 (s, 1H, H4), 7.77 (d, J = 7.3 Hz, 1H, H5"), 7.50-7.44 (m, 2H, H6" and H4"), 7.38-
7.35 (m, 1H, H7"), 7.12-7.10 (m, 1H, H3"), 6.89 (s, 1H, H5'), 6.57 (s, 1H, H3'), 3.57 (s, 3H, 
OMe), 2.25 (s, 3H, H9'), 2.18 (s, 3H, H7'), 1.57 (s, 3H, H8'); 13C NMR (126 MHz, CDCl3) δ 
151.6 (C2"), 138.9 (C8a"), 138.8 (C4'), 138.7 (C2'), 137.8 (C6'), 134.4 (C4), 131.8 (C5"), 
130.9 (C4a"), 128.9 (C4"), 128.3 (C3'), 128.1 (C5'), 128.0 (C7"), 127.9 (C8"), 124.4 (C6"), 
123.3 (C1'), 122.7 (C5), 118.4 (C3"), 112.7 (C1"), 55.6 (OMe), 21.1 (C8'), 20.8 (C9'), 20.7 
(C7'); IR (neat) νmax 2924, 2845, 1710, 1630, 1511, 1481, 1357, 1276, 1219, 1066, 1021, 967, 
810, 749 cm-1. MS (ESI +ve) m/z 344 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for 




This compound was prepared according to the General procedure VI, 
1-azidonaphthalene 99 (0.05 g, 0.29 mmol) was treated with 5-methyl-
1-hexyne (0.03 g, 0.32 mmol) and EtMgCl (0.03 g, 0.3 mmol; 2 M in 
Et2O) in dry THF (2 mL) at 50 °C for 4 h to give 114 (0.068 g, 88%) 





hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 
1H NMR (500 MHz, CDCl3) 
δ 8.04 (d, J = 8.3 Hz, 1H, H8"), 7.95 (d, J = 8.2 Hz, 1H, H5"), 7.70 (s, 1H, H4), 7.61-7.54 
(m, 2H, H6" and H7"), 7.50-7.47 (m, 2H, H3" and H4"), 7.16 (dd, J = 8.5, 0.8 Hz, 1H, H2"), 
2.45-2.42 (m, 2H, H1'), 1.46-1.36 (m, 3H, H2' and H3'), 0.72 (d, J = 6.2 Hz, 6H, H4' and 
H5'); 13C NMR (126 MHz, CDCl3) δ 140.3 (C5), 134.2 (C8a"), 132.7 (C4a"), 131.8 (C4), 
130.7 (C8"), 130.0 (C5"), 128.4 (C4"), 128.0 (C6"), 127.2 (C7"), 125.2 (C3"), 125.1 (C1"), 
122.4 (C2"), 37.2 (C2'), 27.4 (C3'), 22.2 (C4' and C5'), 21.3 (C1'); IR (neat) νmax 2955, 2868, 
1598, 1468, 1430, 1247, 1077, 960, 802, 773, 661 cm-1. MS (ESI +ve) m/z 266 ([M + H]+, 




This compound was prepared according to the General procedure 
VI, 1-azidonaphthalene 99 (0.05 g, 0.29 mmol) was treated with  
ethynylcyclohexane (0.03 g, 0.32 mmol) and EtMgCl (0.03 g, 0.3 
mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 4 h to give 115 (0.071 g, 88%) as a 
brown gummy solid after purification by column chromatography over SiO2 gel (EtOAc/n-
hexane - 40:60 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf  = 0.4; 
1H NMR (500 MHz, CDCl3) 
δ 8.04 (d, J = 8.3 Hz, 1H, H8"), 7.95 (d, J = 8.2 Hz, 1H, H5"), 7.70 (s, 1H, H4), 7.61-7.54 
(m, 2H, H6" and H7"), 7.50-7.46 (m, 2H, H3" and H4"), 7.12 (dd, J = 8.5, 0.8 Hz, 1H, H2"), 
2.40-2.34 (m, 1H, H1'), 1.77-1.70 (m, 2H, H2' and H6'), 1.66-1.55 (m, 3H, H3', H4' and H5'), 
1.41-1.33 (m, 2H, H3' and H5'), 1.20-1.12 (m, 1H, H4'), 1.08-1.00 (m, 2H, H2' and H6'); 13C 
NMR (126 MHz, CDCl3) δ 145.3 (C5), 134.2 (C8a"), 132.9 (C4a"), 130.8 (C4), 130.5 (C8"), 
130.3 (C5"), 128.3 (C4"), 128.0 (C6"), 127.2 (C7"), 125.2 (C3"), 125.1 (C1"), 122.4 (C2"), 





1448, 1238, 1084, 1005, 960, 802, 772 cm-1. MS (ESI +ve) m/z 278 ([M + H]+, 100%); HRMS 




This compound was prepared according to the General procedure 
VI, 1-azidonaphthalene 99 (0.05 g, 0.29 mmol) was treated with 1-
ethynyl-2-methoxybenzene (0.04 g, 0.32 mmol) and EtMgCl (0.03 g, 
0.3 mmol; 2 M in Et2O) in dry THF (2 mL) at 50 °C for 12 h to give 
116 (0.009 g, 10%) as a brown waxy solid after purification by column chromatography over 
SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.1; 
1H NMR 
(500 MHz, CDCl3) δ 7.99 (s, 1H, H4), 7.91-7.88 (m, 2H, H8" and H6'), 7.62-7.60 (m, 1H, 
H5"), 7.54-7.48 (m, 2H, H6" and H7"), 7.39 (dd, J = 7.4, 1.0 Hz, 1H, H3"), 7.26-7.21 (m, 
2H, H4" and H5'), 7.14 (dd, J = 7.4, 1.7 Hz, 1H, H2"), 6.83 (dt, J = 9.4, 1.2 Hz, 1H, H4'), 
6.69 (dd, J = 8.4, 1.0 Hz, 1H, H3'), 3.16 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ 156.6 
(C2'), 136.8 (C8a"), 134.2 (C4a"), 134.1 (C1'), 133.8 (C4), 131.1 (C5"), 130.9 (C2"), 130.0 
(C8"), 129.6 (C4"), 128.0 (C6'), 127.5 (C7"), 126.8 (C6"), 124.8 (C3"), 124.1 (C1"), 123.5 
(C5), 120.6 (C4'), 115.8 (C5'), 111.0 (C3'), 54.7 (OMe); IR (neat) νmax 3051, 2928, 1597, 
1481, 1464, 1270, 1103, 1050, 1023, 955, 802, 754 cm-1. MS (ESI +ve) m/z 302 ([M + H]+, 










6.4.2 – Ruthenium catalysed click reactions 
5-Isopentyl-1-(2-methoxyphenyl)-1H-1,2,3-triazole (119) 
This compound was prepared according to the General procedure V, 
1-azido-2-methoxybenzene 118 (0.02 g, 0.13 mmol) was treated with 5-
methyl-1-hexyne (0.014 g, 0.15 mmol) and Cp*RuCl(PPh3)2 (0.01 g, 
0.01 mmol) in 1,4-dioxane (2 mL) at 70 °C for 12 h to give 119 (0.028 g, 87%) as a brown 
oil after purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 → 
100:0). TLC (EtOAc/n-hexane 2:3): Rf = 0.5; 
1H NMR (500 MHz, CDCl3) δ 7.55 (s, 1H, 
H4), 7.50-7.47 (m, 1H, H4"), 7.32 (dd, J = 7.9, 1.7 Hz, 1H, H6"), 7.11-7.06 (m, 2H, H3"and 
H5"), 3.78 (s, 3H, OMe), 2.47 (t, J = 7.9 Hz, 2H, H1'), 1.56-1.41 (m, 3H, H2' and H3'), 0.82 
(d, J = 8.0 Hz, 6H, H4' and H5'); 13C NMR (126 MHz, CDCl3) δ 154.2 (C2"), 140.0 (C5), 
131.5 (C4"), 131.3 (C4), 128.7 (C6"), 125.1 (C1"), 120.9 (C5"), 112.1 (C3"), 55.7 (OMe), 
36.9 (C2'), 27.4 (C3'), 22.1 (C4' and C5'), 21.0 (C1'); IR (neat) νmax 2954, 2868, 1602, 1506, 
1473, 1285, 1251, 1233, 1122, 1043, 1021, 750 cm-1. MS (ESI +ve) m/z 246 ([M + H]+, 




This compound was prepared according to the General procedure V, 
1-azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 
ethynyl cyclohexane (0.04 g, 0.37 mmol) and Cp*RuCl(PPh3)2 (0.03 g, 
0.03 mmol) in 1,4-dioxane (2 mL) at 70 °C for 12 h to give 120 (0.066 g, 78%) as a yellow 
waxy solid after purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 
20:80 → 100:0).  TLC (EtOAc/n-hexane 2:3): Rf = 0.5; 
1H NMR (500 MHz, CDCl3) δ 7.56 





H5" and H3"), 3.77 (s, 3H, OMe), 2.44-2.38 (m, 1H, H1'), 1.89-1.71 (m, 2H, H2' and H6'), 
1.67-1.64 (m, 3H, H3', H4' and H5'), 1.38-1.31 (m, 2H, H3' and H5'), 1.27-1.23 (m, 1H, H4'), 
1.22-1.16 (m, 2H, H6' and H2'); 13C NMR (126 MHz, CDCl3) δ 154.3 (C2"), 144.8 (C5), 
131.4 (C4"), 130.0 (C4), 128.8 (C6"), 125.3 (C1"), 120.9 (C5"), 112.2 (C3"), 55.8 (OMe), 
33.4 (C1'), 26.0 (C2', C4' and C6'), 25.6 (C3' and C5'); IR (neat) νmax 2928, 2850, 1506, 1457, 
1280, 1233, 1046, 1020, 994, 974, 838, 770, 671 cm-1. MS (ESI +ve) m/z 258 ([M + H]+, 




This compound was prepared according to the General procedure V, 1-
azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 1-
ethynyl-2-methoxybenzene (0.05 g, 0.37 mmol) and Cp*RuCl(PPh3)2 
(0.03 g, 0.03 mmol) in 1,4-dioxane (2 mL) at 70 °C for 36 h to give 121 
(0.054 g, 58%) as a pale yellow waxy solid after purification by column 
chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 
2:3): Rf = 0.3; 
1H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H, H4), 7.41 (dd, J = 7.8, 1.7 Hz, 1H, 
H3'), 7.38-7.34 (m, 1H, H4"), 7.30-7.26 (m, 1H, H5'), 7.10 (dd, J = 8.0, 1.7 Hz, 1H, H6"), 
7.02 (ddd, J = 7.6, 1.2 Hz, 1H, H4'), 6.88-6.85 (m, 2H, H5" and H6'), 6.83 (dd, J = 8.0, 1.0 
Hz, 1H, H3"), 3.56 (s, 3H, OMe), 3.46 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ 156.5 
(C2'), 153.4 (C2"), 136.1 (C5), 133.6 (C4), 130.7 (C4"), 130.5 (C6'), 130.3 (C4'), 128.0 (C6"), 
126.4 (C1"), 120.5 (C5"), 120.3 (C5'), 116.7 (C1'), 112.0 (C3"), 110.9 (C3'), 55.4 (C7'), 55.0 
(OMe); IR (neat) νmax 2932, 2838, 1602, 1506, 1471, 1465, 1436, 1283, 1246, 1108, 1022, 
989, 753 cm-1. MS (ESI +ve) m/z 282 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for 







This compound was prepared according to the General procedure V, 1-
azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 1-
ethynylnaphthalene (0.056 g, 0.37 mmol) and Cp*RuCl(PPh3)2 (0.03 g, 
0.03 mmol) in 1,4-dioxane (2 mL) at 70 °C for 48 h to give 122 (0.007 
g, 7%) as a pale brown waxy solid after purification by column chromatography over SiO2 
gel (EtOAc/n-hexane - 30:70 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 
1H NMR (500 
MHz, CDCl3) δ 7.96 (s, 1H, H4), 7.88-7.81 (m, 3H, H4', H7' and H10'), 7.50-7.44 (m, 3H, 
H5', H6' and H9'), 7.34-7.28 (m, 2H, H4" and H8'), 7.16 (dd, J = 7.1, 1.1 Hz, 1H, H6"), 6.96 
(td, J = 7.7, 1.1 Hz, 1H, H5"), 6.72 (dd, J = 8.3, 0.9 Hz, 1H, H3"), 3.14 (s, 3H, OMe); 13C 
NMR (126 MHz, CDCl3) δ 153.2 (C2"), 137.4 (C5), 134.2 (C1'), 133.3 (C4), 131.6 (C3'), 
131.0 (C4"), 129.4 (C6"), 128.2 (C2'), 128.1 (C7'), 127.6 (C10'), 126.7 (C8'), 126.2 (C9'), 
125.2 (C1"), 125.1 (C4'), 124.9 (C5'), 124.7 (C6'), 120.6 (C5"), 111.8 (C3"), 54.9 (OMe); IR 
(neat) νmax 2925, 2849,1602, 1506, 1437, 1275, 1248, 1048, 1021, 977, 803, 778, 755 cm
-1. 
MS (ESI +ve) m/z 302 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C19H16N3O 
302.1293, found 302.1297 ([M + H]+). 
 
6.4.3 – Copper catalysed click reactions 
4-Isopentyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (123) 
This compound was prepared according to the General procedure IV, 
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated with  
5-methyl-1-hexyne (0.05 g, 0.5 mmol), CuSO4.5H2O (0.012 g, 0.05 
mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1 mL:0.25 





purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). 
TLC (EtOAc/n-hexane 1:4): Rf = 0.4; 
1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 11.3 Hz, 
1H, H8"), 7.83 (d, J = 9.5 Hz, 1H, H5"), 7.52 (s, 1H, H5), 7.46-7.35 (m, 3H, H6", H7" and 
H4"), 7.16 (d, J = 10.5 Hz 1H, H3"), 3.87 (s, 3H, OMe), 2.91-2.87 (m, 2H, H1'), 1.73-1.69 
(m, 3H, H2' and H3'), 0.99 (d, J = 7.9, 6H, H4' and H5'); 13C NMR (126 MHz, CDCl3) δ 
152.1 (C2"), 131.6 (C8a"), 131.2 (C4), 128.6 (C4"), 128.2 (C4a"), 127.8 (C5"), 124.5 (C7"), 
124.3 (C8"), 122.1 (C6"), 121.4 (C5), 119.7 (C3"), 113.1 (C1"), 56.7 (OMe), 38.4 (C2'), 27.8 
(C1'), 23.7 (C3'), 22.4 (C4' and C5'); IR (neat) νmax 2952, 2869, 2352, 1630, 1600, 1507, 
1457, 1365, 1275, 1255, 1149, 1110, 1064, 1041, 905, 809, 747 cm-1. MS (ESI +ve) m/z 296 
([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C18H22N3O 296.1763, found 296.1771 
([M + H]+). 
 
4-Cyclohexyl-1-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole (124) 
This compound was prepared according to the General procedure IV, 
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated 
with ethynylcyclohexane (0.054 g, 0.5 mmol), CuSO4.5H2O (0.012 g, 
0.05 mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1 
mL:0.25 mL) at rt for and 48 h to give 124 (0.062 g, 81%) as a pale yellow waxy solid after 
purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 → 100:0). 
TLC (EtOAc/n-hexane 1:4): Rf = 0.4; 
1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 9.1 Hz, 1H, 
H8"), 7.83-7.81 (m, 1H, H5"), 7.48 (s, 1H, H5), 7.44-7.36 (m, 2H, H6" and H7"), 7.35 (d, J 
= 8.8 Hz, 1H, H4"), 7.14 (dd, J = 8.8, 0.7 Hz, 1H, H3"), 3.86 (s, 3H, OMe), 2.93 (tt, J = 11.3, 
3.5 Hz, 1H, H1'), 2.24-2.20 (m, 2H, H2' and H6'), 1.86 (m, 2H, H3' and H5'), 1.77-1.74 (m, 





MHz, CDCl3) δ 153.1 (C2"), 152.1 (C4), 131.6 (C8a"), 131.3 (C4"), 128.6 (C4a"), 128.2 
(C5"), 127.7 (C7"), 124.5 (C8"), 123.1 (C5), 121.5 (C6"), 119.8 (C3"), 113.1 (C1"), 56.7 
(OMe), 35.3 (C1'), 33.0 (C2' and C6'), 26.2 (C4'), 26.1 (C3' and C5'); IR (neat) νmax 2923, 
2850, 1739, 1631, 1599, 1487, 1512, 1448, 1364, 1252, 1235, 1069, 1028, 809, 796, 760, 
652 cm-1. MS (ESI +ve) m/z 308 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for 




This compound was prepared according to the General procedure 
IV, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with 1-ethynyl-2-methoxybenzene (0.066 g, 0.5 mmol), 
CuSO4.5H2O (0.012 g, 0.05 mmol) and Na. ascorbate (0.02 g, 0.1 
mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt for 36 h to give 125 
(0.074 g, 89%) as a light brown solid after purification by column chromatography over SiO2 
gel (EtOAc/n-hexane - 40:60 → 100:0). M.P: 112-114 °C. TLC (EtOAc/n-hexane 1:4): Rf = 
0.4; 1H NMR (500 MHz, CDCl3) δ 8.54 (dd, J = 7.7, 1.7 Hz, 1H, H2'), 8.33 (s, 1H, H5), 8.02 
(d, J = 9.1 Hz, 1H, H8"), 7.87-7.85 (m, 1H, H5"), 7.46-7.39 (m, 3H, H6", H7" and H4"), 
7.36-7.33 (m, 1H, H4'), 7.25-7.23 (m, 1H, H3'), 7.15 (dd, J = 7.6, 1.0 Hz, 1H, H5'), 7.00 (dd, 
J = 8.3 Hz, 1H, H3"), 3.90 (s, 3H, OMe), 3.89 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ 
155.6 (C2"), 152.3 (C6'), 142.7 (C4), 131.8 (C8a"), 131.2 (C2'), 128.88 (C4"), 128.84 (C4'), 
128.2 (C4a"), 127.8 (C5"), 127.6 (C7"), 126.9 (C5), 124.5 (C8"), 121.4 (C6"), 121.0 (C3'), 
119.6 (C1'), 119.3 (C3"), 113.0 (C1"), 110.7 (C5'), 56.7 (C7'), 55.2 (OMe); IR (neat) νmax 





669 cm-1. MS (ESI +ve) m/z 332 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for 




This compound was prepared according to the General procedure IV, 
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated with 
1-ethynyl-4-fluorobenzene (0.06 g, 0.5 mmol), CuSO4.5H2O (0.012 g, 
0.05 mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1 
mL:0.25 mL) at rt for 12 h to give 126 (0.074 g, 92%) as an off-white 
solid after purification by column chromatography over SiO2 gel (EtOAc/n-hexane - 30:70 
→ 100:0). M.P: 109-111 °C. TLC (EtOAc/n-hexane 1:4): Rf = 0.4; 
1H NMR (500 MHz, 
CDCl3) δ 8.00 (d, J = 9.1 Hz, 1H, H8"), 7.97 (s, 1H, H5), 7.92 (dd, J = 9.1, 2.1 Hz 2H, 
H2'/H6'), 7.84 (d, J = 8.0 Hz, 1H, H5"), 7.46-7.37 (m, 3H, H6", H7" and H4"), 7.25 (d, J = 
8.3 Hz, 1H, H3"), 7.14 (apparent t, J = 8.6 Hz, 2H, H3'/H5'),  3.88 (s, 3H, OMe); 13C NMR 
(126 MHz, CDCl3) δ 162.6 (d, JC-F = 198.7 Hz, C4'), 152.1 (C2"), 146.4 (C4), 132.0 (C8a"), 
131.0 (C4a"), 128.5 (d, JC-F = 18.1 Hz, C2'/C6'), 127.9 (C4"), 127.58 (C5"), 127.52 (C5), 
126.8 (d, JC-F = 2.0 Hz, C1'), 124.7 (C7"), 123.3 (C8"), 121.3 (C6"), 119.2 (C3"), 115.8 (d, 
JC-F = 86.3 Hz C3'/C5'), 113.0 (C1"), 56.7 (OMe); IR (neat) νmax 2919, 2849, 1714, 1598, 
1507, 1482, 1457, 1276, 1258, 1223, 1218, 1146, 1079, 1032, 838, 811, 796, 755, 658 cm-1. 
MS (ESI +ve) m/z 320 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C19H15FN3O 









This compound was prepared according to the General procedure 
IV, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with 1-ethynyl-4-nitrobenzene (0.074 g, 0.5 mmol),  
CuSO4.5H2O (0.012 g, 0.05 mmol) and Na. ascorbate (0.02 g, 0.1 
mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt for 16 h to give 127 (0.07 
g, 79%) as a yellow solid after purification by column chromatography over SiO2 gel 
(EtOAc/n-hexane - 30:70 → 100:0). M.P: 118-120 °C. TLC (EtOAc/n-hexane 1:4): Rf = 0.3; 
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H, H3' and H5'), 8.18 (s, 1H, H5), 8.14 
(d, J = 8.8 Hz, 2H, H2' and H6'), 8.07 (d, J = 9.1 Hz, 1H, H8"), 7.89 (d, J = 8.0 Hz, 1H, H5"), 
7.50-7.45 (m, 2H, H6" and H7"), 7.43 (d, J = 9.1 Hz, 1H, H4"), 7.26 (d, J = 9.1 Hz, 1H, H3"), 
3.93 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ 152.1 (C2"), 147.3 (C4), 145.1 (C8a"), 
136.9 (C1'), 132.3 (C4'), 130.8 (C4"), 128.6 (C4a"), 128.0 (C5"), 126.2 (C2'/C6'), 126.1 
(C7"), 125.1 (C5), 124.8 (C8"), 124.3 (C3'/C5'), 121.1 (C6"), 118.9 (C3"), 112.8 (C1"), 56.7 
(OMe); IR (neat) νmax 3162, 2943, 2845, 1603, 1510, 1335, 1276, 1257, 1108, 1079, 1059, 
1028, 852, 801, 757, 753 cm-1. MS (ESI +ve) m/z 347 ([M + H]+, 100%); HRMS (ESI +ve 




This compound was prepared according to the General procedure 
IV, 1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was 
treated with 1-ethynylnaphthalene (0.076 g, 0.5 mmol),  
CuSO4.5H2O (0.012 g, 0.05 mmol) and Na. ascorbate (0.02 g, 0.1 





(0.08 g, 91%) as a pale yellow waxy solid after purification by column chromatography over 
SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.3; 
1H NMR 
(500 MHz, CDCl3) δ 8.58-8.55 (m, 1H, H10'), 8.09 (s, 1H, H5), 8.02 (d, J = 10.7 Hz, 1H, 
H8"), 7.94-7.86 (m, 4H, H5", H2', H4' and H7'), 7.60-7.49 (m, 4H, H6", H7", H9' and H3'), 
7.45-7.38 (m, 3H, H4", H3" and H8'), 3.93 (s, 3H, OMe); 13C NMR (126 MHz, CDCl3) δ 
152.1 (C2"), 146.2 (C4), 134.0 (C1'), 131.9 (C8a"), 131.2 (C4b'), 131.1 (C8b'), 128.9 (C4a"), 
128.7 (C4"), 128.5 (C5'), 128.4 (C8'), 128.0 (C4'), 127.9 (C5"), 127.4 (C7'), 126.6 (C7"), 
126.5 (C5), 126.0 (C6'), 125.5 (C8"), 125.4 (C3'), 124.7 (C6"), 121.5 (C2'), 119.4 (C3"), 
113.0 (C1"), 56.8 (OMe); IR (neat) νmax 3137, 2936, 2846, 1629, 1506, 1462, 1390, 1278, 
1264, 1064, 1044, 1021, 905, 803, 778, 749, 663 cm-1. MS (ESI +ve) m/z 352 ([M + H]+, 
100%); HRMS (ESI +ve TOF) calcd for C23H18N3O 352.1450, found 352.1459 ([M + H]
+). 
 
2-(1-(2-Methoxynaphthalen-1-yl)-1H-1,2,3-triazol-4-yl) propan-2-ol (129) 
This compound was prepared according to the General procedure IV, 
1-azido-2-methoxynaphthalene 82 (0.05 g, 0.25 mmol) was treated with 
2-methylbut-3-yn-2-ol (0.043 g, 0.5 mmol), CuSO4.5H2O (0.012 g, 0.05 
mmol) and Na. ascorbate (0.02 g, 0.1 mmol) in t-BuOH:H2O (1 mL:0.25 
mL) at rt for 12 h to give 129 (0.06 g, 86%) as a yellow solid after purification by column 
chromatography over SiO2 gel (EtOAc/n-hexane - 40:60 → 100:0). M.P: 122-124 °C; TLC 
(EtOAc/n-hexane 1:4): Rf = 0.2; 
1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 9.1 Hz, 1H, H8"), 
7.84-7.82 (m, 1H, H5"), 7.69 (s, 1H, H5), 7.44-7.38 (m, 2H, H6" and H7"), 7.36 (d, J = 8.7 
Hz, 1H, H4"), 7.14 (dd, J = 8.7 Hz, 1H, H3"), 3.87 (s, 3H, OMe), 2.94 (brs, 1H, -OH), 1.77 
(s, 6H, H2' and H3'); 13C NMR (126 MHz, CDCl3) δ 155.0 (C2"), 152.1 (C8a"), 131.8 (C4), 





119.4 (C3"), 113.0 (C1"), 68.6 (C1'), 56.6 (OMe), 30.5 (C2' and C3'); IR (neat) νmax 3333, 
2981, 2919, 2849, 1632, 1511, 1456, 1359, 1275, 1219, 1143, 1067, 1045, 805, 776, 757 cm-
1. MS (ESI +ve) m/z 284 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C16H18N3O2 
284.1399, found 284.1396 ([M + H]+). 
 
4-Isopentyl-1-(2-methoxyphenyl)-1H-1,2,3-triazole (130) 
This compound was prepared according to the General procedure IV, 1-
azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 5-methyl-
1-hexyne (0.065 g, 0.66 mmol), CuSO4.5H2O (0.017 g, 0.06 mmol) and Na. 
ascorbate (0.026 g, 0.13 mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt for 12 
h to give 130 (0.078 g, 96%) as a pale-yellow oil after purification by column 
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0). TLC (EtOAc/n-hexane 
1:4): Rf = 0.5; 
1H NMR (500 MHz, CDCl3) δ 7.83 (s, 1H, H5), 7.73 (dd, J = 10.3, 2.2 Hz, 
1H, H6"), 7.40-7.35 (m, 1H, H4"), 7.08-7.04 (m, 2H, H5" and H3"), 3.86 (s, 3H, OMe), 2.82-
2.78 (m, 2H, H1'), 1.70-1.60 (m, 3H, H2' and H3'), 0.96 (d, J = 7.8 Hz, 6H, H4' and H5'); 13C 
NMR (126 MHz, CDCl3) δ 151.4 (C2"), 147.9 (C4), 129.8 (C4"), 126.5 (C6"), 125.4 (C5"), 
122.7 (C5), 121.1 (C3"), 112.2 (C1"), 55.9 (OMe), 38.4 (C2'), 27.7 (C1'), 23.6 (C3'), 22.4 
(C4' and C5'); IR (neat) νmax 2953, 2868, 1601, 1506, 1473, 1285, 1251, 1233, 1122, 1043, 
1021, 985, 795, 750 cm-1. MS (ESI +ve) m/z 246 ([M + H]+, 100%); HRMS (ESI +ve TOF) 











This compound was prepared according to the General procedure IV, 1-
azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with ethynyl 
cyclohexane (0.07 g, 0.66 mmol), CuSO4.5H2O (0.017 g, 0.06 mmol) and 
Na. ascorbate (0.026 g, 0.13 mmol) in t-BuOH:H2O (1 mL:0.25 mL) at rt 
for 12 h to give 131 (0.077 g, 90%) as a pale-yellow oil after purification by column 
chromatography over SiO2 gel (EtOAc/n-hexane - 20:80 → 100:0). TLC (EtOAc/n-hexane 
1:4): Rf = 0.5; 
1H NMR (500 MHz, CDCl3) δ 7.79 (s, 1H, H5), 7.75-7.73 (m, 1H, H6"), 7.40-
7.35 (m, 1H, H4"), 7.08-7.04 (m, 2H, H5" and H3"), 3.86 (s, 3H, OMe), 2.88-2.80 (m, 1H, 
H1'), 2.16-2.11 (m, 2H, H2' and H6'), 1.85-1.71 (m, 3H, H3', H4' and H5'), 1.51-1.40 (m, 4H, 
H2', H3', H5' and H6'), 1.34-1.25 (m, 1H, H4'); 13C NMR (126 MHz, CDCl3) δ 153.0 (C2"), 
151.1 (C4), 129.7 (C4"), 126.6 (C6"), 125.5 (C5"), 121.5 (C5), 121.1 (C3"), 112.2 (C1"), 
55.9 (OMe), 35.3 (C1'), 33.0 (C2' and C6'), 26.2 (C4'), 26.1 (C3' and C5'); IR (neat) νmax 
2929, 2849, 1602, 1504, 1473, 1458, 1282, 1248, 1181, 1124, 1049, 1021, 748 cm-1. MS (ESI 
+ve) m/z 258 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C15H20N3O 258.1606, found 
258.1602 ([M + H]+). 
 
1,4-Bis(2-methoxyphenyl)-1H-1,2,3-triazole (132) 
This compound was prepared according to the General procedure IV, 1-
azido-2-methoxybenzene 118 (0.05 g, 0.33 mmol) was treated with 1-
ethynyl-2-methoxybenzene (0.09 g, 0.66 mmol), CuSO4.5H2O (0.017 g, 
0.06 mmol) and Na. ascorbate (0.026 g, 0.13 mmol) in t-BuOH:H2O (1 
mL:0.25 mL) at rt for 12 h to give 132 (0.082 g, 88%) as a pale brown 





→ 100:0). TLC (EtOAc/n-hexane 1:4): Rf = 0.2; 
1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H, 
H5), 8.40 (dd, J = 9.6, 2.2 Hz, 1H, H2'), 7.74 (dd, J = 9.8, 2.1 Hz, 1H, H6"), 7.41-7.37 (m, 
1H, H4"), 7.32-7.28 (m, 1H, H5") , 7.10-7.04 (m, 3H, H3', H4' and H5'), 6.96 (dd, J = 10.4, 
1.0 Hz, 1H, H3"), 3.90 (s, 3H, OMe), 3.84 (s, 3H, H7'); 13C NMR (126 MHz, CDCl3) δ 155.7 
(C6'), 151.6 (C2"), 142.6 (C4), 130.0 (C2'), 128.8 (C4"), 127.7 (C4'), 126.5 (C6"), 125.7 
(C3'), 125.2 (C5), 121.1 (C5"), 121.0 (C1'), 119.5 (C3"), 112.3 (C1"), 110.9 (C5'), 55.9 
(OMe), 55.4 (C7'); IR (neat) νmax 2936, 2838, 1601, 1506, 1489, 1465, 1287, 1247, 1161, 
1130, 1078, 1022, 748, 689 cm-1. MS (ESI +ve) m/z 282 ([M + H]+, 100%); HRMS (ESI +ve 
TOF) calcd for C16H16N3O2 282.1243, found 282.1234 ([M + H]
+). 
 
Synthesis of Azides and alkynes: 
The known azides 8282, 9783 and 9984 were prepared from their corresponding 1-
naphthylamines according to the method of Hu et al.85 All alkynes were commercially 
sourced expect for 1-ethynylnaphthalene,86 1-ethynyl-4-nitrobenzene,87 and 2-ethynyl-1,3,5-
trimethylbenzene88 which were prepared by literature methods.  
 
6.5 – Experimental procedures for biological and pharmacological assays 
6.5.1 – Minimum inhibitory concentration (MIC)  
6.5.1.1 – Primary screening  
The primary screening experiments were performed at University of Western 
Australia by Dr. Katherine Hammer and Dr. Daniel Knight. MIC analyses were executed on 
Staphylococcus aureus (ATCC 29213), methicillin-resistant Staphylococcus aureus (NCTC 
10442), Enterococcus faecalis (ATCC 29212) and Escherichia coli (ATCC 25922) in 





Streptococcus pneumoniae (ATCC 49619) was cultivated in MH broth with 2.5% lysed horse 
blood and incubated with 5% CO2 at 35 °C for 24 h. MIC tests for Clostridium difficile 
(ATCC 700057) and Clostridium difficile (NSW132 – RT027) were performed in Brucella 
broth supplemented with haemin and vitamin K and incubation was completed anaerobically 
at 35 °C for 48 h. Every compound was dissolved in DMSO at 3 – 5 mg/mL and then diluted 
to 512 μg/mL with sterile, distilled water. The compounds were then diluted sequentially in 
100 μL volumes of sterile, distilled water in a 96-well microtitre plate. Every testing 
bacterium in double strength broth (100 μL) was then added to each well and incubated as 
explained above. Testing concentrations of every compound ranged from 0.25 μg/mL to 128 
μg/mL. Vancomycin and a control well (i.e. no antibacterial compound present) were 
involved in the assays. A DMSO control (5% v/v) was also analyzed to confirm the solvent 
did not inhibit bacterial growth. The test was performed in triplicate for each organism and 
compound mixture and the average MIC values were verified. The lowest concentration that 
inhibits bacterial development completely will be recorded as the compound’s MIC value. 
The MBC (minimum bactericidal concentration) was also noted as the lowest concentration 
that caused cellular death. 
 
6.5.1.2 – Secondary screening and cytotoxicity assays (CO-ADD) 
Antibacterial compounds were screened at CO-ADD for antimicrobial testing by 
complete cell development inhibition analyses. The inhibition of development was measured 
against five bacterial strains: Escherichia coli (ATCC 25922), Klebsiella pneumoniae 
(ATCC 700603), Acinetobacter baumannii (ATCC 19606), Pseudomonas aeruginosa 
(ATCC 27853) and Staphylococcus aureus (ATCC 43300), and two fungi: Candida albicans 





compounds were tested for cytotoxicity against a human embryonic kidney cell line 
(HEK293) by ascertaining their CC50 value. Antibacterial compound solution was prepared 
in DMSO to a final screening concentration of 32 μg/mL and serially diluted 1:2 fold for 8 
times. Each compound concentration was prepared in 384 – well plates, non-binding surface 
(NBS) plate (Corning 3640) for each bacterial/fungal strain and tissue-culture treated 
(Corning 3712/3764) black for mammalian cell types, all in duplicate (n = 2) and keeping the 
final DMSO concentration to a maximum of 0.5%. All the compound’s preparation was 
accomplished using liquid handling robots. 
 
6.5.1.3 – Bacterial Inhibition 
All of the bacterial strains were cultured in cation-adjusted MH broth at 37 °C 
overnight. Each compound culture was then diluted 40-fold in fresh broth and incubated at 
37 °C for 1 – 3.5 h. The resultant mid-log phase cultures were diluted (CFU/mL measured 
by OD600), then added to each well of the compound-containing plates, giving a cell density 
of 5 × 105 CFU/mL and a total volume of 50 μL. All plates were protected and incubated at 
37 °C for 18 h without shaking. Inhibition of bacterial development was verified by 
calculating absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate 
reader. The percentage of growing inhibition was determined for each well, utilizing the 
negative control (media only) and positive control (bacteria without inhibitors) on the same 
plate as references. The MIC was revealed as the lowest concentration at which bacterial 
development was completely inhibited, identified by an inhibition ≥ 80%. Vancomycin was 
utilized as a positive control for Gram-positive bacteria and colistin was used as a positive 





with two above and two below its MIC value, and plated into the first eight wells of column 
23 of the 384 – well NBS plates. 
 
6.5.1.4 – Fungal Inhibition 
Fungal strains were cultured for three days on Yeast Extract-Peptone Dextrose agar 
at 30 °C. A yeast suspension of 1 × 106 to 5 × 106 CFU/mL (as determined by OD530) was 
prepared from five colonies. The suspension was diluted and added to each well of the 
compound-containing plates giving a final cell density of fungi suspension of 2.5 × 103 
CFU/mL and a total volume of 50 μL. All plates were protected and incubated at 35 °C for 
36 h without shaking. The inhibition of C. albicans development was decided by evaluating 
absorbance at 630 nm (OD630), and the inhibition of C. neoformans development was 
decided by assessing the difference in absorbance between 600 and 570 nm (OD600 – 570), 
after the addition of resazurin (0.001 % final concentration) and incubation at 35 °C for 2 h. 
The absorbance was measured using a Biotek Multiflo Synergy HTX plate reader. The 
percentage of growing inhibition for both fungi were calculated for each well, using the 
negative control (media only) and positive control (fungi without inhibitors) on the same 
plate.  
The MIC was decided as the lowest concentration at which the fungal development 
was fully inhibited, defined as an inhibition ≥ 80% for C. albicans and an inhibition ≥ 70% 
for C. neoformans. Due to the higher difference in growth and inhibition, a lower threshold 
was employed to the data for C. neoformans. Fluconazole was used as a positive control for 
anti-fungal assay of C. albicans and C. neoformans. The antifungal control was given in four 
concentrations, with two above and two below its MIC value, and plated into the first eight 





6.5.2 – Cytotoxicity Assay 
HEK293 cells were counted manually in a Neubauer haemocytometer and then plated 
in the 384 – well plates containing the compounds to give a density of 5000 cells/well in a 
final volume of 50 μL. Dulbecco’s modified eagle medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) was used as a growth media and the cells were incubated together 
with the compounds for 20 h at 37 °C in 5% CO2. Cytotoxicity (cell viability) was evaluated 
by fluorescence, ex: 560/10 nm, em: 590/10 nm (F560/590), after addition of 5 μL of 25 
μg/mL resazurin (2.3 μg/mL final concentration) and after incubation for further 3 h at 37 °C 
in 5% CO2. The intensity of fluorescence was measured using a Tecan M1000 Pro 
monochromator plate reader, using automatic gain calculation. CC50 (concentration at 50% 
cytotoxicity) values were calculated by curve-fitting the inhibition values vs. 
log(concentration) using a sigmoidal dose-response function, with variable fitting values for 
bottom, top and slope. Tamoxifen was used as a positive cytotoxicity control, used in eight 
concentrations in two-fold serial dilutions with 50 μg/mL as the highest concentration tested. 
 
6.5.3 – In vivo CDI mouse model (Monash University) 
6.5.3.1 – Study design 
 The in vivo CDI mouse model study was performed by Prof. Dena Lyras, Dr. 
Melanie Hutton and Dr. Amy King. Mice were pre-treated with an antibiotic cocktail 
containing kanamycin (0.4 mg/mL; Amresco), gentamicin (0.035 mg/mL; Sigma), colistin 
(850 mg/mL; Sigma), metronidazole (0.215 mg/mL; Sigma), vancomycin (0.045 mg/mL; 
Sigma) and cefaclor (0.3 mg/mL; Sigma) in the drinking water for seven days, followed by 
three days of cefaclor alone to obstruct the commensal microbiota to bring infection with C. 





infection. Group of infected five mice with 105 C. difficile spores of the RT027 strain M7404. 
After six hours post-infection, 2.5 mg of the selected compounds (in 10% aqueous DMSO) 
were given to the mice via oral gavage. The mice were then administered fresh compound 
every 12 h after the initial dose. The mice were monitored twice in a day for weight loss and 
other physiological signs of infection. The blood was collected and left to clot at room 
temperature prior to centrifugation. The serum and faeces were collected and frozen at – 80 
°C for later pharmacokinetic evaluation. Note that mice were euthanized according to animal 
ethics guidelines: i.e. if the mice lose ≥ 10 % of their total body weight in the first 24 h or ≥ 
15 % at any point after 24 h. 
 
6.5.3.2 – Sample preparation 
Each compound was dissolved in 100% DMSO to attain a stock concentration of 250 
mg/mL. Twenty minutes before the administration, the compound stock solution was diluted 
(1:10) with warm water (37 °C) to accomplish a final concentration of 25 mg/mL. The 
compounds were vortexed and carried to the animal house floating in warm water in an 
attempt to maintain a homogeneous solution. The compounds were then vortexed again 
immediately preceding to gavaging the mice. Each mouse received 100 μL of solution 
containing 2.5 mg of compound – this equates to a dose of 100 mg/kg (based on an average 
25 g mouse). 
 
6.5.4 – Comparative solubility assay 
6.5.4.1 –Procedure 
Five milligrams of the target compound was fully dissolved in 50 μL DMSO. Small 





addition; additions were continued until a visible turbidity or cloudiness was apparent that 
did not fade after mixing. The quantity of H2O needed for precipitation of the compound was 
recorded; this value was then divided by the standard value (i.e. 15 μL = quantity of H2O 
required to precipitate lead compound AVX-13616) to obtain a comparative solubility ratio. 
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